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Summary
A Coordination chemistry based historical perspective of contrast agents which are utilised in 
various imaging modalities, forms the basis of Chapter 1. Chapter 1 also highlights the 
various latest advancements and the challenges confronted therein. Chapter 1 culminates in 
highlighting the need for dual purpose contrast agents.
Chapter 2 and Chapter 3 deals with polyamino poly carboxylate derivatives 
based on EDTA and DTPA respectively. Chapter 2 sheds light upon Teslascan and other 
related manganese based potential contrast agents. It also highlights the emergence of Mn (II) 
as the direct competitor for Gd (III) in the face of Nephrogenic Systemic Fibrosis (NSF) 
reported for Gd based contrast agents. The chapter culminates in describing the synthesis of a 
library of EDTA bisamides, including four new EDTA bisamides. Chapter 3 in turn takes a 
detailed look at a series of DTPA analogues and DTPA bisamides synthesized by scientists all 
over the world. It also highlights the various synthetic methodologies undertaken by the able 
scientists. The chapter culminates in describing four new multidentate ligands synthesized in 
this project, namely two new DTPA analogues and two new DTPA Bisamides. It has been 
shown that the synthetic methodology utilised to synthesize symmetric naphtha derivative L5 
is fairly unique.
Chapter 4 and Chapter 5 report the investigations carried out on these new 
multidentate ligands in terms of relaxometry, potentiometry and luminescence. Interesting 
results were obtained from relaxometric and luminescence measurements. For instance, 
symmetric naphtha derivative, reported a relaxivity of 8 .8  mM'1s'1, relaxivity obtained for Mn 
(II) complex of EDTA bisamide of 4-aminomethylpyridine is also highly commendable.
Investigations on the optical properties of the multidentate ligands require a 
separate chapter. Thus it is has been allotted Chapter 5. DTPA bisamide of N, N-Bis[(tert- 
butoxycarbonyl)methyl-2 -bromoethylamine was found to quench the fluorescence upon 
binding with Cu (II), indicating its application as luminescent sensor for Cu (II).
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Chapter 1 
Contrast Agents for Medical Imaging
1.0 Introduction to Molecular Imaging
Imaging science is gaining momentum, with the advancement of various imaging modalities. 
Among the number of available imaging modalities (such as CT, PET etc), magnetic 
resonance imaging has proved its significance over past three decades. This could mainly be 
attributed to its spatial resolution and specificity, which are great advantages in medical 
imaging.
Molecular medicine is the future of patient management and health care.1 Imaging has a 
key role to play in achieving this objective. Significant advancement could be realised 
through the translation, from a dominant in-vitro technology to an in-vivo one. This is 
possible through a combination of chemical synthesis, molecular biology and imaging 
hardware.
The in-depth study of the inside of the human body has been a persistent challenge to 
medical doctors, scientists and also the designers of commercial devices. In fact, when X-rays 
were discovered at the end of nineteenth century, it brought about a powerful impact and was 
considered the ultimate instrument of such study. With time it became evident that X-ray 
radiography could hardly be called a non-invasive technique due to destructive effect on the 
tissues caused by ionizing radiation. Even with modem advancements in X-ray techniques, 
though considered as much more safe and sophisticated than it was in the earlier stages, it still 
employs the same kind of radiation and therefore contributes to the same kind of health risks 
as years ago.
So, as it could be seen, there was need of better technique, capable of eliminating or 
having negligible impact on health. It so happened that the technique known as Nuclear 
Magnetic Resonance, which was discovered in the mid-nineteen forties did not seem to be of
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much importance initially. After a short period of time, however, it was realized that it had
tremendous potential for a great variety of applications, including its contribution to Imaging
Science. Actually, the thought of making use of it to study the human body was conceived in
sixties. It, however, nearly took a decade alongside advancements in computer technology
before these thoughts were put into practice.
Nuclear Magnetic Resonance involves radiofrequency electromagnetic waves with low
intensity. This helps in the study of substances placed in a strong magnetic field. The
interesting thing to note here is that neither the radiation employed, nor the strong magnetic
field have been proven to be harmful to living organisms in any way so far. Remarkable
progress has been achieved using this non-invasive technique during the last decade, yet more
new dimensions of this worthy invention are in rapid progress.
The very significant place attained by today’s imaging modalities, has not taken place
overnight. What follows is a brief historical account on the developments of imaging
technology, specifically related to Medicine/Healthcare. The following section describes the
parallel development of appropriate contrast agents for the modalities discussed. While doing
so, we shall focus our attention mostly on contrast agents for MRI and/or PET.
1.1 History of Medical Imaging: An Outlook
1.1.1 X-ray
In fact Philip Leonard observed that electrons are generated in a glass vacuum tube, when a 
voltage is applied between a cathode and an anode. When these electrons strike the glass, they 
cause it to glow - and this can be seen in a darkened room. He named this phenomenon as 
‘’Cathode Rays’. In 1895, Nov 8th, Wilhelm Rontgen first discovered a fascinating 
phenomenon.2
He had acknowledged the fascinating finding of a high energy emission, which could be 
able to pass through the material that was opaque to light. Rontgen had sealed up a tube, such 
that light emission is prevented from the glass. When he tested the device to make sure it was
3
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completely light sealed, however, he noticed a glow from a table at some distance- a distance
far too great to be reached with cathode rays. On the table was a sheet of cardboard painted
with the barium platinocyanide. Since the origin of the rays could not be understood by
Roentgen, he called it as “ X” rays. Finally he submitted a publication that depicted a
photograph of a skeletal hand in 28th of December in 1895. He was the first to receive Nobel
Prize for Physics in 1901.
Presently, X-rays are known to be electromagnetic radiation emitted by electrons that 
have relatively higher energy and far shorter wavelengths in comparison to photons. 
Formerly, X-rays were distinguished from gamma rays based on the relatively higher energy 
and relatively shorter wavelength possessed by gamma rays. The origin of the latter, however, 
is now attributed to the nucleus.
1.1.1.1 Origin of Tomography
The driving motive behind the history of Tomography was to get a better look inside the 
chest. Thereby the heart, lungs, and any tuberculosis or tumours could be better seen, without 
the interference of the rib cage in front and behind. To accomplish this, a Topographic system 
was developed with the following principle.
X-ray source to the left while the image plate is moved to the right. The axis of rotation 
of a line from the source to the plate must be on a plane of interest inside the body; structures 
in the middle of the patient would remain relatively clear while those in back and front will be 
blurred. Many patents based on purely mechanical devices followed. In 1937, however, 
William Watson filed a patent application for the first important system that made a series of 
axial topographic images (slices). The patient sat on a stool that was rotated through a full 
circle as the image was being made along with the simultaneous movement of the the X-ray 
plate. The seat of the stool was mounted on a telescoping column that could be raised or 
lowered to get axial sections at various locations in the body. This device actually achieved 
considerable commercial success.
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The birth of Computerised Axial Tomography
Following Watson, there were several developments on this area of technology. “None 
blurring” is one such method. Although these worked, they involved a truly enormous 
amount of X-ray exposure. Therefore Gabriel Frank et a l3,4 discovered a fascinating 
principle, namely “ Back Projection” technology.
HounsfieUPs Computerized Tomography (CT/CAT)
In the early 1960’s, four entirely independent researchers (Oldendorf at UCLA, Kiev in 
Russia, Brownell and Chesler from Massachusetts) took advantage of recent advances in 
computers at that time. They tried their best to utilise this advantage to develop, computer 
based, back projection, axial tomography system. Their efforts, however, were not so fruitful. 
It was in 1973, the British scientist, Hounsfield, was awarded a patent for discovering the 
first, computerised axial tomography system.
On the other hand, ‘Allan Cormack’, a South African scientist, independently 
discovered the solution of the problem of “line integrals”5 ,6 a mathematical technique that is 
used in most modem CT scan computation. In honour of this great work, both, Hounsfield 
and Allan Comrack received the coveted Nobel Prize in Medicine in 1979.
Advances of CT Scanning include dramatic achievement in the speed of scanning and 
the utilisation of simultaneous acquisition to obtain as many as 128 image slices. All these 
have impacted CT’s capabilities to prevent motion similar to a fast camera.
Along with the advancement of improved intravenous contrast agents, the quality of 
CT angiography targeted for coronary and cerebral vessels continues to improve. In fact, in 
the recent past, there were developments for real time CT scanning with ‘’O’-’arm units. 
Contrast agents used in CT, are iodine based and are absorbed by abnormal tissues. Though 
one may say resolution is lower in CT, it has extremely good low contrast resolution, which 
enables the detection of very small changes in tissue type. CT gives accurate diagnostic 
information about the distribution of structures inside the body.
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1.1.1.2 Positron Emission Tomography (PET)
This imaging technique also has 40 years of history since the initial attempt to obtain an 
image using positron emitters as a clinically useful tool. This long period of time could be 
justified by the fact that several elements had to be merged to produce the imaging modality 
of today. There were attempts in the history to demonstrate the advantages of positron 
imaging, using coincidence-counting technique. In fact, the first, clinically useful positron 
camera was developed in 1960s. The image produced by the camera mainly of planar
m
tomographic nature. Kuhl and Edwards successfully accomplished ‘Transaxial emission 
tomography’ thereafter advancements in PET were fairly slow until CT became powerful. In 
the 1970’s, a more modem version of positron emission CT refer to dual-modality imaging, 
was introduced by Phelps et al.1 Thereafter many more developments took place, culminating 
in a very sensitive modality.
With regard to in-vivo imaging, PET is considered to be the current solution where 
sensitivity is concerned. It is this sensitivity (femto or nano molar biological concentrations), 
which makes PET suitable for imaging molecular events. The use of PET is limited by access 
to hardware as it requires ready access to a Cyclotron, since commonly used isotopes (13N (10 
min), n C (20.3 min), lsO (2.07 min), 18F (1.83 h)) can have prohibitively short half lives. PET 
is quantitative in the sense it does provide the ability to characterize receptors and ligands at 
molecular concentrations.8 In fact the great contribution in drug development comes from its 
ability to label a compound with radio nuclide isotope thus maintaining its physiochemical 
properties. PET radio nuclides based on 18F particularly, fluorodeoxyglucose (glycolysis 
marker) have been useful in probing neoplastic processes and has been widely used. 
Transcription (the process of transcribing DNA to RNA), which dominates the manufacture 
of cellular proteins, often considered to be the focal point in investigating cancer. PET is 
found to be really useful in imaging the regulation of transcription.
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1.1.1.3 Single photon emission computerized tomography (SPECT)
SPECT is another powerful technique that has been used to image several molecular 
processes and is comparatively cheaper than PET. SPECT acts by detecting y-emitting 
radionuclides.
1.1.2 Magnetic Resonance Imaging (MRI), How it has originated
Tracing back the history of MRI, one may discover that there were three major phases. 
Firstly, the discovery of the fundamental physics and biological properties of nuclear 
magnetic resonance, secondly, the emergence of designs to accomplish imaging with MRI, 
and finally the emergence of neurologically optimized methods such as functional MRI. It is 
necessary to have a detailed outlook on each phase. To begin with, let us consider the 
emergence of Nuclear Magnetic Resonance.
Olfgang Pauli (1900-1958) initially proposed the existence of the physical basis of 
magnetic resonance. After which, Isidor Rabi (1898-1988) conducted the first experiment that 
proved the existence of magnetic resonance. Felix Bloch (1905-1983) and Edward Purcell 
(1912-1997) independently established the presence of nuclear magnetic resonance in solids. 
Erwin Hahn (bom 1921) fully explained the refocusing pulse/spin echo concept that greatly 
enhances the utility of measurement of T2 relaxation in most biological situations. Most 
importantly for MRI, noticing some irregularities in some spectra he was evaluating, he made 
the suggestion in 1924 that atomic nuclei should have magnetically related spins. He was 
indeed correct. In fact it has layed the foundation for the physical basis of magnetic resonance 
upon which everything else in this field is built up.
Having understood the background of various dimensions of this medical imaging 
science we are now in a position to appreciate the comparative importance of MRI. The 
necessity of dual modalities and the role of MRI in that area also need to be discussed. In 
order to do this, we should try to understand the principles underlying MRI.
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1.1.2.1 Principles of Magnetic Resonance Imaging (MRI)
Very similar to X-Ray, Computerized Axial Tomography (CAT), MRI is a method of 
obtaining images of the body in thin slices. The method measures the characteristics of 
hydrogen nuclei of water and nuclei with similar chemical shifts, altered by chemical 
environment across the slice.
This is the major difference of MRI from proton coupling constants.9 MRI gives spatial 
distribution of the intensity of water proton signal in the volume of the body under 
investigation. This signal intensity depends on the amount of water in the given place and on 
the magnetic relaxation times Ti and T2 which in turn are influenced by a range of 
factors.10,11 Deducing these factors in each case are the ultimate goal of the radiologist, who 
is attempting to diagnose the problem by way of examining the MR images. In many cases 
MRI is the only way to do unambiguous diagnosis, especially in detection of cerebral 
abnormalities, multiple sclerosis and lesions in sites often obscured by bone artefact on CT 
scans.
In comparison to CT, MRI has inherently superior contrast scale, because of that, 
despite of relatively high cost of equipment and maintenance; it has established its presence in 
most hospitals, clinics and research institutes in developed countries. Its increasing influence 
in the third world countries also commendable.
1.2 Need for contrast enhancement
1.2.1 Improving Image Quality of MRI -  Need & Solutions
Plain MRI also has a few disadvantages when compared to contrast-enhanced computed 
tomography. The difficulty in reliably distinguishing the tumours from the surrounds in head 
examinations, difficulty in identify loops of small bowel, thus creating problems in diagnosis 
of lesions in abdominal images are good examples to cite a few. Undoubtedly these short 
comings have prompted the significant amount of effort that has been put up to improve the 
image quality. Since the signal intensity in MRI depends not only on the amount of water in a
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given place, but also on the magnetic relaxation times Ti and T2, the chances are more to
change the resolution of the picture. It is not easy, however, to effect changes in the proton
density of the tissue. Therefore, the ideality of the solution for the problem lies on changing
Ti and T2 relaxivities of water protons in vivo.12
Spin-lattice relaxation time Ti and Spin-Spin relaxation time T2 (see Chapter 4) could
be shortened considerably in the presence of paramagnetic species. While Tj shortening
results in increase in signal intensity, shortening T2 gives the opposite results. The
concentration of the paramagnetic species is inversely proportional to signal intensity. This
could be further interpreted as follows. In the low concentrations, increase in the
concentration of the contrast agent leads to enhanced signal intensity due to Ti. This will
continue until an optimum value for the concentration is achieved. Further increase in
concentration results in decrease in signal intensity due to the effect of T2. It has proved in
clinical practise that less than optimal contrast or negative contrast is achievable. This
phenomenon justifies the more frequent usage of Ti contrast agents than T2 contrast agents.
1.2.2 Need for contrast enhancement- Brief History
Contrast agents have been used in diagnostic radiology since 1905 when Voelcker and Von
I 'XLichtenberg used colloidal silver for retrograde pyelography. Radio opaque iodinated 
contrast agents are in widespread clinical use and for each new imaging modality; radiologists 
have sought potential contrast agents.14"35 With some modalities contrast agents have brought 
major advances and are in everyday clinical use, for example X-ray computed tomography,’ 
whereas in ultrasound, contrast agents have failed to make an impact.
Following is a brief description of the history of contrast agents used in variety of modalities 
MRI, PET, PET /CT, PET /MRI with the attention mostly focused upon MRI and PET /MRI 
contrast agents.
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1.3 Image Enhancement through MRI Contrast Agents.
Contrast
Agents
StructuralFunctional
L A c y c lic  > M a c ro c y c lic
Non-Specific
pH. pC>2, Ca“ , Zn‘+,Cu enzyme sensitive, radical
^ncentmtion^
Figure 1:- Schematic representation of the types of modern contrast agents
Initial investigations leading on to the new area of contrast agents are being described here.
The fact that ferric nitrate (a paramagnetic salt) could be utilised in enhancing the relaxation 
rate of water protons was first described by Bloch et al.36 Well acknowledged theory related 
to solvent nuclear relaxation rate in the presence of paramagnetic chelates was first developed 
by Bloembergen, Solomon, Eisinger, Schulman, and Blumberg. They have demonstrated that 
binding of a paramagnetic metal ion to a macromolecule, (in their case DNA), enhances the 
water proton relaxation efficiency via lengthening of the rotational correlation time.37'39 
This phenomenon, which came to be known as proton relaxation enhancement (PRE), has 
been utilised extensively to study hydration and structure of metalloenzymes.40
The pioneering 1973 work of Lauterbur et a l41 towards imaging with NMR were 
extended to human imaging in 1977. Lauterbur, Mendoca-Dias, and Rudin were first to 
demonstrate the ability of paramagnetic chelates in the identification of tissues, this was
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postulated on the basis of different water proton relaxation times. They have investigated a
salt of manganese (II), a cation, which was known to be concentrated in normal myocardial
tissue when compared to infarcted regions, was injected into dogs with an occluded coronary
artery. The spin-lattice relaxation rates (1/Ti) of tissue samples correlated with Mn (II)
concentration and it were established that, normal myocardium possibly be distinguished from
the infarcted zone by relaxation behaviour alone.
Subsequently, Brady and Goldman confirmed the capability of using the paramagnetic 
agents in imaging studies, where they have treated excised dog hearts in a similar fashion. 
The experiment showed that signal intensity of the normal myocardium containing Mn (II) is 
better than infarcted regions on NMR images. In fact there was no contrast was observed in 
the absence of Mn (II). Young et al.42 in 1981, had performed first ever NMR imaging study 
on humans. The experiment involved a paramagnetic agent. The enhanced images of the 
gastrointestinal tract were obtained through ferric chloride (an oral contrast agent).
After three years, the first ever demonstration of diagnostic potential of paramagnetic
A“X A Aagents was pronounced by Carr et al. In 1985, Burnett et al described the use of Gd2(>3 
particles as a prototype MR contrast agent shown to reduce liver and spleen Ti by 50% at 
relatively low doses. Due to toxicity issues, however, it was also dropped in to low profile.
The prominent problem with paramagnetic naked heavy metal ions is their toxicity. 
Investigation has directed on the development of stable paramagnetic ion complexes. Both the 
metal ion and the ligand usually exhibit substantial toxicity in the unbound state. Together, 
however, they may create a thermodynamically and kinetically stable compound which is 
much less toxic.
Complexation of the metal ion with an organic ligand, while considerably decreasing 
toxicity, may alter paramagnetic properties of the metal. Cr-EDTA complex was the first of 
such agent attempted, however constraints with synthesis and long-term stability prevented its 
clinical application (see Chapter 2). After which comes the famous Gd (III) 
diethylenetriaminepentaacetate [Gd(DTPA) (H2O)]2’ it was administered intravenously to
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patients with cerebral tumours, providing enhancement of the lesion in the region of cerebral
capillary breakdown. Gd(DTPA)2'complex, a renally excreted chelate with a very high
formation constant (Table-1), had sufficiently favourable properties to be approved by Food
and Drug Administration of USA for use in cranial disease diagnostics in mid-1988.
Thereafter Bayer.Plc took its commercial production and brought out the brand name
‘Magnevist’.
S tability  c o n s ta n t of Gd-DTPA: 1023
Half-life in  u rine  21 .0  m in  a fte r in travenous injection
in  blood
Table 1:
19.6 m in
Compound LD50(with intravenous dose in rats)
Gd-DTPA 10.0
Gd-EDTA 0.3
Gd-Cl3 0.4
Meglucamine diatrizoate 
(Common X-ray contrast agent) 18.0
1.3.1 Lanthanide metal ions in contrast agents
Although some iron-and manganese-containing materials are commercially important, the 
predominant contrast agents in commercial use today is still the “ Magnevist” and its DOTA 
analogue “ Dotarem”. The interesting story of Magnevist is reserved for Chapter 3.
“ Dotarem” are comprised of a Gd (III) ion within chelating ligands based on a 
polyaminocarboxylate motif (linear DTPA and cyclic DOTA respectively) .45 As acyclic poly 
amino carboxylates are being dealt in detail in Chapter 2, we shall focus the attention mostly 
towards cyclic poly amino carboxylates in this section.
The tetra-aza cycle of DOTA is capable to adopt its most stable conformation. Thus DOTA 
forms highly stable lanthanide chelates. The solid state X-ray structure of Gd(DOTA)' 
indicates that the Gd (III) situated in the centre of a capped square anti prismatic cage, with 
the water molecule in an axial position.46 When in solution, it exists as a pair of 
interchangeable isomers; the major square anti prismatic and the minor twisted square anti
Anprismatic (see Fig-2).
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Figure 2:- Gd (III) complex of DOTA47
1.3.1.1 Gadolinium (III) complexes
As Chapter 3, describes in detail Gd (III) and its chelate’s unique properties, this section will 
be looking at its application possibilities as targeted contrast agents.
Targeted contrast agents contribute an additional layer of molecular specificity to the 
richness of anatomical and functional information already attainable by MRI. The major 
challenge, however, for molecular MR imaging is sensitivity: micro molar concentrations of 
Gd (III) are required to cause a detectable signal change, which makes detecting proteins by 
MRI a challenge. Most of the gadolinium chelates are bifunctional molecules comprising a 
protein-targeting moiety and typically one or more gadolinium chelates for detection by MRI.
Relaxivity of contrast agent depends on protein binding itself. As in other imaging 
modalities, binding with proteins enables the contrast agent to be concentrated at region of 
interest. This process is carried out through the facilitation of the relevant pharmacodynamic 
effects. One of the notable pharmacodynamic effects is the increasing the relaxivity of the 
contrast agent. This in turn will increase MR signal.48 In designing new agents, optimization 
of both the targeting function and the relaxivity is crucial. In the past, there were many acyclic 
and cyclic and macrocyclic chelates of Gadolinium that had been tested and verified for this 
purpose (See Fig-4).
MS-325 is one such agent. It has been approved as serum-albumin-targeted contrast 
agent. This was specifically designed for blood vessel imaging. In MS-325, the 
Gd(DTPA)(H20) ligand core (DTPA) had been modified to attach a biphenylcyclohexyl
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moiety via a phosphodiester linkage.49 This amphiphilic complex targets serum albumin: the
most abundant blood plasma protein.
■°'V/ -i-.J X
[od( 1IP-D03 A)(H^Ojj 
q= 1
..:-:Gd=- . - - - :G d = -
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q= 1
[Gd(E0B-DTPAXH20|" 
q= 1
[g <x b o pt a x h ,c>! 
q= 1
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O
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[GdtUKH^O):]2" 
q = 2
Figure 4:- Some functionalised Gd Chelates48, q:- Number of water molecules in the inner coordination
sphere of the complex (Hydration number)
The complexes, whose participation in in vivo transmetallation reactions, much slower than 
renal excretion rates, will have significant increase in their toxicities (compared to prediction 
based on thermodynamics). In short, the delay in clearance of any Gd (III) complexes will 
result in significant increase in toxicity. The following Fig-5 shows other ligands often used 
in gadolinium studies.
O'
HO. ,OH
Figure 5:- A representation of the Chelates typically used for Gd complexation
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Gd (III) has been shown to inhibit Ca (II) binding to mammalian cardiac sarcoplasmic
reticulum. The mechanism of toxicity could involve hemodynamic disruption. An example50
of two another perspective ligands is shown on Figure 6.
■OH
HO HO
HOOH
0:
HO OH
Figure 6:- Cyclic and Acyclic Chelating agents some more examples 
Gadolinium Chelates -  Pros and Cons
Potential improvement also lies in the idea of covalently coupling the ligand to protein to 
generate tissue-specific contrast agents.51 Understandably, search for new potential ligands for 
Gd (III) complexation is still a hot area of investigation. Gd-DTPA ' (also known as 
“ Gado” among medics) now serves as a bench mark for new contrast agents that are being 
synthesized and evaluated. The criteria include thermodynamic stability, rates of excretion, 
toxicity, lipophilicity, bio distribution and percent change in MR signal intensity. Some of the 
complexes are slightly better than Gd-DTPA in particular tests, others are a little worse. 
Neither of them, however, has received much attention as Gd-DTPA itself.52
This complex is by far not the best choice as of today, but it is relatively well-known 
choice, widely used in many MRI facilities on a daily basis. Accumulated experience paves 
the way forward to offset the shortcomings of Gd-DTPA2' in many cases. Therefore the agent 
continues to play indispensable role in modem MR imaging.
1.3.1.2 Comparison of Acyclic and Macrocyclic complexes of Gadolinium
There are six clinically approved contrast agents used worldwide for intravenous 
administration. Among them, four are gadolinium based with a polyaminocarboxylate ligand 
forming highly stable complexes.
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The other two are mangafodipir trisodium.53 (also known as Teslascan) and ferumoxides54,55
which are super paramagnetic iron oxide nanoparticles often coated with dextrans.
The anionic complexes of Gd(DTPA)2’ (Magnevist) and Gd(DOTA)' (Dotarem) were
the first complexes used in clinical practice. The Gd(DTPA-BMA) (Omniscan) and
Gd(HPD03A) (Prohance) are neutral compounds based on the structures of the anionic
complexes. Gd(DTPA)2" forms a stable octa dentate, similarly to Gd(DOTA)', but their
formation is very different. Preparation of DTPA is relatively easier than preparation of
DOTA, further DOTA requires the synthesis of 1, 4, 7, 10-tetra-azacyclododecane, which is
time consuming.56 The DTPA ligand forms stable chelates based on a distorted tricapped
trigonal prism with the three nitrogens, five carboxylic oxygens, and the necessary water
sn #
molecule coordinating to the gadolinium centre. Lanthanide chelates produced with DOTA 
exhibits excellent stability, owing to its tetra-aza cycle, which could adapt the most stable 
confirmation. Through the X-ray crystallography of Gd(DOTA)‘, it was evident that Gd (III) 
is situated in the centre of a capped square antiprismatic cage, while the water molecule
M l
occupies the axial position. In solution, however, it exists as a pair of interchangeable 
isomers; the major square antiprismatic and the minor twisted square anti prismatic.
Thermodynamically stable, neutral gadolinium complexes are formed with DTPA-BMA
c o
and HP-D03A complexes. Kinetically stronger complexes are formed with HP-D03A.
It is because of its rigid ring structure of the macrocycle (minimum five coordination sites 
need to break down simultaneously), which prevents release of the metal. In the case of 
DTPA-BMA, however, sequential breaking of the coordination sites could be seen.59,60
These first generation contrast agents are very useful, and have accounted for the rise in 
MRI scans being used in diagnosis. They distribute mainly into the intravascular and 
interstitial space, and although they are deemed to be nonspecific, they can accumulate within 
the kidneys due to glomerular filtration.61 The next generation of contrast agents are designed 
to be more specific and more efficient, with remarkably very high relaxivity,62 higher 
thermodynamic stability and a more favourable rate of excretion. As will be seen in some
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examples discussed later, this can be achieved by attaching the contrast agent to larger
structures such as dendrimers63 or micelles.64 In efficiency terms, the new reagents are
usually compared to the DOTA and DTPA complexes due to their prior clinical approval.65,66
There were other elements in lanthanide series of the periodic table that were also considered
to produce contrast agents.
Table 2: Physiochemical characteristics of commercially available, extra cellular, predominantly renally 
excreted gadolinium-based commercially available MR contrast agents-Safety Profile67 ___________
Characteristics
Magnevist 
gadopentetate 
dimegl umine
Dotarem
gadoterate
meglumine
Prohance
gadoteridol
Omniscan
gadodiamide
Multihance
gadobenate
dimeglumine
Gadovist
Gadobutrol
Optimark
gadoversetamide
(0.5 mol/L) (0.5 mol/L) (0.5 mol/L) (0.5 mol/L) (0.5 mol/L) (1.0 mol/L) (0.5 mol/L)
Molecular Structure Linear,ionic Cyclic, ionic
Cyclic, 
non ionic
Linear, 
non ionic
Linear,
ionic
Cyclic, 
non ionic
Linear, 
non ionic
Thermodynamic 
Stability Constant 
dog K*,)
22.1 25.8 23.8 16.9 22.6 21.8 16.6
Conditional Stability 
Constant 
at pH 7.4
18.1 18.8 17.1 14.9 18.4 15.0
Acid dissociation 
rate (kfabsK1) 1.2 xlO'3 2.1 x 10'5 6.3 x 10'5 > 2 x 10'2
Osmolality
(Osm/Kg) 1.96 1.35 0.63 0.65 1.97 1.6 1.11
Viscosity 
(mPa at37°C) 2.9 2.0 1.3 1.4 5.3 4.96 2.0
Ti relaxivity 
(L/mmol s'1) 1.5 T, 
plasma
4.1 3.6 4.1 4.3 8.3 4.7 4.7
Ti relaxivity 
(L/mmol s ' ! ) 3.0  T, 
plasma
3.7 3.5 3.7 4.0 6.2 3.6 4.5
Metal Chelate 
(mg/ml) 469 278.3 279.3 287 334 605 330.9
Excess Chelate 
(mg/ml) 0.4 0 0.23 12 0 0.5 28.4
1.3.13 Dysprosium Complexes as MRI contrast agents
Dysprosium (III) is one such lanthanide ion that has been used in MRI. It has been classified 
as negative contrast agent. As the clinical MRI is moving towards the utilisation of higher 
magnetic fields, where the commercial contrast agents based on Gd (III) shows poor 
relaxation times. One way of overcoming this shortcoming is the increasing attention on 
dysprosium-based complexes, due to their relatively slow water exchange rates. Thereby 
these complexes increase the residence time thus having an impact on optimising the t2 
relaxivity. Also dysprosium-based complexes, owing to their high magnetic susceptibility, 
which creates local field gradients resulting in lowering of T2.68
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The magnetic field dependence of 1/Ti and 1/T2 of solvent protons in water has been
examined in numerous accounts using some Dy (III) analogues of clinically used Gd (III)
. 68-70agents.
In essence, dysprosium complexes in which the water molecules have a long mean
water residence time hold the potential application as negative contrast agents at high
magnetic fields due to their efficient transverse relaxivity.
Muller et al. have demonstrated, via Dy(DOTA)", that lengthening the residence time of
•  •  •water can actually be detrimental, because the transverse relaxivity can then be limiting. 
Experiments have shown that the transverse relaxivity of complexes with fast exchange of
• 72water protons increases with the square of the magnetic field and the residence tune ( im ) .
At high magnetic fields, mean water residence time, which is greater than 1 ms imposes 
limitations on the relaxivity for dysprosium complexes, whereas mean water residence times, 
greater than 100 ns imposes limitations on the relaxivity at both high and low magnetic fields. 
Therefore, optimisation of mean water residence time (in between 0.1 and 1 ms) will result in 
obtaining r2, at the required high magnetic fields. Therefore it can be concluded that structural 
design of a molecule is inevitable to optimising r2, due to its balancing factors required. 
Further fine tuning of these mean water residence times and thereby the relaxivities, may
71result in promising contrast agents, which can be of use in high field MRI.
The use of Dysprosium (III) compounds as negative contrast agents is still fairly new, 
and it will be interesting to look at their development over the next decade. On the other hand, 
analogues of Eu (II) which are isoelectronic to Gd (III) had been proposed as alternative to Gd 
(III) chelates. Further, it was thought to be a good choice as a spectroscopic probe for Ca (II). 
It is because its ionic radius lies between those of Ca (II) and Sr (II) (i.e. 125 pm Vs 112 and 
126 pm). Moreover its chemical properties are similar to those of the alkaline earth metal 
ion Merbach et al ’ investigated the water exchange kinetics and electronic relaxation of 
the following Eu (II) complexes: [Eu(DTPA)(H2 0 )]3\  [Eu(ODDM)]2' and
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[Eu(ODDAXH2O)], ligands in the latter two complexes are ODDMH4 and ODDAH2
respectively
r o  O--------y ------------------------------------------------------- 1-------o  o -> COOH HOOC (Lj  \_s) N-------------------------------N-------(  '---- “ N N-
HOOC /  f  COOH (  )  COOH
w  w
h 4o d d m  h 2o d d a
Figure 7:- Cyclic ligands as chelates for Eu
1.3.2 Metalloporphyrins of Iron (III) and Manganese (III)
Porphyrins have been known for decades as indicators of various metabolic disorders and 
disease states.76, 77 They are used in photodynamic therapy of tumors,78 the low toxicity of 
metalloporphyrins and their selective retention in tumours has led recently to their study as 
MRI contrast agents.79-81
Theoretical treatment of relaxivity of some of the metalloporphyrins is relatively new 
area of development. Metalloporphyrins of Mn (III) and Fe (III), however, show favourable 
properties as MRI contrast agents for tumour detection. They are strongly influencing MRI 
contrast agent research and should lead to interesting discoveries in the near future.
1.3.3 Native Proteins Acting as Contrast Agents
Heme-containing proteins could be considered as "natural” contrast agents, similar to 
previously discussed iron (III) porphyrins. Hematomas are easily identified by MRI. 
Paramagnetic deoxyheamoglobin within intact blood cells causes a local region of high 
magnetic field. This results in rapid dephasing of water protons diffusing in the region of 
acute hematoma with shortening of T2, which results in low signal.
A similar observation was made when magnetically susceptible ferritin is deposited in 
macrophages in hemochromatosis. Even though, these are not site specific contrast agents, 
they could be put to successful use in certain diagnostics.
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1.3.4 Gastrointestinal Contrast Agents
So far, the only clinically approved agents employed in gastrointestinal imaging are soluble
2 r .iron compounds (Ferrous gluconate, ferric ammonium citrate) and Gd(DTPA) There is a 
shortcoming with dosage of iron salts, which may not exceed the levels above those, when 
iron supplementation is used. The usage of iron oxide nano particles as oral contrast agent is 
yet to be discovered.
1.3.5 Stable nitroxide Radicals as MRI contrast agents
R
Figure 8:- Stable Nitroxide Radical 
Radicals generally cause damage to the living tissues, the cyclic nitroxides, however, are a
diverse range of stable free radicals that have unique antioxidant properties. It is because of
their ability to interact with free radicals they had been used as biophysical tools for many
years.
Protection against radiation-induced radicals, cell signalling, functional imaging, 
chemoprevention and anticancer activity are a few of the numerous applications of these 
nitroxide radicals. Recently with the advent of EPR imaging (a concept which will be dealt in 
detail in the later sections), there was a new dimension of its usage had emerged.
In order to utilize nitroxides as MRI contrast agents, their reduction in a variety of 
normal tissues must be documented. The distribution and reduction of the nitroxides Tempol, 
3CP,and carboxy-Proxyl were examined in MRI experiments84.
Using MRI, it was possible to monitor the distribution and reduction of all three 
nitroxides. The reduction rates in normal tissue and tumour were calculated from these 
experiments.
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Oxammonium Cation
Nitroxide radical
Hydroxylamine
Figure 9:- A typical in vivo equilibria of the nitroxide compounds between the 
EPR detectable form (Nitroxide radicals) and that of EPR-non 
detectable form (hydroxylamine)
Even though, the parmagnetic effect of oxygen has been proved, its introduction as contrast 
agents is far from trivial.
1.3.6 Super Paramagnetic Iron oxide Particles (IO)
This is a relatively new type of contrast agents, which is advancing rapidly in the contrast 
agent research. They are made out of nonstoichiometric microcrystalline magnetite cores, on 
to which dextranes or siloxanes are coated. These colloids are now widely used in the
Off Oi'
pharmaceutical development, especially as tissue -specific contrast agents. ’
Use of these colloids as tissue-specific contrast agents is now a well-established area of 
pharmaceutical development.85,86 Today, by injecting iron oxide based nano particles as MRI 
contrast agents, it is possible to study lymphatic system and some specific tumours and their
87metastasis.
In particular, the type of surface coating, and the coating characteristics of nano particles 
are significant factors for the biological properties of nano particles and their destination 
target. Dextran coated iron oxides have been used for a long time.
They have been shown to decrease signal intensity in brain to mural regions on T2 weighted 
images. Comparative evaluation of IO particles coated with Starch and Dextran was also 
carried out in the past.88
In an alternative comparative study, effect of different amine and hydroxyl groups on 
the surface was evaluated in rat liver.89 Surface modification of super paramagnetic nano
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particles using different coating materials was also investigated by other workers for in vivo
bio-medical applications and MR imaging, surface modification of superparamagentic nano
particles using different coating materials were also attempted.90 Uptake of anionic 10
particles (AMNP) was also shown.91
The light absorption ability is considerably high. The characteristic magnetic hysteresis 
observed in most of the super paramagnetic materials is not to be seen.
Utilisation of Mossbauer spectra, experimentally proved that there is no covalent bonding 
between the ion surface and that of coated dextran.92,93
Apart from Mossbauer Spectroscopy there was and still is much interest in studying 
these non stoichiometric compounds with all the other vast array of modem physical-chemical 
methods: single crystal X-ray diffraction, powder X-ray diffraction, transmission electron 
microscopy, dynamic light scattering, atomic absorption spectroscopy, spectrophotometry, 
electron microscopy, superconducting quantum interference devices etc.92,94
The compositions and physiochemical properties of nonstoichiometric magnetites are 
continuously variable between those of Fe3C>4 and Fe2C>3.
Conceptually, these cation-deficient, inverse-spine phases are formed by partial oxidation of 
Fe (II) in stoichiometric magnetite. The Fe (II) content is typically 8-15 mol%. The lattice 
parameters of these colloids also fall between those of Fe3C>4 and Fe2C>3.
Versatility of SPIO compounds, owing to their fine tunable properties for specific 
applications, put them as promising contrast agents. Furthermore, their toxicity levels are low 
and that it could be cleared from the organism rapidly. Site specific experiments (receptor- 
specific) SPIO delivery has been proved to be successful. Feridex I.V™, Endorem™, Gastro 
mark™, Lumirem™, Sinerem™ and much more are on the waiting list to be patented.
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1.4 Latest developments & Modifications in Contrast 
Agents.
It is imperative to design systems with enhanced relaxivity, responsiveness and specific 
targeting abilities, to combat the challenges faced by molecular imaging.
1.4.1 Smart Contrast Agents
This is one of the rapidly advancing areas in MRI contrast agent research, where design and 
utilisation of “ smart” contrast agents are on the rise. These are also known as responsive 
contrast agents. It is because their relaxivity is susceptible to changes in physiological 
surroundings. These changes could be in terms of pH, partial pressure of oxygen (this was 
well noted in Eu (n)/Eu (m) redox pairs) metal ion con concentration or enzyme activity. There 
are several reviews published on this important area of MRI research. For instance, review
A£
pulished by Lowe et al in 2002 was a commendable one. It will be appropriate however, to 
look in to some important advancement in the area. Lowe95 mentions that, the drive behind 
this area of smart contrast agents is supported by the fact that healthy tissue has a pH of 7.4, 
whereas tumour tissue is more acidic (6 .8). This could be utilised to produce contrast agents 
that can be used to map tumours. Fullerene based, pH responsive contrast agents have been 
published by Toth et al . In this agent, metallo fullerenes encapsulate metal ions in to their 
interior space. This has paved the way for potential medicinal applications as the fullerene 
cage protects the metal ion from being released in to the body. This in turn potentially 
increases the mean water residence time in vivoT  In fact Toth et al.96 were not the first to 
bring up the idea of introducing gadofullerene derivatives as MRI agents.98, 99 The general 
trend is that the values are high side, (up to 81 mM~’s"1), but also very varied.
The availability of water-soluble gadofullerenes however, enabled further developments 
in this area, even though initially the relaxivities of these compounds was on lower side (when 
compared to commercial contrast agents). Therefore, Toth et al have attempted to understand 
the underlying mechanism for relaxivity in these compounds. They have synthesized fully 
characterised water soluble gadofullerene derivatives GdC6o(OH)x and GdC6o[C(COOH)2].
23
Potential Multimodal Imaging Agents 
The measured relaxivities GdC6o(OH)x were approximately ten times those of the commercial
contrast agents. The high field maxima were discovered to be at approximately 40 MHz and
the relaxivities were measured at 60 MHz as a function of pH.
They have discovered that with the decrease of pH, the relaxivities increased for 
compounds GdC6o(OH)x and GdC6o[C(COOH)2] by a factor 2.6 and 3.8 respectively. This 
could be explained in terms of proton exchange rate influenced by pH and also the 
temperature. Temperature effect was evident from the studies of static and dynamic light 
scattering (SLS and DLS) which showed aggregation. This in turn will affect the tumbling 
rate thereby the proton relaxivity.
These contrast agents were subsequently used for more specific biological applications, 
such as to track DNA delivery to specific cells, detect gene expression, and to monitor the 
changes in the activity of enzymes beyond their value in basic research; all of these 
procedures have potential applications in clinical work in the area of gene therapy, etc.
In theory, the relaxivity of these designer switchable contrast agents can tailor made to 
be conditionally dependent on certain variables like enzymatic activities, signalling 
messenger, calcium ion concentration, ion channel functions, receptors systems, degree of 
glycation of proteins, temperature, pH, pC>2, gene expression and molecular recognition 
involved.
1.4.2 pH-activated Contrast Agents
This is one of most important factor in designing SCAs. While the extracellular pH is 
maintained slightly basic, the opposite scenario could be observed in tumour tissues. On the 
other hand, intracellular pH for both normal and tumour cells remain the same.
This was attributed to homeostatic mechanism. Stimulating MRI contrast agents by pH 
variation seems to be a promising way to high light tumours. Comparatively, an increase in 
the glycolytic activity could result in pH decrease in the intracellular region of tumours than 
its surrounding healthy tissues. This also forms the basis for pH related MRI contrast agents.
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1.4.3 Metal ion Concentration Activated Contrast Agents
Sufficient concentration of metal ions (eg calcium, magnesium, iron, copper etc.) is vital to 
healthy living. Their deficiency may result in serious diseases. Therefore, monitoring their 
distribution in vivo, is highly desirable. Thus, several potential SCAs are being developed, 
which are sensitive to concentration variation of metal ions.
1.4.4 Enzyme-activated Contrast Agents
These agents potentially provide means for measuring enzyme activity and also their 
localization. The sensitivity of these agents depends upon their interaction with specific 
enzymes. If the interaction is sufficiently strong to increase the rotational correlation time of 
adducts, significantly higher relaxivities could be observed. Li et al. reported the first such 
contrast agent based on macrocylic ligands.
1.4.5 Site specific Agents
MRI contrast media contributes to diagnostic imaging through its biophysical dimension. That 
has resulted upon the introduction of this novel type of contrast agent. These agents are also 
known as targeted relaxation enhancement agent (TREE) or a site specific agent (as it is 
commonly known).
The major advantage of these agents is that, their response will depend not on only on
cellular or organ uptake (mass transfer events -  as governing CT or scintigraphic images) but
also on the fraction of the agent bound to macro molecules at any given time in the tissue of 
100interest. As shown m Fig-18, intelligent use of this binding-enhancement effect can 
considerably increase target-to-nontarget ratios in terms of relaxation rate changes.
In essence, the relaxation enhancement effect is designed to work synergistically with optimal 
bio distribution properties, permitting the highest contrast on the MRI image with the lowest 
possible dose of contrast media.
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Normal Uptake 
Non-target tissue Target tissue
Target: Non Target ratio interms of 
Concentration 1/Ti changes
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Targetted Relaxation Enhancement 
Non-target tissue Target tissue
Figure 10:-. The enhancement of MRI contrasts with targeted relaxation agents. The binding of a fraction 
of the agent molecules (triangles) to target macromolecules can increase relaxivity and tissue contrasts 
above that possible with "normal” uptake processes. The increase in the 1 ITy target: nontarget ratio is 
calculated based on the assumption that relaxivities increase by 2- to 10-fold upon binding.100
The blood pool contrast agents in present use are not specific to a type of tissue. They 
however, preferably distributed within the blood stream, owing to their hypophilicity.101 Since 
it is a rapidly advancing area, it is worthy to mention a few examples which could indicate the 
versatility of these contrat agents. DOTA analogues are extensively used in MRI derivatives 
of this basic cyclen macrocycle, such as phosphonate esters,102 and methylene 
phosphonates. ~ are of interest as well. In fact, it was proposed by Luke et al. that 
bisphosphonate monoamide analogue of DOTA could be utilised as potential bone imaging 
contrast agent. Nearly two decades, geminal bisphonates have been in usage for treatment of 
bone diseases.106 due to their high attraction for the bone surface.107 The presence of 
phosphorus acid moieties on cyclen macrocycles has been shown to lead to faster water 
exchange.
The optimal application of the TREE concept will involve reversible, non covalent 
binding of the metal chelate to the target protein or macromolecule of interest. The 
importance of this is largely toxicological: the unbound chelate molecules in equilibrium with 
the bound will be continuously excreted from the body by normal (and presumably safe) 
pathways such as the renal and hepatobiliary routes.
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An alternative approach to take advantage of the binding-enhancement effect is to covalently
attach chelates to macromolecules prior to injection. These conjugates, however, must be
degraded in the body, potentially releasing toxic metal ions and other metabolites.
An optimal candidate for a TREE agent would be a kinetically inert gadolinium (III) 
chelate with one or two open coordination sites for water. Though outer sphere relaxation 
contributions are appreciable,108 the inner sphere relaxivity enhancement upon binding to a 
target protein would be expected to be considerably larger. Two early applications of the 
TREE concept to practical agents for MRI involve the targeting of the blood pool (by binding 
to human serum albumin) and the hepatocytes of the liver (by binding to certain cytosolic 
proteins). Gadolinium( 111) chelates suitable for these applications have been patented109'110
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Figure 11: Distribution sites and excretion pathways for intravenously 
administered soluble metal complexes
Other Contrast Agents
Other than these paramagnetic agents mentioned so far, there are other materials and methods 
that could also act as MRI contrast agents. These agents are quite similar to one used in X-ray 
methods. One recent example is the utilisation of vegetable oils for rectal imaging through 
MRI."1-1,2
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1.5 Emerging Trends in Imaging Technology
Apart from the Bio-Medical Imaging techniques, it is worth mentioning its various advanced 
dimensions. In this ‘Era of Information’, advancement of technology to unimaginable heights 
is frequently encountered and the imaging science is no exception to this.
We shall now direct our attention to more advanced facets of imaging technology within the 
context of chemistry.
1.5.1 EPR (Electron Paramagnetic Resonance)
An extension of this MRI is the use of techniques previously reserved for the laboratory such 
as EPR imaging, which detects unpaired electrons in such species as transition metal 
complexes and free radicals.113"115
The availability of unpaired electrons in normal, biological tissues is scarce to an extent that 
any EPR signal could be detected. This was initially considered to be a limitation to the 
utilisation of EPR signals for bio-medical imaging.
It was rapidly realised that agents containing free electrons or compounds converted to 
such agents in-vivo could be introduced into a living system and detected. The detection is 
possible in terms of frequencies similar to those used in MRI. llsAfter their administration in- 
vivo, nitroxide compounds are found in an equilibrium between the nitroxide radical form, 
which is detected by EPR, and the reduced hydroxylamine form, which is not detected by 
EPR because of its diamagnetic nature.116 It is because cellular redox processes convert the 
compound.
1.5.2 Optical Imaging (Optical Tomography)
There are techniques having an optical basis (such as bio luminescence, fluorescence), are 
rising as powerful alternative imaging modalities. Their contribution especially, to molecular 
imaging in disease and therapy becoming more commendable in recent times. This was 
achieved through the combination of innovative molecular biology and innovative chemistry.
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The researchers have recently developed optical methods, which are capable of imaging a
range of cellular and molecular processes in- vivo (protein interaction, degradation of proteins
and activity of protease enzymes to name a few). Although optical imaging was introduced
•  •  117initially for researching small animals, its scope has been extended to clinical medicme.
The in vivo fluorescence and bioluminescence imaging have enacted a vital role of 
interrogating biological systems, especially in rodent models for human diseases. Through the 
utilisation of integrated light distributions that are being emitted from the surface of the 
animal, most of the systems to date produce 2-D images only. This will in turn severely 
compromise the ability to quantify and also localizing the signals accurately, which is 
attributed to their strong dependence on optical properties of the tissue on depth. This has a 
significant impact on.
There is great interest in extending the in-vivo fluorescence and bioluminescence 
imaging modalities to the reconstruction of volumetric images that accurately localize signals 
and enable quantitative studies of fluorescent contrast agents and proteins. This is significant, 
as potentially higher temporal and spatial resolution than competing modalities like PET can 
be achieved at a considerably low cost.
In fluorescence imaging, an external light of appropriate wavelength is used to excite a 
target fluorescent molecule, followed almost immediately by release of longer-wavelength, 
lower-energy light for imaging. Targets for fluorescence imaging may be endogenous 
molecules (such as collagen or haemoglobin), fluorescent proteins (green fluorescent protein 
[GFP] and related molecules), or optical contrast agents with fluorescent molecules.
Although each of these sources of fluorescence can be used for cellular and molecular 
imaging in small-animal models, optical contrast agents have the potential to extend from 
preclinical research to patient care.
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1.5.3 Overcoming Challenges with NIRF Imaging Agents
The most pressing challenge faced by optical imaging probes and instrumentation, targeted 
toward eventual clinical applications, is overcoming attenuation and scattering of light by 
tissues. For light in the visible spectrum, absorption by haemoglobin and other molecules may 
decrease optical signals by approximately 10-fold per centimetre of tissue. Therefore to image 
fluorescence in deeper tissues, investigators have devised strategies for imaging near-infrared 
fluorescence (NIRF) with emission wavelengths between 650 and 900 nm.
Further, within these wavelengths, absorption of light by haemoglobin, lipids, and 
water is lowest, and a dramatic reduction in the tissue auto fluorescence also observed. As a 
result, the sensitivity of NIRF imaging agents is greatly enhanced, potentially enhancing the 
chances of tomographic optical imaging signals to be detected at depths of 7-14 cm.
1.5.4 Functional Imaging
This is an area of Medical Imaging and which is also an extension of MRI technique. In the 
horizons it is expected to revolutionize the whole area. For more than 20 years, magnetic 
resonance imaging (MRI) has been an important tool for studying the brain. Application of 
MRI to problems in neuroscience blossomed in the early 1990s with the development of 
functional MRI (fMRI) methods to map spatio temporal patterns of brain activity in human
• 11JL17Asubjects. The basis of most current fMRI experiments in humans and animals is the 
blood oxygen-level dependence (BOLD) effect,121’ 123 a combination of changes in local blood 
oxygenation, flow and volume that in healthy individuals are reflexively triggered by elevated 
neural activity. It is because, hemodynamic changes can be monitored directly by MRI, the 
BOLD effect offers a non-invasive, although indirect, readout of regional brain activity. 
Temporal characteristics of the BOLD effect were established by correlating defined patterns 
of sensory stimulation with time series of evoked fMRI signal changes118
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CHAPTER 2
EDTA Based Derivatives
2.1 Introduction to EDTA based derivatives
2.1.1 EDTA
EDTA is a hexadentate ligand, where the ethylene diamine backbone has been modified by 
four carboxy methyl groups and has been classified as a 'complexone’. Complexones by 
definition are aminopoly carboxylic acids, in which several carboxy alkyl groups bind to one 
or more nitrogen atoms. As a result, coordination of a single metal ion establishes several 
chelate rings. The practical value of EDTA lies in its ability to form stable, water-soluble 
complexes with many metal ions. In 1946, Schwarzenbach utilised this property to determine 
hardness of water. Since then it has found application in areas such as biology, 
phytochemistry,1 sequestration of metal ions,2 extraction and separation of metals3 to name a 
few.
OH HO
N N
HO— 6 h— OH
O O
Figure I:- Ethylene Diamine Tetra acetic Acid (EDTAH4)
2.1.2 Detoxification of Metal Ions
Studies investigating the chelating ability of EDTA to detoxify (removal of toxic substances) 
metal ions was initiated as early as 1950s,4 though these studies were not directed towards 
synthesizing a contrast agent. With regard to MRI contrast agents, however, a key question is 
if the ligand can ‘detoxify’ the ubiquitous Gd (III) ion.
The literature has an interesting account about this piece of research. 1 [Gd-EDTA]' 
(which has LD5o, 0.3 mmol/kg in rats) have been shown to be more toxic than GdCl3
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(which has LD50 0.5 mmol/kg in rats1, because, it is able to labilize gadolinium (log Kstab 17)
for distribution to a wide variety of sites in vivo (mainly skeletal bones). Also, the gadolinium
complex of EDTA has a net charge of -1, and is generally administered as soluble salts
(sodium and N-methylglucamine). Unfortunately, these salts can cause localized disturbances
in osmolality, which in turn, lead to edema and other undesirable effects within the body.
For the above and other reasons, Gd-EDTA and related complexes are generally 
considered too toxic for clinical use. In fact, there is literature evidence which states that 
attempts to coordinate Y3+ with EDTA4" yielded both positive and negative results; that is 
Y[EDTA]" dissociated in vivo1 and it was discovered later on that this complex was an 
excellent reagent for selective delivery of yttrium to bone surfaces.
2.13 Salts of Transition Metals as MRI Contrast Agents and Their Early 
History
“Nephrogenic Systemic Fibrosis”  (NSF) is a fibrotic disorder generally observed in renal 
failure patients. It was recently discovered that some (for eg:- Gadoversetamide) extracellular 
gadolinium based contrast agents (Gd-CAs) trigger the development of NSF.5 As reported by 
FDA in the recent past, the delayed adverse reactions caused by NSF is the worst among the 
other side effects (such as Contrast induced nephropathy (CIN), anaphylactoid reactions) 
created by other Gd-CAs.6 Therefore NSF, prompting the scientists to look for non 
gadolinium based contrast agents. Tracing back the history of contrast agents indicates that 
the pioneering attempts to produce viable contrast agents for MRI, has involved the usage of 
two of the transition metal ions (Mn (II) and Cr (III)).
Among the potential transition metal ions bearing a maximum five unpaired electrons 
((Mn (II), Fe (III), Cr(III), Co (III), Tc (III) and Ru (II) ), three of them have played a 
significant role as potential MRI contrast agents throughout the history. Therefore it is 
essential for the scope of the thesis to have a brief historical outlook on these most potential 
transition metal ions.
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Manganese (II): This transition metal ion has five unpaired electrons and the longest electron
spin relaxation time among the transition elements. In fact the first true MRI contrast
enhancing agent examined in vivo was MnCk- Perhaps because of its abundance in the
pancreas, liver, kidney and heart,1 it was used to demonstrate contrast enhancement of canine
myocardial tissues. Later it was used as a gastrointestinal tract (GIT) imaging agent,
(commercially known as ‘LumenHance’). The utilisation of ‘LumenHance’ as a GIT agent
was possible due to uptake of the paramagnetic manganese ion (Mn (II)) by hepatocytes
(chief functional cells of the liver and liver is a part of GIT). It was found that 30-35% of the
manganese exisisting in the portal vein is being absorbed by the liver, thus contributing to
reduced toxicity. Further it has exhibited good relaxivities. The ri value of the
‘LumenHance’solution (where the major component is MnCL) is 20.9 mM'ls'1 at 10 MHz ,
37 °C and the T2 is 35.0 mM‘1s'1 at 10 MHz , 37 °C.7 Since it has high ri and r2 values, it has
been utilised both as aTi contrast agent (by increasing the signal intensity of the Ti weighted
images as well as a T2 agent (by reducing the signal intensity of T2 weighted images). This
has undergone its Phase III clinical trials in 1999. It was discovered in the clinical trials that
large volumes needs to be consumed, this was a major short coming (In the clinical trials
carried out, it was discovered that 14% of the patients were not able to consume at least
800 ml of the ‘Lumenhance’ solution)
Iron (III): Another transition element which needs to be considered is the ferric ion (Fe3+). 
This high spin d5 ion may also potentially have 5 unpaired electrons and may be of interest on 
the basis of its biological importance. There is a very large volume of literature available on 
the biochemistry of iron. It is also interesting to note, Fe (III) has an ri of 6.8 mM'V1 at 20 
MHz and 37 °C. These factors make it stand as a candidate for potential MRI contrast agent. 
The free Fe (III), however, is toxic (L D 50  0.42 mmol/Kg). Iron poisoning leads to increased 
respiration rate and pulse rates. Also it was found to cause congestion in blood vessels.
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Further, Fe (III) was found to act as a Lewis acid catalyst for the hydrolysis of
phosphates.Therefore, the complete complexation of Fe (III) with potential ligands will lead
to the reduction in toxicity, through the reduction in oxidative cell damage. Moreover, by
eliminating the excess coordination sites, due to coordination, will minimize its Lewis acid
character. Thereby it contributes to the reduction in toxicity.
Therefore investigations for suitable ligand systems were carried out. One such ligand is 
the ammonium citrate, which has afforded Ferric Ammonium Citrate. This is the major 
ingredient in Gerritol and has been considered as oral contrast agent. The rj value discovered 
to be 1.60 mM'V^at 16 MHz). Gerritol, however, came across two shortcomings. Firstly it 
went though inhomogeneous distribution in small bowel. Secondly it contained 12% ethanol, 
which had prevented its use in large volumes. Complexation with N, N’- Ethylenebis-[2-(o- 
hydroxyphenyl) glycine] (EHPG) was also investigated. Fe-EHPG exhibited ri value of 0.9 
mM’Is'1 at 10.70 MHz and 37 °C. Further several derivatives of EHPG also been complexed- 
with Fe (III) towards the investigation as MRI contrast agent. A complex of Fe (III) with 
N,N’-bis (2-hydroxybenzyl)ethylene diamine-N,N’-diacetate (HBED) was also investigated 
as an MRI contrast agent. The ri value obtained was 1.10 m M 'V1 at 10.7 MHz and 37 °C.8
Chromium (HI): The Cr- EDTA complex was prepared by McDonald and Downes by direct 
reaction of chromium (III) chloride with EDTA bisanhydride under aqueous conditions at 
pH 10. The alkaline condition was used as chromium (III) Hydroxide has a low solubility 
product, (Ksp = 10'30), meaning that the amount of free chromium ion is negligible when 
compared to Cr-EDTA, making its contribution to proton relaxation insignificant. Cr-EDTA 
was found to decrease the Ti value significantly (See Table 1). The Cr- EDTA was found to 
be useful in the observation of tissue muscularity, breakdown of the blood -  brain barrier and 
renal function.9
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Table 1: Ti and T2 values of Cr-EDTA complex prepared by Runge et aL9
Variation in Tl and T2 with 
concentration of Cr-EDTA(ste 
vitro at 2.5 MHz
changes in 
rile water, in-
Concentration 
of Cr-EDTA 
(mg/ml)
Ti
(milliseconds)
t2
(milliseconds)
0.016 1,016 ± 3 230 ±70
0.080 941 ± 4 230 ±60
0.400 584 ± 3 190 ± 70
2.000 159 ± 1 120 ± 30
10.000 30 ± 10 40 ±90
Cu (II) Complexes of copper have received little attention as contrast agents for MRI. Cu (II) 
ions have unfavourable electronic relaxation times and have only one unpaired electron, 
therefore they have a significantly lower relaxivity than ions of manganese and iron. In the 
past Cu(II)EDTA was studied by Vymazal et al.10 and had been compared with other 
paramagnetic ion chelates (see Table 2).
Table 2:- Depicting the comparison of relaxivities of paramagnetic chelates 
(Based on transition and lanthanide metal ions) 10
Longitudinal Relaxivity (L.moC.sec1) of chelated 
Paramagnetic Ions at Five different Field Strengths
Chelate
Frequency at 37 °C (MHz)
2.13 10.00 21.29 42.57 63.86
Gd(III)-DTPA 6.2 4.8 3.6 3.2 3.2
Gd(IH)-EDTA 11.7 7.6 6.4 5.2 4.9
Fe (III)-EDTA 2.8 2.1 1.4 ....................
Mn (II)-EDTA 4.2 3.3 •  •  • • • 2.2 2.2
Cu (II)-EDTA 0.4 03 0.2 0.2 0.2
They have reported comparatively low relaxivities. On the other hand, free Cu (II) ion is 
relatively non toxic (i.e. LD50 in mice is 55 mmol kg'1) in comparison with Mn (II) and Fe 
(III) ions (LD50 in mice is 0.3 mmol/Kg in mice and 0.88 mmol/Kg in mice respectively). 
This fact invokes the possibility to use higher concentrations of copper complexes. This in 
turn could help to compensate its low relaxivity.
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Further Cu-EDTA was examined to be a potential contrast agent for MR Microscopy
cartilage in comparison with Cu (II) chloride. It was found however, that interaction with
anionic proteoglycan molecules slows the relative rate of diffusion of Cu (II) ions when
compared with EDTA. This was experimentally proved. The neutralization of the anionic
groups on the proteoglycans by either acid or enzymatic digestion led to a decrease in the
relaxivity of local protons. Cu(EDTA-doped polyacrylamide gels) were spotted with
sulphuric acid, and thereby the change in the relaxivity of the copper (II) solution was
visualised, while the acid diffused throughout the gel (non GD). A series of derivatives of
tetramic acid (TA) were synthesized and then complexed with copper (II) (Cu-TA). The
ability of the Cu-TA derivatives to cross membranes was measured using deflocculated
oocytes cells. The T2 time value for intracellular water of an oocyte is very short and does not
qualify for analysis of the membrane permeation of a contrast agent, whereas the Ti values of
the water signal of the oocytes, are a parameter well suited for this purpose as reported.
Copper clusters formed by the reaction of D-pencil amine with copper (II) chloride had been
attached with antibodies or other biotinylated proteins via linker molecule and been used as
imaging agents.
Cu- EDTA
Finally organic polymers of Cu-EDTA were tested as potential contrast agents. Similarly 
copper complexes of mercaptosuccinic acid and carboxymethylcellulose were tested as 
potential contrast agents. It is worth noting that the relaxivities reported for these contrast 
agents lies on the lower side. For instance, Cu (Il)-mercaptosuccinic acid-dextran conjugate 
exhibited an ri value of 0.6 mM'V1 (at 10 MHz, 37 °C), in a 1: 2.13 glycerol-water solvent 
mixture. Further Cu (Il)-carboxymethylcellulose complex exhibited ri value of 2 mM'V1 
under the same conditions. The relaxation properties of the Glycerol-water solution are 
similar to those of body fluids. Therefore it has been selected instead of water.11
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2.1.4 Mn (II) emerging as the immediate competitor for Gd (111)
Contrary to the Gd (III) (the most widely used MRI contrast agent of choice), manganese is 
an essential trace element present in all mammal cells: this is undoubtedly a major advantage. 
The widespread abundance has facilitated studies on the biochemical significance of Mn (II). 
The biochemistry of manganese is well established. It is essential for glucose and lipid 
metabolism and also plays an important role in oxidative phosphorylation along with a 
number of other important biochemical processes.12
Yet, the manganese ion can cause toxicity when released from the corresponding 
chelates in vivo; this mainly applies when the manganese ion is administered intravascularly, 
as in this case the natural regulation of its adsorption by the intestine fails. Further, the 
chronic exposure to manganese resulted in neurological disorders similar to that of Parkinson 
disease.13 In an actute condition, it could result in hepatic failure,14 sometimes may lead to 
cardiac failure.15
2.1.5 Subsequent research into Mn (II) complexes as MRI CAs
Therefore it is necessary for Mn (II) to be administered as a stable complex, in order to 
prevent any toxicity due to the free metal ion and also improve its elimination from the body. 
There now exisists a significant body of research into the co-ordination chemistry of Mn (II), 
targeted towards identifying new potential contrast agents:
2.1.5.1 Story of Tesla Scan and the challenges faced at the outset 
Investigation with N, ”-dipyridoxylethylenediamine-N, N'-diacetic acid (PLED)
Initially Taliaferro et al}6 have investigated the solution properties of the N,N- 
dipyridoxylethylenediamine-N,N’-diaceticacid (PLED). PLED contains six donor groups as 
does N,N-Bis(hydroxybenzyl)ethylenediamine-N,N-diaceticacid (HBED) and N,N- 
ethylenebis [2-(o-hydroxyphenyl) glycine] (EHPG). With respect to steric effects, however, 
geometries and basicities of the respected ligands, contribute to the variation of the overall 
stabilities of these chelates. For instance, aliphatic nitrogens contribute to reduction in the
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thermodynamic stabilities of HBED and EHPG. This is further justified by the fact that
attempts to prepare complexes of Mn (II) with HBED and EHPG ended up in oxidation and
unwanted hydrolysis. These factors favour PLED over the other two chelates aforementioned.
OH HO
OHOH
HO.
HO.'OH
HO'
OH HO„
HO' OH
N
HO.
HO.
PLED EHPG HBED
Fig 2:- Depicting N,”-dipyridoxylethylenediamine-N, N’-diacetic acid (PLED), N, N’- 
Ethylenebis (2-(o-hydroxyphenyl) glycine] (EHPG) and N, N’-bis (hydroxybenzyl) 
ethylenediamine-N, N’-diacetic acid (HBED)
Synthesis of Mn-PLED
Therefore Rocklage et al.11 have prepared the Mn (II) complex of the PLED. They have 
structurally characterized this complex. Also it was discovered that Mn-PLED was stable to 
hydrolysis at pH-7. It was also discovered, however, that it has slightly lower thermodynamic 
constant than that of Mn-EDTA (log K of 12.56 vs 13.95) and it exhibited very limited 
aqueous solubility (<50 mM). Therefore, they have diverted their investigations towards 
discovering a more water soluble chelates as it will facilitate the in-vivo applications. 
Co-enzyme PLP being converted to DPDP
In fact they found the derivatives of Pyridoxal 5-phosphate (PLP) (see Fig -3), a coenzyme of 
Vitamin B6. Although, in its free acid form, PLP was not appreciably water soluble, it readily 
gives 1M solution upon the addition of base (4 equivalents).
In an innovative approach they have utilised the PLP to produce Mn-DPDP. The 
synthetic procedure adapted could be described as follows. They have initially synthesized 
N,N’-Dipyridoxylethylenediimine-5,5’-Bis (phosphate). This was then converted to N, N’- 
Dipyridoxylethylenediamine-N,N’-diaceticacid-5,5 ’ -Bis(phosphate) (DPDP). Subsequently 
DPDP under went coordination with MnCl2.4H20 to afford Mn- DPDP. Rocklage et al also 
have reported thermodynamic studies with Cu (II), Zn (II) and Mn (II). It was found out that
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Mn (II) forms stable complexes with DPDP. The complexes were further developed to afford
the commercially available ‘Tesla Scan’.
h3c ^ ^ ^ n
Figure 3:-Pyridoxal-5’-phosphate (PLP), co-enzyme for vitamin B6 
Mn-DPDP complex: Tesla Scan
The commercially available manganese based MRI contrast agent, Teslascan, is actually the 
manganese complex of DPDP, saltified with Na(I) (1:3). This is also known as mangafodipir 
trisodium. ‘Teslascan’ was considered useful for MRI diagnosis of pancreas, adenocarcinoma 
and pancreatitis1. Mn-DPDP has a safety factor of 360 at the recommended clinical dosage 
(0.005 mmol/kg). Also the ri and r2 relaxivities measured were 1.88 mM'1s'1 and 3.7 mM'V1 
respectively (at 20 MHz and 37 °C). Mn-DPDP uptake preferentially been carried out by 
normal hepatocytes. Therefore the uptake mechanism was attributed to pyridoxine
1 fttransporters in the early stages of investigation. It was later discovered however, that uptake 
of indivual components of Mn-DPDP takes place through two different mechanisms. Further 
it was pointed out that uptake mechanism involved the release of manganese from the 
complex due to transmetallation with Zn (II). This is further justified by the stability constants 
of Mn-DPDP and Zn-DPDP (10151 and 10 IMS respectively).
OH HO
\
N N;
OH HO,
OP(OH) 2
DPDP
Figure 4:- N, N’-Dipyridoxylethylenediamine-N, N’-diaceticacid-5,5’-Bis(phosphate),
synthesized by Rocklage et aL
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Challenges faced by Teslascan
Mn-DPDP, however, shows some instability in vivo. A  recent biodistribution study proved 
that this complex dissociates and releases manganese which accumulates in liver, pancreas 
and kidneys, whereas the undissociated chelate is removed through glomerular filtration. The 
MRI properties of Mn-DPDP would therefore be ascribable mainly to the manganese ion 
released by the complex, which accumulates in the liver and pancreas. While Mn-DPDP is 
successful in imaging focal liver lesions, it has a limited ability to differentiate these lesions.
2.1.5.2 Complexation of Mn (II) with acyclic amino poly carboxylates
2.1.5.2.1 PDTA
There is one paper which states19 the longitudinal proton relaxation times in rabbit tissues 
after intravenous administration of MnCL and of Mn-PDTA (1,3-propylenediamino-N, N', 
N", Nllf-tetraacetate) have been evaluated. They have observed a peak relaxivity of around 
45 mNf's'1 at 10 MHz and 37 °C for a low dosage (80 pmol/Kg) of MnCl2. They have 
reported the similar values for Mn-PDTA for spleen (for the minimal up take of Mn (II).
2.1.5.2.2 Backbone substituted EDTA analogues
Later the investigations were diverted towards EDTA, specifically EDTA bisamides. The 
investigations of EDTA analogues, however, preceded EDTA bisamides even though they 
were not precisely targeted towards MRI contrast agents. Following is the brief introduction 
to the synthesis of such EDTA analogues.
EDTA analogue from, 1-phenylglycinonttrile hydrochloride
The efforts have been concentrated in making analogues of EDTA as well. Sundberg et al.20 
described the synthesis of l-(p-benzenediazonium)ethylenediaminetetraaceticacid, the 
coupling of this compound to proteins and the binding of radioactive metal ions to the 
protein-bound chelating groups. In their synthesis, 1-phenylglycinonitrile hydrochloride was 
converted to N,N’-diacetyl-1-phenylethylenediamine by catalytic hydrogenation. The 
aromatic ring of diamine was nitrated.
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The resulting product was refluxed in mixed acetic acid-hydrochloric acid to yield diamine-4
and the Compound 4 was reacted with aminopolycarboxylic acid to yield 5, and the aromatic 
nitro group of 5 then was reduced to yield 6 (see Fig-5).
analogues of EDTA to produce bleomycin derivative (BLEDTA) containing a powerful 
metal-chelating group, which was radio labelled with In -111 to study its in-vivo distribution. 
Co(III)-bleomycin converted to its active form and alkylated with l-(p- 
bromoacetamidophenyl) ethylenedinitrilotetraacetic acid. Upon fractionation BLEDTA was 
isolated (see Fig-6). In this approach they have ensured that the EDTA moiety in BLEDTA is 
free to coordinate with other metal ions.
2 3 4
O O
5  R = N O ,
6  R = N H j
7  R - N ; f
Figure 5:- Depicting the conversion of Product 4 to the EDTA analogue 
Synthesized by Sundberg et al 
Bleomycin derivative: Another EDTA analogue
De Riemer et a l21 in 1979 along with his colleagues, utilised this strategy of making
o
II
o o
Figure 6:-l-(p-bromoacetamidophenyl) ethylenedinitrilotetraacetic acid specifically 
synthesized by De Reimer et aL to produce thermodynamically stable 
Bleomycin derivative.
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EDTA analogue of IDAPr (3,4-HP)2
M.A.Santos et a l22 reports the synthesis of Bis(3-hydroxy-4-pyridinone) - EDTA derivative 
which was targeted to chelate Al (III) to produce potential therapeutic Al- chelating agent.
In order to find a substitute for Desferrioxamine(DFB), which is commonly used as 
aluminium-decoporating agent in the chelation therapy, Santos and his colleagues sort the 
help of bidentate ligands containing an alpha- hydroxy-acetone group, having high affinity for 
trivalent hard metal ions (eg- Fe (III) and Al (III)). They have initially found that 3-hydroxy-
4-pyridinones (3,4HP) is the suitable candidate. Moreover unlike DFB, the compound found 
to possess very high stability under extreme biological conditions. The fact that, bidentate 
mono-hydroxy pryridinones, however, needs high clinical doses lead to the development of 
multidentate ligands, which could potentially increase the chelating efficacy and thus 
minimizing drug induced toxicity. Therefore they have produced a tetradentate derivative of 
Imino diacetic acid (IDA) by condensing two equivalents of l-(3-aminopropyl)-3-benzyloxy- 
2-methyl-4-pyridinone with N-benzyliminodiacetic acid( activated via ethylchloroformate in 
THF), which was then flash chromatographed to afford the bis-hydroxypyridinone N,0- 
protected intermediate, IDABzPr(3,4-HPBz)2. Upon deprotection imino-bis(acetyl(l-(3- 
aminopropyl)-3-hydroxy-2-methyl-4-pyridinone (IDAPr(3,4-HP)2) was yielded.
Later in the following year, as they have found that the, hydrophilicity of the
'j'y
aforementioned derivative was not sufficient enough, Santos et al. have prepared the 
ethylenodiaminodiacetic acid analogue (see Fig-7). This was thought to possess higher 
potential for metal-complexation and eventual derivatization because of the two extra methyl 
carboxylic groups.
OH HO
IDAPi(3,4-HP)2 EDTAPt(3,4-HP)2 3,4-DMHP
Figure 7:- Ethylenodiaminodiacetic acid analogue of IDAPr (3, 4-HP) 2, synthesized by Santos et al.
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2.1-5.2.3 Synthesis o f EDTA bisamides
Among the acyclic poly amino carboxylates mentioned so far, EDTA stands out. This could 
be justified by the fact that it undergoes biodegradation readily when compared to PDTA. 
Further it has the most suitable chelating properties.24 As such, combining these two (i.e. Mn 
and EDTA) to produce a synergistic effect, is seems to be quite logical and this is exactly 
what the scientists carried out.
Moreover, efforts have been directed to design new ionic and neutral paramagnetic metal 
complexes which avoid or minimize the aforementioned disadvantages. In general, this goal 
can be achieved by converting one or more of the free carboxylic acid groups of the 
complexing agent to neutral, non-ionizable groups. Thus in the case of EDTA, one such 
approach is to synthesize derivatives of EDTA through amide formation. Talking about amide 
formation with EDTA, again various accounts of various methods of preparation of EDTA 
bisamides could be seen in the literature. What follows is a brief account of the literature 
review on various ways and means of synthesizing EDTA bisamides and their complexation 
with transition metal cations, specifically with Mn (II).
EPT4  anides of X -  Amine naphthalene sulfonic acid derivatives
A series of derivatives of x-Aminenaphthalene-jy-sulfonic acid as EDTA bisamides have been 
prepared. Further their fluorescence behaviour towards transition metals has also been 
investigated, in which naphthalene moiety acted the role of fluorophore. Ortega et al.25 had 
combined the advantageous aspects of both fluorosensing along with selective metal 
irnmobilization (via exploring the metal binding properties of EDTA). Initially, the four 
different resins (Argopore, Merrifield (4% DVB), Merrifield (1% DVB), and Wang-OH) were 
chlorinated to give each of their respected chlorinated forms. Subsequently these chlorinated 
resins were attached with corresponding alkyldiamines. After which these resins were reacted 
with EDTA bisanhydride in dimethylformamide. These resin derivatives were then treated 
with corresponding amine derivatives of naphthalene sulphonic acid.
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F igu re  8 :- S ynthetic schem e fo r EDTA bisam ides as resin derivatives, to  be used as sensor m ateria l 
fo r th e  recognition , detection and  m easu rem en t o f  d iffe ren t m etal ions
EDTA bisam ides o f 5-A m ino salicylic acid
Bagley et al.26 have utilised 5-Aminosalicylic acid to prepare EDTA based bisamide. The 
conjugated ethylenedimainetetraacetic acid bis-(5-aminosalicylic acid methyl ester) (5- 
EBAME) showed similar activity to super oxide dismutase (SOD). The synthetic procedure 
adapted to synthesize EBAME as follows. The EDTAA suspended in THF was refluxed with
5-amionsalicylic acid methyl ester and pyridine. The resulted precipitate was washed with 
ethanol. Precipitate was dissolved in hot water. The product was isolated after hot filtration 
and subsequent wash with acetone. Similar procedure was adapted to synthesize 4- EBAME 
as well.
EDTA based bisam ides o f a lipha tic  and  a ro m a tic  am ines
a) EDTA Based bisamides of aliphatic amine derivatives
A review of the literature indicated a few examples of preparation of EDTA bisamides. 
Although there are many examples for chelation of EDTA with lanthanides, relatively a few 
examples could be discovered on the coordination chemistry of EDTA functionalised 
derivatives. There were instances in the literature which indicates the incorporation of propyl
7 7  • n oamine , iso-propylamine, tert-butylamine, and hydroxypropyl groups to EDTA backbone.
In all of these, EDTA bisamides are produced by the amide groups which are both N- 
substituted by the respected alkyl amines. These alkyl amines were reacted with EDTAA in 
1:2 stoichiometric ratios. These EDTA bisamides were subsequently complexed with suitable 
metal cations (such as Zn (II), Cu (II), etc).
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b) EDTA based bisamides of aromatic amine derivatives
Literature review also revealed the synthesis of EDTA bisamides, prepared by the 
incorporation of 2 amino pyridine, aniline (EDTAPA and EDDADA respectively), through 
the reaction with EDTA bisanhydride (1:2 stoichiometric ratio) in 4-dimethyl amino pyridine
bisamides to investigate the thermodynamic properties (specifically enthalpy and entropy 
changes) of the EDTA derivatives. The observed differences between first and second 
protonation contants of the EDTAPA was mainly attributed to enthalpic term. They also 
observed that unlike EDTA, EDTAPA do not show any selective properties towards Co (II), 
Zn (II), Ni (II), Cd (II), Cu (II), and Pb (II) in water due to complete enthalpy -  entropy 
compensation effect.
amino sulphonamides such as sulphanilamide 8, metanilamide 9, homosulfanilalmide 10, 
4-aminoethyl-benzenesulfonamide 11 and 5-amino-1,3,4-thiadiazole-2-sulfonamide
benzenesulfonamide 12 (see Fig-10) towards producing carbonic anhydrase inhibitors of the 
tumour-associated isoforms, through the complexation with Cu (II).
(DMAP). Formic acid was used as a catalyst. Tanaka et a l29 synthesized the aforementioned
Figure 9:- Ethylenedinitrilo-N,N-diacetic-N,N-bis(2-pyridylacetamido) EDTAPA
Rami et a l30 describes the synthesis of EDTA bissulfonamides through the incorporation of
OH HO
•S02NH2
u -s j-* 0*** a x
s \  S *S O j NHj
Figure 10:- Amino sulphonamides used in Carbonic anhydrase inhibitors
EDTA based bisamides of sulfathiazole, aniline and naphthalic acid
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Guiry et a l31 prepared EDTA based bisamides of Sulfathiazole, 5-Amino naphthalic acid and
4-Hydroxyaniline EDTA bisamide, through more or less, similar procedure described by
Rami et al. when conducting studies on polymorphism of paracetamol. The synthetic
procedure undertaken as follows. EDTAA was reacted with 5-amionisothalic acid,
triethylamine in DMF at room temperature. The crude product was stirred overnight in excess
isopropyl alcohol. The removal of the solvents yielded the product. A similar procedure was
adapted for the synthesis of other amides (see Fig-11).
OH HO
o \
N N
H
Figure 11:- Schematic representation of EDTA bisamides prepared by Guiry etaL,
ArNH2: Sulfathiazole, 5-Amino naphthalic acid and 4-Hydroxyaniline
Macrocyclic EDTA based bisamides
Ki-young Choi et al. studied the metal ion biding properties of the macrocyclic EDTA based 
bisamide. The preparation of 4,10,13-Tris(carboxymethyl)-8,15-dioxo-l,4,7,10,13-pentacyclo- 
pentadecane (EDTA-DAM) was achieved first synthesizing 10,13-Bis(carboxymethyl)-8,15- 
dioxo-l,4,7,10,13-pentaazacyclopentadecane(EDTA-DET) through the cyclization of EDTA 
bis(anhydride) and diethylenetriamine in DMSO/l,5-diazobicyclo[4.3.0]nonene(DBN) 
solvent medium. This was then alkylated with t-butyl bromoacetate in diisopropylethylamine, 
thereafter it was deprotected to yield EDTA-DAM. They have discovered that the copper 
complexes of EDTA bisamides possess higher stability constants than their lanthanide counter 
parts, owing to the matching capabilities of the ligand cavity size and also could be the result 
of ionic radi of Cu (II).
Figure 12:- Macro cyclic EDTA bisamide prepared by Choi et al.
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2.1.5.2.4 Intrinsic stability o f Manganese complexes
Most of the manganese complexes known until now are relatively unstable in-vivo. There is 
an extensive research has been carried out in the past to understand the extent and the vigour 
of toxicological effects of manganese complexes in-vivo, which revealed the potential harm 
caused by these manganese complexes.33 The intrinsic stability of manganese complexes is on 
the lower side, when compared to lanthanides. This in fact predominantly contributes to the 
challenges faced by the manganese complex, on its way towards a successful contrast agent. 
These challenges could be viewed from two perspectives. Firstly, from the manganese 
perspective, it is the challenge about the transmetallation. So as to say it could be displaced 
from the complex by other divalent cations like Ca (II), Mg (II), and Zn (II). From the ligand 
perspective, unlike gadolinium, manganese is an essential nutrient for mammals and some
34organisms have developed special carrier systems and cellular uptake mechanisms, 
indicating the potential competitor threat, which could be faced by the ligand (when it’s 
dissociates from the complex due to low stability of the complex) by the endogenous 
chelators. As a result there is a great concern about the potential harmful effects for the human 
body has been widely studied, The study reveals that the free Manganese could cause 
tetratogenic effects, which in fact had been proved in the case of Mn-DPDP. Further 
problems relating to chronic exposure to manganese are well documented. The severe 
disorder caused in the central nervous system has also been accounted. A recent study reveals 
the accumulation of free manganese from the potential contrast agent in the brain of mice and 
the harmful effects incurred.
Mn complex o f the EDTA based derivative bearing diphenylcyclohexyl moiety (MnLl)
In contrast, Lauffer et al.37 had stated in his research in 1987, that Mn (II) bound to proteins 
could produce extremely large relaxivities (for eg 275mM-ls-l) and for Mn(II)-pyruvate 
kinase; 96mM'1s'1 for Mn (Il)-concanavlin A, which are slow tumbling compounds.
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In the very recent past, the details obtained from the fact that [Mn(EDTA)(H20)] ' could be a
good starting point to synthesize a contrast agent, attracted Troughton and colleagues to
synthesize a high relaxivity manganese based contrast agent.
Starting from L-serinamide hydrochloride, through a five step synthesis they have 
obtained the protected form of the (R)-({2-(Bis-/er/-butoxycarbonylmethyl-amino)-l-[(4,4- 
diphenyl-cyclohexyloxyj-hydroxy-phosphoryloxymethylj-ethyl-terf-butoxycarbonylmethyl- 
amino)-acetic acid te/t-butylester t-butyl protection was removed by using the mixture of 
HCl/MeCN to obtained the pure ligand, which then complexed with manganese chloride 
under acidic condition.
A diphenylcyclohexyl moiety, as used in the MS-325 was then linked to the EDTA 
derivative through a phosphodiester bond which is then conjugated to serum albumin in the 
blood (see Fig-13).
, Ph
Vh
o—p —o
3N a
MnL1
Figure 13:- Mn complex of the EDTA based derivative synthesized by Troughton et aL 
The usage of a binding group has the advantage to provide means for targeting blood vessels,
which will reduce Ti due to the reduction in the tumbling rate. This will significantly enhance
relaxativity.38
Mn-EDTA-DDP
Although Mn-EDTA and some of its derivatives acted as good liver imaging agents, they 
could not be considered as blood pool imaging agents or, to image bone marrow and spleen. 
Under these circumstances Mn derivatives of liposome proved to be successful MR contrast 
agents and are effective in imaging the blood pool,liver ,spleen and bone marrow and also it
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has been proved that when they are smaller in size ( i.e <50nm ) they responded more
effectively.
In a recent study, MRI contrast agents were evaluated consisting of Mn-EDTA 
lipophilic derivatives (for example, Mn-EDTA-DDP) bound to the membranes of small 
unilamellar liposomes ("memsomes"), which are potentially valuable for hepatic and cardiac 
perfusion imaging. Taking these facts into consideration! Unger et al.39,40 in their patented 
research reports the synthesis of Mn-EDTA-DDP, Mn—EDTA-LDP, Mn-EDTA-ODP 
((DDP: Carboxy-decylamidomethyl-N-2,3 -dihydroxypropyl)-ethylenediamine-N,N'-diacetate, 
LDP: N,N,-Bis-(Carboxy-laurylamidomethyl-N-2,3-dihydroxypropyl)-ethylenediamine-N,N'- 
diacetate, ODP: N,N'-Bis(Carboxy-octadecylamidomethylene-N-1,2-dihydroxypropyl)-
ethylenediamine-N,N- diacetate. The synthetic procedure involved in Mn-EDTA-DDP as 
follows. They initially synthesized DDP, by refluxing decvlamine with glycidol in methanol. 
Product was purified by recrystallisation. Purified DDP was then reacted with EDTAA in 
methanol, applying slight heat. The removal of solvent yielded the product. A similar 
procedure was adapted to synthesize EDTA derivatives of LDP and ODP. These ligands were 
subsequently complexed with Mn (II).
These chelates or, more preferably, in combination with lipids or liposomes, are 
reportedly particularly useful. These kind of chelated complexes have been reported in 
number of other patents as well. Interruption of alkylene chain by one or more substituents 
selected from O, S, CHOH, CHSH, are stated to be particularly useful for imaging of liver, 
kidneys, pancreas and gastrointestinal tract.
EDTA based bisamides from blood proteins
Differing from the above approaches, Lauffer et al. prepared EDTA amides through the 
conjugation of proteins such as Bovine Immunoglobulin (IgG) and Bovine Serum Albumin in 
an attempt to produce enhanced paramagnetic based contrast agent which could have 
enhanced relaxivity.41 Bovine Immunoglobulin (IgG) and Bovine Serum Albumin were 
multiply labelled with EDTA. Mn (II) was inserted in to the binary conjugate to form ternary
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conjugate (i.e. protein-ligand-metal ion). Measured relaxivities revealed the dramatic
difference in relaxivity of ternary conjugates from that of binary conjugate (5-10 fold increase
in relaxivity in the 10-40 MHz filed range). Synthetic procedure adapted could be briefed as
follows. Protein was reacted with large excess of EDTAA according the procedure of
Hnatowich et al. Thereafter reaction mixture was dialyzed.
2.1.5.3 Utilising Bifunctional Chelates
Ligands that were bearing a second functional group, which will enable the ligand to 
covalently attach to a targeting moiety is becoming more popular. These are known as 
‘bifunctional chelates’.42 The functional groups commonly found in the chelates are 
electrophiles, which will react with nucleophilic groups of the targeting vector.
Further this takes place under mild conditions. The pioneers of bifunctional chelates are 
the polyamino poly carboxylates or complexones. In ‘complexones’ one or more of the 
carboxylate group is activated to react with an amine group. More over , in the case of amides 
they only coordinate quite readily with transition metal cations (such as Mn2+ , Cu2+, Zn2+, 
Cr2+ and/or lanthanide metal ions (such as Gd 3+,Eu3+, Yb3+). This coordination will not result 
in the change of denticity (i.e. EDTA based bisamides remains as Hexadentate and most 
commonly for DTPA based bisamides as Octadentate), It does affect, however, the overall 
charge of the complex and the electron density on the metal ion.43 Depending upon 
application, these features may or may not be detrimental. Although there were extensive 
physical studies undertaken to investigate the physical properties of the parent EDTA and 
DTPA complexes, the bifunctional ligands have been put up in low profile.
So far the investigations have clearly outlined that small variations in the structure 
could result in widely differing properties. This thesis is concerned about the synthesis of 
contrast agents, which will have the fluorescence capability; a special attention has been given 
to incorporate precursors having both amine functional group and the chromophoric moieties, 
with the EDTA bisanhydride. We have successfully incorporated precursors, such as amino
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anthraquinone and amine functionalised naphtha derivative, which will be dealt in detail in
the proceeding sections.
2.2 Results and Discussion
2.2.1 Ligand Design and Synthesis
It may be obvious from Section 2.1, in order to produce a novel dual purpose contrast agent 
which could be utilised in MRI and/or PET requires a chromophore to be part of the desired 
bifunctional ligand.44 Therefore our first objective is to find the precursor which has an 
inherent chromophore in itself.
Since naphthalene moiety has the inherent conjugation, it was thought to incorporate N- 
(2-aminoethyl)-l,8-naphthalimide. This is because 1,8-naphthalimides are well known for 
their strong absorption and remarkable fluorescence yields 45 They are also known for their 
anticancer activity.
Synthesis o f N-(2-Aminoethyl)-l, 8-naphthaIimide
The procedure reported by Licchelli et al.46 was employed with slight modification. 1,8 
naphthalic anhydride was added portion wise, to a stirring large excess (10 times) of ethylene 
diamine. The reaction mixture was refluxed overnight. Thereafter, excess ethylene diamine 
was removed by distillation. The crude product was washed several times with diethyl ether. 
To yield the product as pale yellow precipitate.
l
F ig u re  1:- N -(2 -A m inoethy l)-l, 8 -n ap h th a lim id e  
The product was sufficiently pure enough (a trace amount of dimer was also visible in the
proton NMR spectrum) to be carried on to the next step.
Having identified and synthesized the chromophoric moiety for a hexa coordinate
ligand, our next objective is to synthesize the EDTA bisanhydride, which is then prepared
according to a literature procedure46 (see Fig-2).
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F ig u re  2 :- dep icting  the  synthetic p a th w ay  fo r th e  syn thesis  o f  E D T A  bisam ides
2.2.1.1 Synthesis of EDTA bis amide of N-(2-Aminoethyl)-l, 8-naphthalimide (L1)
Initially it was decided to synthesize L1 (see Fig-3) in dichloromethane by reacting EDTAA 
with 1 in 1:2 stoichiometric ratio. The lH NMR spectrum of the crude product, however, 
indicated the presence of mixture of mono and bis amides. Therefore it was decided to change 
the reaction media to acetonitrile.
Once again the reaction ended up in a mixture of amides rather than the expected pure 
bisamide. Purification through recrystallisation in methanol, toluene, and ethanol also failed. 
Further, thin layer chromatography also proved futile (in spite of the usage of various 
combinations of DCM/Methanol). This has prevented the possibility for column 
chromatography.
L1
F igu re  3 :- ED TA  bisam ide o f  N -(2 -A m in o eth y l)-l, 8 -n ap h th a lim id e
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2.2.1.2 Synthesis of EDTA bisamide of sulphonamide (L2)
This continuous failure prompted us to investigate other procedures highlighted by our 
literature search. At this point, we came across the procedure of making EDTA bisamides 
reported by Rami et a l30 We were not successful in synthesizing L2 according to the 
procedure. The method was modified by mixing solutions of the EDTA bisanhydride and the 
respective sulphonamide precursor in a small amount of DMF, at room temperature giving 
rise to a mixture of mono and bis amides (determined by 1H NMR spectroscopy).
A successful outcome was achieved by slow (dropwise) addition of the sulphonamide 
solution to a solution of the EDTAA. The product was obtained as an off white, free flowing 
powder. Yield was 35%. The crude product was further washed with acetone and 
subsequently with acetonitrile. In the lH NMR spectrum, a singlet resonance was observed for 
the methylene protons indicating the two fold symmetry of the desired bisamide.
O H  H O
h 2n  n h 2
L2
F igu re  4 :- ED TA  b issu lp h o n am id e
2.2.1.3 Synthesis of EDTA bisamide of Para Aminophenol (L3)
This was prepared according to a synthetic procedure reported by Guiry et al the procedure 
could be summarised as follows. To a mixture comprising of EDTAA and triethylamine in 
DMF was added 4-amino phenol portion wise. The reaction was then allowed to stir for 24 h 
at room temperature. Then the solvent was removed. Thereafter isopropyl alcohol was added 
to the dark brown crude product and allowed to stir for 72 h. After which, the product was 
obtained by filtration and the precipitate was dried.
It was discovered that by allowing the reaction mixture to stir for more than 72 h in IPA 
(96 h), noticeable improvement was observed in the purity of the final product. This could be
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attributed to the complete removal of impurities from the ligand by the IP A. The hydroxyl
T • • 47group in the L (see Fig-5) could provide the site for conjugation with micro spheres.
OH HO
H H
L3
F igu re  5 :- ED TA  bisam ide o f  4 -am ino  pheno l
2.2.1.4 Preparation of four new EDTA bis amides and some challenges faced therein
EDTA bisamides o f  N-(2-Aminoethyl)-l, 8-naphthalimide (L6)  and amino methyl pyridine (L4)
The above described modified procedure was used to prepare EDTA bisamide of N-(2-
Aminoethyl)-l, 8-naphthalimide (L1) (see Fig-2) and EDTA bisamides of amino methyl
pyridine (L4), It is interesting to note, similar to our ligand L4, Tanaka et al. reports a
synthesis of ethylenedinitrilo-N, N’-diacetic-N, ISP-bis (2-pyridylacetamido) acid (EDTAPA)
(see Fig-6) through the incorporation of 2-aminopyridine to EDTA bisanhydride in 1:2 molar
ratio. They have used dichloromethane as a solvent instead of DMF. Additionally they have
used DMAP (as base) and formic acid (as catalyst). Further, it was noted that EDTAPA is
sparingly soluble in cold water and is readily recrytallised from hot water, whereas L4 is more
freely water soluble.
OH HO
L4
F ig u re  6 :- ED TA  b isam ide o f  4 -am ino  m ethy l p y rid in e
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NMR Spectroscopy (* H and13 C)
In L1, due to the symmetric nature of the ligand, one would expect 6 peaks to be visible in the
]H NMR spectrum, which was clearly visible in the spectrum, except for two solvent peaks, a
broad singlet in 4.7 ppm, which was assigned as water peak. Other than this there is only one
peak visible which could not be assigned to any protons in the structure of L1, as this appears
in 1.9ppm with the negligible integral, it has been assigned as methyl proton of acetone,
which normally appears around 2 ppm in D2O, and except for these two solvent peaks the
1 ^proton NMR spectrum indicated a very pure ligand. C NMR spectrum of the same ligand 
indicated 8 peaks which were assigned to the carbons in the structure.
EDTA bisamide o f Amino Anthraquinone (L5)
In the case of L5 (see Fig-7) also, the modified procedure described for L4 was followed. At 
the work up, however, addition of dichloromethane did not yield the precipitate. Therefore it 
was decided to evaporate the filtrate and analyse the crude product. The proton NMR 
spectrum indicated the presence of the product along with excess starting material, namely 
2-aminoanthraquinone.
Further, purification was attempted with methanol and ethanol wash; however impure 
product was still observed. At this point it was decided to wash the crude product with 
dichloromethane. The proton NMR spectrum of the washings indicated the presence of 
2-aminoanthraquinone, while the proton NMR spectrum of the undissolved solid indicated the 
presence of the product along with small amount of starting material. Repeated washings with 
dichloromethane yielded a substantially pure product, good enough for characterisation and 
further use. The product (dark brown glassy material) was characterised by proton NMR 
spectrum. In the NMR spectrum a trace amount of starting material was visible. The broad 
singlets at 6.7 ppm, 6.9 ppm & 7.3 ppm were assigned to protons of aminoanthraquinone, 
while the proton NMR spectrum of the washings indicated the 2 amino anthraquinone, the 
starting material.
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F igu re  7:- ED TA  b isam ide o f  2 -am ino  an th ra q u in o n e  
EDTA bisamide o f  Amino Methyl Sulponic Acid (L6)
The modified procedure of L4 was attempted for L6 (see Fig-8) EDTAA was mixed with 
Amino methyl sulphonic acid 2 (see Figure-9). The reaction mixture was allowed to stir 
overnight. A distinct colour change was observed (dark brown solution turned to dark ash 
coloured solution).
HO
O
6
F ig u re  8 :- ED TA  b isam ide o f  am ino  m ethy l su lp h o n ic  acid
h 2n  s o 3h  
2
F igu re  9 :- A m ino m ethyl su lphon ic  ac id
The lH NMR spectrum of the crude product exhibited peaks of EDTA as well as peaks due to
excess amino methyl sulphonic acid. Failure of this attempt diverted our attention towards an 
alternate approach. Inonue et a l4S reported a procedure to synthesize diester derivatives from 
dioxotetraazacycloalkane diacetic acid. The procedure is summarised as follows.
The 12edtaen 3 (see Fig-10) was suspended in DMF. To which added pulverized KHCO3 and 
subsequently added ethyl iodide. The reaction mixture was stirred for 20 h at room 
temperature. To the resulting solution, water was added and the product was extracted, 
initially with dichloromethane and subsequently washed with sodium sulphite and water. The 
removal of the solvent yielded the product as colourless solid.
63
xo2c
''NH 
\
/
XO2C // N'S
Potential Multimodal Imaging Agents
o
L
3
F ig u re  10:- X :H  -12ed taen -H 2 a n d  X -C 2H 5 : 12edtaen-des 
It was expected that adapting the procedure of long chain alkylation to alkylate the L6 will
enable the akylated product to be extracted in to the organic layer during solvent extraction,
while retaining the impurity in the aqueous layer facilitating removal of the starting materials
(Amino methyl sulphonic acid).
We have adapted this procedure and used iodoheptane instead of idodoethane, 
(See Fig-6). After the work up, NMR spectrum of the final product indicated a prominent 
peak corresponding to methine proton of the amino methyl sulphonic acid and the peak 
related to heptyl group was not visible. Thereafter the same reaction was carried out with 
iodobutane, in order to facilitate alkylation with less steric hindrance. ‘H NMR spectrum once 
again revealed the attempt was futile, as a huge peak corresponding to methine proton of the 
amino methyl sulphonic acid is visible. Reaction was repeated from potassium carbonate to 
cesium carbonate. The cesium carbonate was powdered in order to effectively neutralise the 
HI formed in the reaction. Expected improvement could not be observed in the proton NMR 
spectrum.
0 0  \  /
°= <  f-\  ) = °  -j  * V
N—' ° \ d  /  V _ J °
" J -  C " >  ( .«
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F ig u re  11:- D epicting the  expected , e s te rif ied  E D T A  m ono sp ace r
At this point we came across a synthetic procedure for DTPA bisamide of para amino benzoic 
acid, reported by Liu et a l49 They mixed DTPAA with para amino benzoic acid in water at 
273 K for 4 h and then allowed the reaction to stir for a further 24 h at room temperature.
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Thereafter, when the pH was adjusted to 3-4, a great deal of precipitate appeared. The
precipitate was filtered and recrystallised with hot methanol.
The aforementioned procedure was adapted to synthesize EDTA bisamide of amino 
methyl sulphonic acid. Upon adjustment of pH, however, only a negligible amount of 
precipitate was formed. It was then decided to evaporate the reaction mixture to dryness. The 
proton NMR spectrum was obtained. The proton NMR spectrum indicated the presence of 
expected product along with large excess of starting material (i.e. amino methyl sulphonic 
acid). After which the solid was dissolved in hot methanol. The proton NMR spectrum of the 
undissolved solid indicated the presence of substantially pure product, which could be utilised 
in subsequent synthetic steps.
Although we were successful in making the reaction to go to completion, however, the 
purity of the ligand and the yield was comparatively low in comparison to other 
aforementioned bisamides. It was found that the purity and yield of the reaction was highly 
dependent on the quality of the EDTAA starting material.
Despite a similar melting point and NMR data, when the EDTAA was prepared using 
distilled acetic anhydride and distilled diethyl ether under nitrogen atmosphere throughout the 
preparation, a better yield (95%) could be obtained with substantial increase in purity 
(compared to the previous yield of 80%).
2.2.1.5 Attempted Synthesis of some Chromophore bearing EDTA bisamides 
EDTA bisamide o f Amino Acridine (L7)
In line with the modified procedure used to prepare L1, L4 and L5, initially decided to react 9- 
amino acridine with EDTAA. As the reagent was supplied as the HC1 salt, first the ligand was 
deprotonated. The supplied reagent (9-amino acridine hydrochloride) was initially suspended 
in water, after which 2-3 pellets of NaOH was added and observed the formation of 
deprotonated aminoacridine as precipitate in the solution. The solution was extracted with 
dichloromethane (the problem of partial insolubility of the precipitate in dichloromethane was 
overcome by the addition of small amount of toluene and acetone). The deprotonation yielded
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a pure activated form of 9-amino acridine (see Fig-12). The proton NMR spectrum clearly
indicated the proton of the free amine along with the expected peaks.
F igure  12:- D ep ro to n a ted  A m ino ac rid in e
This deprotonated 9-amino acridine had been utilised to produce the EDTA bisamide of
9-amino acridine (see Fig-13). In the proton NMR spectrum of L , one would expect to see 7 
peaks comprising, four peaks related to aromatic hydrogens (two triplets and two doublets) 
and three peaks contributed by the aliphatic hydrogens (three singlets belong to the acid, 
amide protons and methylene protons of the ethylene diamine backbone). While the expected 
peaks were present and the integrals related to aromatic peaks and the NH peak indicated 4H 
each, integrals of the two aliphatic peaks also related to 4H each. The integral of the peak, 
however, assigned to methylene proton of ethylene diamine backbone indicated an unusual 
8H. This has made the purity of the ligand in question.
F igu re  13: - ED TA  b isam ide o f  d e p ro to n a ted  9 -am ino  a c rid in e
g
Solubility problems o f  5-aminonapthalene -2-sulphonic acid (L  )
The modified procedure used for L4 was employed in the synthesis of L8 as well. It was 
observed, however, that 5-amino naphthalene-2-sulphonic acid was sparingly soluble in 
DMF. This has resulted in incomplete transfer (both via cannula and syringe transfers) of the
5-amino naphthalene-2-sulphonic acid to EDTAA. The proton NMR spectrum of the 
precipitate indicated the presence of a mixture of mono and bis amides.
Therefore, in order to facilitate solubility, the partially dissolved 5-amino naphthalene- 
2-sulphonic acid was slightly heated and then subsequently it was transferred effectively to 
the EDTAA. The proton NMR spectrum of the purified precipitate indicated the product;
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however the peaks could not be assigned properly. All of the six peaks belong to the
naphthalene sulphonic acid was identified with the considerable down field shift in the proton
NMR, when compared to the starting material (i.e 5-amino-naphthalene sulphonic acid). The
three singlets related to methylene hydrogen of ethylene diamine backbone, methylene
hydrogens attached to the amide arm and methylene hydrogen attach to carboxylic arm also
identified (with the help of the correlating the integrals of the respected peaks along with the
aromatic peaks). There were extra three singlets, however, noted in the region of 3.5 ppm -
3.65 ppm, which could not be assigned reasonably to any protons. The amide stretching
vibration, however, was noted in the IR (1645 cm'1).
OH HO
F igu re  14: - ED TA  bisam ide o f  5-am ino n a p h th a le n e -2 -su lp h o n ic  acid 
Attempted synthesis o f  the EDTA bisamide o f  Taurine (L9)
Following the successful synthesis of L6, the Taurine derivative of EDTA was synthesized. 
Initially the same procedure described for L6 was carried out. The proton NMR spectrum, 
however, indicated the presence of EDTA and excess taurine along with the expected product. 
Recrytallisation in methanol and ethanol failed. Thereafter the reaction was repeated with the 
addition of 2.5 times of base (to activate taurine). The solvent was removed. The proton NMR 
spectrum of the solid indicated the presence of product along with excess taurine as well as 
EDTA.
O H  H O
H O 3S  S O 3H
L9
F igu re  15:- ED TA  b isam ide  o f ta u rin e
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2.2.2 Complexation with Transition Metal Ions
OH HO
O \ NN
H
M^ Caq)
DMF/MeOH/H20
O'
Mn+:- Mn++, Cu++, Zn++
F ig u re  16:- S chem atic rep resen ta tio n  o f the  com plex fo rm a tio n  o f  B isam ides, w h ere  R : aux ilia ry  g roups
2.2.2.1 Characterisation of EDTA bisamides
  I »y
The initial H NMR spectrum exhibited solvent peaks for L and L ,which was attributed to
•  ITsolvent peaks related to DMF, triethylamine and water and acetone respectively. C NMR 
spectra were not obtained as they are known ligands.
IR Spectroscopy
Tabulated values exhibited in Table 1 indicate the common trend of amide stretching 
vibrations exhibited by these amides. It could be seen that values lies in the range of 
1633-1674 cm'1 which lies within commonly observed range of 1630-1695 cm'1, indicating 
the validity of the findings.50
Table 1: IR Stretching Frequencies of EDTA bisamides and their complexes
Compound v(C=0) Amide v(O-H) v(C=0)-Acid
v(C=0) amide of EDTA bis amide 
complexes
Mn(II) Zn (II) Cu(II)
L1 1674(s) 3435(br) - 1607(vs) 1632(s) 1625(s)
L2 1672(s) 341 l(br) - 1634(s) 1635(s) -
L3 1633(s) 3272(br) - - - -
L4 1666(s) 3438(br) 1712(w) 1638(br) 1632(vs) 1638(s)
L5 1673(s) 3440(br) 1710(w) 1653(w) 1624(w) 1618(w)
L6 1636(s) 3443(br) - 1641 (s) 1640(s) -
L7 1643(s) 3423(br) - - 1638(s) -
L8 1645(s) 3441(br) 1722(m) 1636(s) 1636(s) -
a IR spectra measured using KBr discs.
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2.22.2 Complexation with Transition metal cations.
For the purpose of complexation along with the targeted Mn (II) ion, two more cations, 
specifically Cu (II) and Zn (II) ions were selected. Each of these selections was on accord of 
two fold objectives. Firstly, Cu (II) and Zn (II) are endogenous cations, thus representing the 
physiological environment. Secondly, Cu (II) also has the potential to be used in PET imaging 
(as its isotope- MCu) and Zn (II) also could facilitate characterisation through proton NMR 
spectroscopy, due to its diamagnetism.
1 H NMR spectroscopic characterisation
1 1 7H NMR spectrum of the Zn complexes of L - L , all exhibited the expected down field shift 
in their proton NMR spectra. It was also observed a characteristic duplication of peaks. This 
may be attributed to the isomers produced in the NMR solution due to donor exchange by the 
metal. The ^  NMR spectra of the Cu (II) complexes of L1 and L4 (CuL1 and Cu L4) and also
%  " X  c  ethe Mn (II) complexes of L (MnL ) and L (MnL ) could not be obtained as these metal ions 
exhibit paramagnetism due to unpaired electron(s) in their d orbital.
Infrared spectroscopic characterisation
It could be observed from Table 1 (see Figure-17), carbonyl stretching vibrations of the 
amide group shifting to lower values. For instance, amide stretching vibration of the EDTA 
bissulphonamide (L2) has shifted from 1672 cm'1 to 1635 cm'1 in ZnL3. This kind of 
significant red shift could be attributed to the weakening of C=0 bond upon complexation, 
indicating the amide oxygen coordination to the transition metal ion. Similar to Zn (II) 
complexes, the shifting of amide stretching vibrations to lower values for CuL1 and CuL5 
could be observed. MnL3 also exhibited a similar shift to the lower value. Shifting to lower 
energy, however was not observed in the case of MnL6 and ZnL6, this may be attributed to 
the weakly coordinating amide oxygen. Further, IR spectra of complexes, specifically, MnL3, 
ZnL3, CuL1 and CuL6 exhibited broad peak around 3200 cm'1 - 3400 cm'1. This could be 
attributed to the presence of water in complexes.51
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Characterisation through Mass Spectrometry
High resolution mass spectra were obtained for L 1, L4 and L5. In the case of L6 only low 
resolution mass spectral data could be obtained. Data for L2 and L3 were not obtained as they 
are known ligands. All the ligands exhibited protonated molecular ion.
2.3 Experimental Section
Experimental 
General Experimental:
Reagents were obtained from commercial sources and used as received unless otherwise 
noted. Solvents were dried and purified under N2 by using standard methods and were 
distilled immediately before use, specifically dimethylformamide and pyridine was distilled 
using anhydrous calcium hydride. All compounds were prepared under N2 unless otherwise 
mentioned. The NMR spectra were obtained using a Bruker ARX 400 at 20 °C in C D C I3 
unless otherwise noted. Mass spectra were performed on a micro mass Platform II system 
operating in Flow Injection Analysis mode with the electro spray method. Infrared spectra 
were recorded with a JASCO FTIR-410 spectrometer between 4000 and 250 cm'1 as KBr 
pellets. UV/Vis spectra were recorded with a JASCO V-570 spectrometer.
Synthesis o f EDTA bisanhydride
EDTA (5.0 g, 17 mmol) was suspended in pyridine (8 mL) and acetic anhydride 
(7.0 g, 68 mmol) was added dropwise to the stirring solution. The reaction mixture was 
allowed to stir for 24 h at 65 °C. The resulting anhydride was filtered off and washed 
thoroughly with freshly distilled acetic anhydride and dry diethylether. The white-cream 
powder was then dried under vacuum until constant weight was obtained. The product was 
characterised by infrared spectroscopy and measuring its melting point. Yield 4.2 g, 96%. IR 
(KBr disc) (cm1): 3445(br), 1810(vs), 1760(s), 1130(s); Melting point: 189-191 °C.
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2.3.1 Synthesis of EDTA bisamides
2.3.1.1 Synthesis of EDTAbisamide of N-(2-Aminoethyl)-l,8-naphthalimide (L1)
O H  H O
The procedure was similar to that of L1. To EDTA bisanhydride (0.308 g, 1.20 mmol) 
dissolved in dimethylformamide (10 ml) was added N-(2-Aminoethyl)-l,8-naphthalimide 1 
(0.579 g, 2.40 mmol) dissolved in dimethylformamide (10 ml) dropwise. After the complete 
addition, the reaction mixture was allowed to stir over night at room temperature. Thereafter 
dichloromethane (50 ml) was added to the reaction mixture, upon which the precipitate was 
formed. The precipitate was filtered and washed initially with acetone and subsequently with 
acetonitrile. Yield 0.38 g, 45%; ]H NMR (400 MHz, c^-DMSO: Me4Si): 6n(ppm) 10.00 (s, 
2H, NH), 8.35 (dd, 4H, J = 7.75, 14.16 Hz, ArH), 8.15 (s, 1H, NH), 7.75 (t, 2H, J = 7.71 Hz, 
ArH), 7.50 (m, 2H, NCH2), 3.4 (s, 2H, NCH2COOH), 3.3 (m, 2H, NCH2CH2), 3.1 (s, 2H, 
NCH2CONH), 2.6 (s, 2H, NCH2CH2N); 13C NMR (400 MHz, D20): 8C 173.00, 171.23, 
163.95, 134.40, 131.47, 130.85, 127.67, 127.38, 122.36, 57.63, 55.35, 52.26, 37.08; IR (KBr 
disc) (cm1): 3435(br), 1674(s), 1590(s).
2.3.1.1.1 Complexation of L1 with MnCh (MnL1)
L1 (0.0736 g, 0.1 mmol) was dissolved in dimethylformamide and MnCl2 (0.01258 g, 0.1 
mmol) was dissolved in minimum amount of distilled water. The solution of the ligand was 
added drop wise to the solution of the salt and allowed to stir for 20 min. Then the solvent 
was removed under vacuum, and the residue was washed with acetone and chloroform several 
times.
Complexation of L1 with ZnCl2 (ZnL1), Complexation of L1 with CuCl2 (CuL1), was 
also carried out as per the procedure outlined for MnL1. In the preparation of CuL1, however,
71
Potential Multimodal Imaging Agents 
the ligand was dissolved in ethanol instead of dimethylformamide. [Zn^L^JIClfi: Yellow
precipitate (90% yield). NMR (400 MHz; D20): 8.45 (m, 4H), 8.00 (m, 4H), 7.80 (m,
4H), 3.55 (s, 2H), 3.40 (s, 2H), 3.15 (s, 2H), 3.05 (s, 2H), 3.00 (s, 4H), 2.90 (s, 2H), 2.70 (s,
2H); IR (KBr pellet, cm 1): 3434(br), 1632(br), 1262(w), 1437(w), 1384(m), 1104(w),
1032(br). [MnI1(L1)][Cl]2: Dark brown precipitate (88% yield). IR (KBr pellet, cm'1):
3545(br), 1686(w), 1616(s), 1594(w), 1443(m), 1378(m), 1261(s), 1099(br). [CoV-^HClh:
Dark green precipitate (85% yield). IR (KBr pellet, cm'1): 3448(br), 1625(br), 1384(w),
1344(w), 1261(s), 1096(s), 1027(m), 803(s).
2.3.1.2 Synthesis of EDTA bisamide of Sulfonamide (L2)
The reaction was carried out according to a slightly modified procedure than what was
TOreported by Rami et al. This is as follows. To EDTA bisanhydride (1.6 g, 6.24 mmol) 
dissolved in dimethylformamide (20  ml) was added completely dissolved solution 
p-aminosulfonamide (2.151 g, 12.48 mmol) dropwise. After the complete addition of 
sulphonamide, the reaction mixture was allowed to stir overnight at room temperature. 
Thereafter, dichloromethane was added in two portions (50 ml), upon which precipitate was 
formed. The precipitate was filtered and washed initially with acetone and subsequently with 
acetonitrile. Yield 1.2 g, 37%; 'H NMR (400 MHz, D20  with K2C03: Me4Si): 5H(ppm) 7.55 
(d, 4H, J = 8.4 Hz, ArHa), 7.35 (d, 4H, J = 8 .6  Hz, ArHb), 3.50 (s, 4H, NCH2COOH), 3.30 (s,
4H, NCH2CONH), 2.95 (s, 4H, NCH2CH2N); IR (KBr disc) (cm1): 341 l(br), 1672(vs), 
1595(vs), 1548(vs), 1521(s), 1316(w), 832(vs).
13C NMR and Accurate Masspec spectral data were not obtained as this is a known 
compound.
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2.3.1.2.1 Complexation of L2 with ZnCl2-(ZnL2)
L2 (0.06 g, 0.1 mmol) was completely dissolved in MeOH and ZnCl2 (0.136 g, 1.0 mmol) was 
dissolved in minimum amount of distilled water. The solution of the ligand was added 
dropwise to the solution of the salt and allowed to stir for 20 min. The solvents were removed 
on the rotaevaporator and then high vacuum, and then the crude product was washed with 
acetone and chloroform, to obtain the complex. [Znn(L2)][Cl]2: Black precipitate (95% 
yield). lH NMR (400 MHz; D20): 7.75 (d, 2H, J = 8 .6  Hz), 7.60 (dd, 4H, J = 6.0, 6.5 Hz), 
7.50 (d, 2H, J = 8.9 Hz), 3.75 (s, 2H), 3.70 (s, 2H), 3.40(s, 2H), 3.35 (s, 2H), 3.05 (s, 2H), 
2.75 (s, 2H); IR (KBr pellet, cm 1): 3414(br), 3079(m), 1632(s), 1366(s), 1262(w), 1029(s); 
ESEMS(-ion): found m/z 661.0388, Calc 661.0365 for [(ZnL2-3H)].’
2.3.1.2.2 Complexation of L2 with MnCh -MnL2
L2 (0.06 g, 0.1 mmol) was completely dissolved in MeOH and MnCl2 (0.0629 g, 0.5 mmol) 
was dissolved in minimum amount of distilled water.The solution of the ligand was added 
dropwise to the solution of the salt and allowed to stir for 20 min. The solvents were removed 
on the rotaevaporator and then high vacuum, and then the crude product was washed with 
acetone and chloroform, to obtain the complex. [Mnn(L2)][Cl]2: Pale white precipitate (95% 
yield). IR (KBr pellet, cm'1): 3446(br), 1634(s), 1592(w), 1549(w), 1405(m), 1324(m), 
1261(s), 1097(s), 1024(w), 801(s), 699(w); ESIMS(-ion): found m/z 652.0486, Calc 652.0454 
for [(MnL2-3H)].'
Complexation of L2 with Cu (II) was not carried out as it was done in the past.30 
23.13 Synthesis of EDTA bisamide of Aminophenol (L3)
OH HO
H H
OH
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To EDTAbisanhydride (1.0 g, 3.90 mmol) was dissolved in dimethylformamide (16 ml) and
was added triethylamine (0.79 g, 7.80 mmol) followed by portion wise addition of 4-amino
phenol (0.85 g, 7.80 mmol). Then reaction mixture was allowed to stir for 48 h at room
temperature. After which, the solvent was removed under reduced pressure. Thereafter
isopropyl alcohol was added to the dark brown oily crude product and allowed to stir for 72 h.
The product was filtered and dried in high vacuum. Yield 0.38 g, 43 %; ]H NMR (400 MHz,
de-DMSO: Me4Si): 5H(ppm) 10.00 (s, 2H, NH), 7.50 (d, 4H, J = 7.8 Hz, ArCHa), 6.70 (d, 4H,
J = 7.9 Hz, ArCHb), 3.45 (s, 8H, NCH2CONH, NCH2COOH), 2.85 (s, 4H, NCH2CH2N); IR
(KBr disc) (cm 1): 3272(br), 2970(w), 1633(s), 1515(vs), 699(s).
I3C NMR and MASS Spectral data were not obtained as it is a known compound.2
2,3.13.1 Complexation o f L3 with ZnCh -ZnL3
L3 (0.079 g, 0.1 mmol) was dissolved in dimethylformamide and ZnCl2 (0.023 g, 0.1 mmol) 
was dissolved in minimum amount of H20. The solution of the ligand was added dropwise to 
the solution of the salt and allowed to stir for 20 min. Then the solvent was removed under 
vacuum and the residue was washed with acetone and chloroform several times.
2: Pale brown precipitate (95% yield). *H NMR (400 MHz; D20): 6.65-6.60 
(m,4H), 6.40-6.35 (m, 4H), 3.65- 2.70 (m, 12H); IR (KBr pellet, cm 1): 3434(br), 1635(s), 
1515(m), 1448(w), 1384(s), 1262(s), 1102(br).
23.1.4 23.1.4 Synthesis of EDTAbisamide of 4-aminomethyl pyridine (L4)
OH HO
0=^ ^-aJ>=0N— N N— 'yt U,[ o o
6  N
To EDTA bisanhydride (0.867 g, 3.38 mmol) completely dissolved in dimethlyformamide (10 
ml) was added 4-aminomethyl pyridine (0.73 g, 6.76 mmol) dissolved in dimethlyformamide 
(10 ml), dropwise. The reaction mixture was allowed to stir overnight at room temperature.
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Thereafter, dichloromethane was added to the reaction mixture, upon which precipitate was
formed. The precipitate was filtered and washed initially with acetone and subsequently with
acetonitrile. Yield 1.4 g, 88 %; *H NMR (400 MHz, D2O with K2CO3: Me4Si): 8h (ppm) 8.30
(d, 2H, J = 5.8 Hz, ArCH6), 7.20 (d, 2H, J = 5.6 Hz, ArCH2), 4.35 (s, 2 H, NHCH2,), 3.30 (s,
2H, NCHjCOOH), 3.15 (s, 2H, NCH2CH2CONH), 2.70 (s, 2H, NCH2CH2N); l3C NMR (400
MHz, D20  with K2C03): 179.26, 175.30, 148.99, 148.78, 122.63, 59.36, 58.69, 53.46, 41.98;
IR (KBr disc) (cm1): 3438(br), 1712cm'(w), 1666(vs), 1561(w); ESIMS(+ion): found m/z
473.2131, Calc 473.2149 for [(L4) H].+
2.3.1.4.1 Complexation of L4 with MnCIfMnL4)
L (0.079 g, 0.1 mmol) was dissolved in dimethylformamide and MnCl2 (0.021 g, 0.1 mmol) 
was dissolved in minimum amount of H20. The solution of the ligand was added dropwise to 
the solution of the salt and allowed to stir for 20 minutes. Then the solvent was removed 
under high vacuum and the residue was washed several times with acetone and chloroform. 
Complexes ZnL4, CuL was also prepared as per the procedure outlined for MnL4, with 1:1, 
ligand to metal ratio, using their respective chlorides. [Zn (L )] [Cl]2: Pale yellow precipitate 
(91% yield). 1H NMR (400 MHz; D20): 8.25 (d, 2H, J = 6.5 Hz), 8.10 (m, 2H),7.10 (d, 2H, J 
= 7.1 Hz), 6.95 (m, 2H), 4.25(s, 2H), 3,55(s, 2H), 3,45(s, 2H), 3.35(s, 2H), 3.30 (s, 2H), 
3.25(s, 2H), 2.85(s, 2H); IR (KBr pellet, cm'1): 3414(br), 3079(m), 1632(s), 1366(s), 1262(w), 
1029(s). UV/Vis [Xmax, nm (sM, M 'W ) ]  in H20: 234(21,197), 333(10,013), 350(8, 831). 
[Mnn(L4)][Cl]2: Pale yellow precipitate (77% yield). IR (KBr pellet, cm'1): 3230(br) 
1638(br), 1459(w), 1384(s), 1118(s), 1064(s), 1025(s). [Cun(L4)[[Cl]2: Pale green precipitate 
(93% yield). IR (KBr pellet, cm'1): 3427(br), 1638(s), 1379(s), 1261(m), 101 l(s), 1027(s). 
ESIMS(-ion): found m/z 534.1306, Calc 534.1288 for [(CuL4-H)].+
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2.3.1.5 Synthesis of EDTA bisamide of AminoAnthraquinone (L5)
OH HO
\
N N
H
To EDTAbisanhydride (0.926 g, 3.62 mmol), completely dissolved in dimethlyformamide (15 
ml), was added 2-aminoanthraquinone (1.614 g, 7.23 mmol) dissolved in dimethlyformamide 
(15 ml), dropwise. After the complete addition, the reaction mixture was allowed to stir 
overnight at room temperature. Then the reaction mixture was filtered, the filtrate was then 
evaporated to dryness. The crude product was washed with dichloromethane several times to 
obtain the product as dark brown glassy material. Yield 1.6 g, 72%; [H NMR (400 MHz, d*,- 
DMSO: Me4Si) 5H(ppm) 10.6 (s, 1H, CH2COOH), 8.25 (s, 1H, NH), 7.95 (m, 5H, ArH), 7.75 
(s, 2H, ArH), 3.6 (s, 2H, NCH2COOH), 3.5 (s, 2H, NCH2CONH), 2.85 (s, 2H, NCH2); 13C 
NMR (DMSO, 400 MHz): Sc 182.32,181.20, 173.05, 170.96, 144.31, 134.62, 134.31, 133.99, 
133.06, 128.90, 127.90, 126.81, 126.74, 123.94, 116.00, 58.71, 55.77, 53.08, 48.96; IR (KBr 
disc) (cm1): 3440(br), 1673(vs), 1624(s), 1591(vs), 1379(w), 1328(s) 1296(m), 1261(vs); 
ESIMS(+ion): found m/z 725.1837, Calc 725.1860 for [(L5) Na].
2.3.1.5.1 Complexation of L5 with MnCh -MnL5
L5 (0.07 g, 0.1 mmol) was dissolved in dimethylformamide and MnCl2 (0.014 g, 0.11 mmol) 
was dissolved in minimum amount of distilled water. The solution of the ligand was added 
dropwise to the solution of the salt and allowed to stir for 2 h. The solvent was removed 
under high vacuum, and the residue was washed several times with acetone and chloroform. 
Complexation of L5 with ZnCl2 (ZnL5) and Complexation of L5 with CuCl2 (CuL5) was also 
carried out as per the procedure out lined for MnL5. [ZnII(L5)][Cl]2: Dark brown precipitate 
(94% yield). lU NMR (400 MHz; DMSO): 10.51 (m, 2H), 8.40 (s,lH), 8.35 (s, 1H), 8.10- 
8.00 (m, 10H), 7.90 (m, 2H), 7.85 (m, 2H); IR (KBr pellet, cm'1): 3435(br), 1674(m),
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1624(w), 1590(s), 1550(w), 1456(w), 1384(s), 1330(s), 1294(s), 1104(br), 930(m).
[Mn11^ 5)]^!]!: Dark brown precipitate (94% yield). IR (KBr pellet, cm"1): 3793(br),
1674(s), 1589(s), 1559(w), 1549(w), 1419(m), 1095(w). UV/Vis [>wnax, nm (cM, M^cm"1)] in
DMF: 270(75, 143), 243(53,450), 210(42, 643), 339(14, 820). [CiAl/^HClh: Pale green
precipitate (94% yield); IR (KBr pellet, cm'1): 3431(br), 1618(w), 1590(s), 1542(s),
1492(m), 1459(m), 1379(s), 1384(s), 1330(s), 1294(s), 1262(s), 1098(s), 1021(s).
2.3.1.6 Synthesis of EDTAbisamide of Aminomethylsulphonic acid (L6)
OH HO
/ “ A
N N '
\ _ >  ( _ / "  r\( o o
s o 3h h o 3s
2-Aminomethanesulfonic acid (1.56 g, 14 mmol) and NaHCC>3 (0.456 g, 5.43 mmol) was 
dissolved in water (30 ml), and was added EDTA bisanhydride (1.8 g, 7.025 mmol) portion 
wise, the reaction mixture was then cooled down to 0 °C and allowed to stir for 4 h. 
After 4 h the ice bath was removed and allowed the reaction mixture to stir at room 
temperature for 24 h. Then the reaction mixture was filtered and the filtrate was evaporated to 
dryness. The crude product was washed with hot methanol. Yield 0.8 g, 53%; ‘H NMR 
(400 MHz, D20: Me4Si): Sn(ppm) 4.40 (s, 2H, NHCH2S03H), 3.80 (s, 4H, NCH2COOH & 
NCH2CONH), 3.50 (s, 2H, NCH2CH2N); I3C NMR (D20 , 400 MHz) 8C 173.95, 169.56, 
68.89, 67.53, 64.58, 49.13; IR (KBr disc) (cm 1): 3443(br), 3240(br), 3079(br), 1636(s), 
1409(s), 1209(s), 1041 (vs); ES(+ion): found m/z 478.11, calc 478.12 for [(L6)H].+
2.3.1.6.1 Complexation o f L6 with MnCh (MnL6)
Ligand L (0.096 g, mmol) was dissolved in water and MnCl2 (0.024 g, mmol) was dissolved 
in minimum amount of distilled water. The solution of the ligand was added drop wise to the 
solution of the salt and the reaction mixture was allowed to stir for 20 minutes. Then the
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solvent was removed under high vacuum, and the residue was washed with acetone and
chloroform several times.
The complexation of L6 with ZnCl2 (ZnL6) was also carried out as per the procedure
outlined for MnL6. The complexation of L6 with CuCh was not carried out. [Znn(L6)][Cl]2:
Yellow precipitate (48% yield). IR (KBr pellet, cm'1): 3443(br), 1640(br), 1605(w), 1504(w),
1445(m), 1187(m), 1313(w), 1261(s), 1043(s). [Mnn(L6)][Cl]2: White precipitate (62%
yield). IR (KBr pellet, cm'1): 3443(br), 1641(m), 1590(w), 1402(s), 1336(m), 1048(s).
2.3.1.7 Synthesis of EDTA bisamide of the amino acridine (L7)
(a) Deprotonation of Aminoacridine hydrochloride (L7a)
nh2h c ix h 2o
The commercially obtained, 9-amino acridine hydrochloride was dissolved in distilled water 
(with occasional heating). Thereafter, 2-3 pellets of NaOH was added, no sooner, it was added 
the formation of the precipitate was observed (indicating the deprotonation of aminoacridine 
hydrochloride). This was then extracted in to dichloromethane (the problem of partial 
insolubility of the precipitate in dichloromethane was overcome by the addition of small 
amount of toluene and acetone). The organic layer was dried with MgSC>4. The removal of the 
solvents under reduced pressure yielded the pure deprotonated amino acridine as yellow 
powdered solid. Yield 0.3 g, 93%;'H NMR (400 MHz, de-DMSO: Me4Si): 8H(ppm) 8.45 (d, 
2H, J = 8.8  Hz, AiCH2), 7.85 (d, 4H, J = 8.4 Hz, ArCH5), 7.70 (t, 4H, J = 8.0 Hz, ArCHi), 
7.35 (t, 2H, J = 7.6 Hz, ArCH3); IR (KBr disc) (cm'1): 3423(br), 3139(br), 1659(s), 1644(m), 
1592(s), 1542(s), 1372(m), 1267(s), 1163(s), 755(s).
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(b)Synthesis of EDTA bisamides of the deprotonated aminoacridine (L7b)
N = h
To EDTA bisanhydride (0.145 g, 0.564 mmol) dissolved in dimethylformamide (5 ml) was 
added 9-amino acridine (0.220 g, 1.133 mmol) dissolved in dimethylformamide (5 ml), 
dropwise. The reaction mixture was allowed to stir over night at room temperature. 
Thereafter, dichloromethane (50 ml) was poured in to the reaction mixture and stirred for 5 
min. The precipitate was washed thoroughly with acetone and subsequently with acetonitrile. 
Yield 0.2 g, 55%;*H NMR (400 MHz, D20  with K2C 03: Me4Si): 5H(ppm) 7.93 (d, 2H, J = 8.7 
Hz, ArCH2), 7.77 (d, 2H, J = 9.0 Hz, ArCH5), 7.59 (t, 2H, J = 8.8 Hz, ArCKU), 7.27 (t, 2H, J 
= 7.6 Hz, ArCH3), 3.25 (s, 2H, NCH2COOH), 3.08 (s, 2H, NCH2CONH), 2.74 (s, 2H, 
NCH2CH2N); IR (KBr disc) (cm-1): 3423(br), 2963(s), 1643(s), 1593(m), 1482(s), 1387(m), 
1262(s), 1164(m), 1095(s), 801(s).
2.3.1.7.1 Complexation of L7 with ZnCh ( ZnL?b)
L7 (0.064 g, 0.1 mmol) was dissolved in dimethylformamide and ZnCl2 (0.014 g, 0.1 mmol) 
was dissolved in minimum amount of distilled water. The solution of the ligand was added 
dropwise to the solution of the salt and allowed to stir for 20 min. Then the solvent was 
removed under vacuum, and the residue was washed with acetone and chloroform several 
times. Product was obtained as glassy material. [Znn(L7)][Cl]2: Dark yellow pecipitate (96% 
yield). IR (KBr pellet, cm'1): 3413(br), 1638(s), 1592(s), 1504(m), 1478(m), 1379(m), 
1373(m), 1265(w), 1165(s), 1032(m), 859(s).
2.3.1.8 Attempted Synthesis of EDTA bisamide of Trien napthaderivative
To EDTA bisanhydride (0.198 g, 0.774 mmol), dissolved in dimethylformamide (7 ml), and 
was added Trien naphtha derivative (0.505 g, 1.548 mmol) dissolved in dimethyl formamide
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(7 ml), dropwise. The reaction was then allowed to stir over night. Then dichloromethane 
(50 ml) was poured in to the reaction mixture and stirred for 5 minutes, mixture was filtered, 
half way through filtration, added another portion of dichloromethane (50 ml) and filtered 
again. The precipitate was washed thoroughly with acetone and then acetonitrile 
subsequently. The proton NMR spectrum of the product indicated that the reaction is not 
successful.
2.3.1.9 Attempted synthesis of EDTA bisamides of 5-aminonapthalene -2 
sulphonicacid (L8)
To EDTA bisanhydride (0.308 g, 1.20 mmol) dissolved in dimethylformamide (5 ml), was 
added 5-aminonapthalene-2-sulphonic acid (0.538 g, 2.40 mmol) dissolved in 
dimethylformamide (5 ml) dropwise. The reaction mixture was allowed to stir over night at 
room temperature. Thereafter, dichloromethane (50 ml) was poured in to the reaction mixture 
and stirred for 5 min. The reaction mixture was filtered; half way through the filtration added 
another portion of dichloromethane (50 ml) was added and filtered again. The precipitate was 
washed thoroughly with acetone and subsequently with acetonitrile. NMR spectrum 
indicated the presence of starting material along with the desired product.
OH HO
2.3.2 Attempted Synthesis of EDTA bisamide of taurine (L9)
OH HO
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Attempt I
Accurately weighed EDTA bisanhydride (0.36 g, 1.405 mmol) was dissolved in water, and 
NaHC0 3  (0.59 g, 7.02 mmol) added slowly and then Taurine (0.352 g, 2.812 mmol) was 
added at 0 °C. The reaction mixture was allowed to stir at 0 °C for 4 h. After that the reaction 
mixture was allowed to stand in room temperature.
Attempt II
EDTA bisanhydride (0.36 g, 1.405 mmol) was dissolved in dimethylformamide (5 ml), 
similarly Taurine (0.352 g, 2.81 mmol) was also dissolved in dimethylformamide (5 ml). 
After ensuring the complete dissolution of taurine, excess NaHCC>3 (0.59 g, 7.02 mmol) was 
added. The reaction mixture was transferred to the completely dissolved EDTAbisanhydride 
solution dropwise. The reaction was then allowed to stir over night at the room temperature. 
Then dichloromethane (50 ml) was poured in to the reaction mixture and stirred for 
5 minutes. The reaction mixture was filtered and half way through filtration added another 
portion of dichloromethane (50 ml) was added and filtered again. The precipitate was washed 
thoroughly with acetone and subsequently with acetonitrile. The NMR spectrum was not 
promising enough.
2.4 Conclusion
The synthesis of 9 new EDTA based bisamides was attempted, of which 6 ligands were 
successfully prepared and 4 of them have never been made before. These ligands represent the 
first attempt to provide an EDTA based bifuctionalised ligands bearing a chromophoric 
moiety, to act as potential multimodal diagnostic tools/probes.
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CHAPTER 3
DTPA Analogues and DTPA Bis Amides
3.1 Introduction to DTPA derivatives
3.1.1 DTPA
Throughout the history of synthesizing imaging agents, polyamino poly carboxylates (which 
are also known as “ complexones” ), play an important role. DTPA is a polyamino 
polycarboxylate ligand like EDTA. It could be viewed as an expanded version of EDTA. It 
contains the diethylene triamine backbone, which has been modified by five carboxymethyl 
groups.
3.1.2 DTPA as a complexing agent- Historical View
Though this chapter predominantly deals with functionalising DTPA, it is necessary to have a 
clear insight, about the history of functionalising DTPA.
OH
OH OH
Figure 1:- Diethylene Triamine Penta Acetic acid (DTPA)
The following is a brief account of the complexation of DTPA with various transition &
lanthanide metal ions
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3.1.2.1 Complexation with Transition metal cations.
DTPA based transition metal complexes in chelation therapy
The initial field of complexones in biomedical applications was in chelation therapy.1,2 Ca- 
DTPA and Zn-DTPA have been used for over 40 years to speed up excretion of the 
radioactive transuranium elements (plutonium, americium and curium) from the body. In the 
study of ‘Iron storage disease’, the DTPA is used as a chelating agent to measure the iron
T • • Acontent in urine in patients with excess iron stores. Alexander el al. reported studies on the 
effectiveness of Co (II)-DTPA and Zn (II)-DTPA in preventing the retention of radio cerium 
and radio yttrium in a rat. This was found to be insignificantly diminished, when compared 
with Ca (II)-DTPA.
Ruthenium complex as Imaging Agent
In an attempt to develop enhanced, cerebrospinal fluid imaging agent, 97Ru-DTPA was 
evaluated.5 It was found that upon electrophoresis on cellulose acetate in borate buffer (pH 8);
07the unbound ruthenium stays at the point of origin, whereas Ru-DTPA moves toward the 
anode. Thin layer chromatography also indicated 97-99 % chelation of the radiotracer. It was 
shown that the kinetics and excretion of 97Ru-DTPA is similar to those of n lln- DTPA.
Above are the few examples to indicate the efforts on complexation with transition 
metals and its impact to the field of health care. One may, however, find many such examples 
in the literature.
3.1.3 Incorporation of reagents to DTPA based transition metal 
complexes
This could be more effectively done by a brief comparison between its counterpart namely, 
EDTA. EDTA is a hexadentate ligand, whereas DTPA is an octadentate ligand. This feature 
seems to be useful, when complexing with transition metals (such as Zn2+, Cu2+ etc). 
Transition metals usually have a coordination number of six or less. Thus after forming a 
complex with a transition metal, DTPA still has the ability to bind to other reagents. For
• •  linstance, m [CuDTPA] ' DTPA binds in a hexadentate manner, utilizing the three amine
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centres and three of the five carboxylates, leaving the rest, two of the carboxylates for
coordination with other potential reagents. Incorporating these reagents, paves the way for
transition metal complexes of DTP A to be used in variety of fields (specifically in medicine).
Incorporation into liposomes
Naoto et al.6 used " mTc-DTPA in tumour imaging, and studied the bio distribution of " mTc- 
DTPA-encapsulated liposomes in tumour bearing mice and reported a remarkable 
accumulation of the complex in the tumour tissue.
3.1.4 Introducing Lanthanides to DTPA
Atoms having larger radius in periods 5 & 6 of the periodic table favour higher coordination 
numbers, whereas bulky ligands favour lower coordination numbers. When we move across 
the d block, higher coordination numbers are more common on the left of the period and low 
coordination numbers are more common on the right of the period.
The stability of the complex, however, depends on the coordination number. Lanthanide 
favours higher coordination numbers and this has prompted scientists to explore complexation 
of DTPA with lanthanides. A review of the literature reveals a vast amount of information 
with regard to the synthesis of various Ln-DTPA complexes and their variety of uses. In 
respect of the relevancy to the thesis, some of the most important complexes are discussed.
La (III) and Tm (III): Daniele et al.1 have carried out studies on strong ion pair interactions 
between oppositely charged La(THP)3+ complex (THP = l,4,7,10-tetrakis(2-hydroxypropyl)- 
1,4,7,10-tetraazacyclododecane) and that of Tm (III) complexes of DOTA , DTPA, TTHA 
and DOTP.
11Through C NMR spectroscopy, they have examined the lanthanide induced chemical 
shifts of La (THP) 3+ upon adduct formation with Tm (III) complexes. The selection of Tm 
(III) has been justified by its large chemical shifts and the enhancement of relaxation rates.
Dy (III): Luce Vander Elst et a l8 reported complexation studies of Dy complexes of DTPA 
and its derivatives as relaxation agents for very high field MRI. They have also reported its
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beneficial effect on slow water exchange on the Transverse Relaxivities. Dy-complexes are
localized in the extra cellular compartment of healthy tissues, and as a result of their relatively
large magnetic susceptibility, they induce local field gradients that result in a decrease of T2*.
This type of T2* effect, however, requires quite high concentrations of compound.
For lanthanide ions characterized by very short electronic relaxation times, such as Dy
(III), Pr (HI), Sm (III), Ho (III), Er (III), and Yb (III), a sizable contribution to longitudinal
nuclear proton relaxation, resulting from the presence of a large static magnetic moment at
high magnetic fields has been proposed by Bertini et al.9
This contribution, known as ‘Curie relaxation’, originates from the dipolar interaction
between the water protons and a large static magnetic moment arising from the electrons. In
their research, Elst et al.8 showed experimental evidence of the Curie longitudinal relaxation
of different Dy-complexes of similar size and illustrated the influence of the magnetic field,
and the residence time of the coordinated water molecule on the proton transverse relaxation
rate.
Their finding on the complexes of Dy with DTPA derivatives shall be discussed later in 
the chapter. Likewise, there are many examples of lanthanide complexes of DTPA and their 
various applications could be found in a good amount of literature.
The importance of lanthanide complexation with DTPA and their significance in medical 
imaging, however, was not well realised until Gd-DTPA emerged as a successful contrast 
agent.
3.1.5 Gadolinium with DTPA
Gadolinium as a counter part
Gd has attracted the attention of scientists involved in coordination chemistry for several 
reasons. Gd (III) is the only lanthanide which has seven unpaired electrons. It is worth 
mentioning the fact, that two other lanthanides in the f-block, specifically dysprosium (III) 
and holmium (HI) also enjoy higher magnetic momentum (due to orbital contributions to
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electron angular momentum) than Gd (III). They, however, have very rapid electron spin
relaxation due to the asymmetry of these electronic states. In contrast, Gd (III), possessing a
symmetric “ S” state creates an environment more advantageous to electron spins.
This will culminate in slower electronic relaxation rates. In comparison with Dy (III), 
Gd (III) is more closely in tune with the water protons frequency, during the process of water 
proton relaxation.10 Gd, being an obscure lanthanide element in the periodic table, has in the 
course of time, become a well known element in medical diagnostics as in the case of 
platinum in cancer therapeutics and technetium in cardiac scanning. With regard to research 
on contrast agents for MRI, gadolinium now appears to be the centre of such research.
The birth ofGd- DTPA
Gd (III) is a toxic ion. When injected intravenously, the lanthanides (rare earth elements) are 
bound to serum proteins and are readily displaced by weak complexing ions11 ( such as Ca 
(II)) from these proteins. Ionic solutions of the lanthanides will form colloids in vivo and 
undergo phagocytosis by the reticuloendothelial system, leading to accumulation in the liver, 
spleen and bone marrow.
They have long biological half lives (for weeks) with slow excretion in urine, bile and 
faeces. Therefore its toxicity needs to be eliminated or minimised, before it could be 
administered in the body. One of the ways of overcoming this problem is to chelate with 
ligands (since the atoms of the rare-earth elements do not form stable, covalent bonds with 
organic molecules, the paramagnetic Gd ion might be detoxified by complexation). Upon 
complexation, Gd will lose its toxicity (as the toxicity of the paramagnetic chelate is related to 
its stability, measurements on stability-especially on stability constants, will be dealt in great 
detail in chapter 4), but not the magnetic properties. This gives rise to the synthesis of 
Gadolinium chelates and among them Gd-DTPA has its place.
90
Potential Multimodal Imaging Agents
Invention o f  “M agnevist”
A brief account on the success story of Gd-DTPA (commercially known as ‘Magnevist’), is 
appropriate to this chapter. Owing to its success, ‘Magnevist’ serves as a bench mark contrast 
agent for past and future MRI contrast agents.
12.0
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Fig 2:- Influence o f param agnetic ions on p ro ton  T , re laxa tion  tim es, it becom es clear
th a t com paratively , Gd possess high T! re laxation  tim es o f hydrogen  pro tons
The powerful proton-relaxing effect of gadolinium can be attributed to a complex 
interplay of several factors, which includes a strong magnetic moment, long electron-spin- 
relaxation time, isotropy of g-tensors, rotational tumbling time, configuration and mobility of 
molecules of hydration and the proximity of hydrogen nuclei to the paramagnetic centre. 
Chelating gadolinium to EDTA or DTPA diminishes, but does not eliminate, gadolinium’s 
strong influence on proton Ti and T2 relaxation.
The coordination number of Gd (III) is estimated to be 9 or 10.12 Therefore by using 
DTPA which has eight coordination sites as a chelating ligand, only eight of gadolinium’s 9 
or 10 possible coordination sites could be filled. This leaves at least one or two sites open for 
fast-exchanging water protons to approach closely to the paramagnetic centre of the complex. 
The relaxivity enhancement of water protons is directly proportional to the number of 
available coordination water protons per paramagnetic ion. Therefore gadolinium complexes 
(Gd-DTPA and Gd-EDTA), compared with free gadolinium species, would be expected to 
have a reduced relaxation effects on water molecules. This expectation was perfectly 
supported by Weinmann’s results.13
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Chelation effects and reduction in toxicity
The combination of Gd and DTPA minimises the toxicity, compared to the two components 
individually.14 This is reflected in the pharmacokinetic behaviour of Gd-DTPA when 
compared with gadolinium trichloride. Whereas the gadolinium ion from the gadolinium 
trichloride is largely retained by the organism; in particular in the liver and spleen, Gd-DTPA 
leaves the body within the first few hours, after its intravenous injection. There is no 
significant amount of dissociation of gadolinium from the Gd-DTPA complex noted within 
the body. In short, Gd-DTPA had been proved to have strong proton relaxation enhancement 
with relatively high in-vivo tolerance and also since it is a hydrophilic complex it is rapidly 
excreted, predominately in the urine. Furthermore, it has not dissociated in vivo.
Need for DTPA based bisamides
As for the above mentioned qualities, one would wonder, what is the need for further 
development and modifications of this unique contrast agent? The answer is quite straight 
forward. As mentioned earlier, the concentration of the gadolinium complex should be 
approximately twice as that of free gadolinium ion (this has been estimated as 0.01-0.05 
mmol/kg body weight). Further, there are medical applications which require higher dosages 
up to 0.3 mmol/kg body weight. At the outset, one may assume, the problem is of an 
economical nature and that, it could be overcome easily. The subtlety of the problem, 
however, lies in osmolarity.
Osmolarity is influenced by the two residual negative charges of the Gd [DTPA] 2' and 
usually the osmolarity is regulated around 300 mmol /L. Raising this level with injected ions 
results in the collection of water within the unbalanced region, ultimately resulting in diluted 
ion concentration. This will lead to an osmotic shock to the red blood cells with consequent 
haemolysis.15 This has brought up the need for two balancing meglumine cations, a total of 
three particles, to contribute to osmolality. This was a powerful stimulus to the development 
of low osmolarity agents (both ionic and non ionic).
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As with the iodinated agents, one way to reduce osmolality without reducing the
concentration of the active agent is to make a non-ionic molecule.16 This very fact supports
the discovery of DTPA based bisamides.
Having established the necessity for DTPA based bisamides let us now see how the 
requirement was fulfilled.
3.1.6 Synthetic methodologies for introducing functionality to DTPA
DTPA offers the advantage of incorporating a well-defined structural molecule, to a chosen 
biological molecule (which could be proteins in the blood, antibodies or similar biological 
macro molecules). To understand how this was made possible, it is necessary for us to know 
the various ways and means of incorporating functionality to DTPA ligands. This has been 
achieved in the past, through two major strategies.
Since we have utilised both these strategies, it will be appropriate to have a clearcut 
understanding of these strategies and how they had been utilised in the past.
First is to synthesize the anhydride of DTPA through condensation with the aid of acetic
17anhydride, then to react the DTPA bisanhydride thus synthesized with the appropriate amine 
functionalised reagents to produce DTPA based bisamides.18 These reagents could contain 
aliphatic or aromatic groups or both.
The second strategy was to use a retro synthetic approach to produce an analogue of 
DTPA, in which N,N-Bis[(tert-butoxycarbonyl)methyl-2-bromoethylamine (see Fig-3) will 
dialkylate an amine containing reagent.
Figure 3:-N, N -Bis [(tert-butoxycarbonyl) methyl -2-bromoethylamine
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Synthetic Methodologies for functionalising DTPA
Based on formation of Analogues of DTPABased on reaction with DTPAA
Backbone SubstitutionSubstitution in 
Terminal Acetic 
Acid group(s)
Confirmationally
constrained
structures
^ C O H
ryNvo-"js:
HO N\
Substitution in the 
Terminal Nitrogen
O H
H O ^ O  0 - _ ,O H
Substitution in the 
Carbon
HO2C-CH2 R
'O H H O '
Figure 4:- Schem atic rep resen tation  o f vario u s stra teg ies  h and led  to  functionalise D TPA 
Eckleman’s preparation o f DTPA bisanhydride (DTPAA)
In 1975, Eckelman et al}9 synthesized DTPAA from DTPA in which DTPA was suspended 
in pyridine, acetic anhydride was added and the mixture was stirred at 65 °C for 24 hours. 
This method is then referenced by many other papers.20
F igure 5:- bis anh y d rid e  form  of D T PA  synthesized by Eckelm an eta l (DTPAA)
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а) Synthesis of Bisamides with a focus on extended alkyl chains to acts as amphilic 
chelating agents
The nature of the derivatives of carboxylic acid groups can have a significant impact on 
solubility. For instance, water solubility of the complex is considerably reduced by 
derivatizing the hydrophilic carboxylic acid groups with hydrophobic alkyl amide groups. 
This will in turn affect the tissue selectivity of the complex in physiological fluids. The 
hydrophobicity of the complex will make them tend to associate with cells.
Extending the alkyl chains is one way of achieving this hyodrophobicity. Alkyl chains 
could be extended with hydrocarbons as well as from amino acids. In 1981, Hnatowich et al.21 
prepared DTPA-Octadecylamine through DTPAA. They have utilised the Eckeleman et al 
method to prepare the DTPAA and have reacted with octadecyl amine (stoichiometric ratio of 
1:1.1) in chloroform at room temperature for 48 h. The precipitate was filtered and the crude 
product was treated with boiling water to remove excess anhydride and subsequently 
recrystallized to obtain the pure product. Later, Kabalka et al.22 had used Hnatowich et al.21 
method to produce DTPA distearylamide (DTPA-SA), DTPA distearylester (DTPA-SE) from 
stearyl alcohol and also DTPA-distearylthiolester (DTPA-ST), from octadecanethiol (see Fig-
б). Octadecanethiol, however, was dissolved in pyridine instead of chloroform. In line with 
Kabalka, amphilic DTPA bisamide of hexadecyl amine and DTPA bisamide of tetradedecyl 
amine were prepared respectively by Jasanada et al.23 and Kimpe et a l24 Jasanada et a l23 also 
prepared DTPA-Octadecylamine (see Fig-7), while Kimpe et a l24 also synthesized DTPA-
BC14, DTPA-BC16 and DTPA-BC18 (see Fig-8).
OH
OH
Figure 6:-Amphipathic derivatives of DTPA prepared via the reaction of DTPAA with 
Stearylamine (X = NH), stearyl alcohol (X = 0), and octadecanethiol (X = S)
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C H 3 - ( C H 2 ) n '- C H 2 - |H 2  O H  ^ - C H 2 -(C H 2)n '-C H 3
'O
Figure 7:- Depicting DTPA-bis (hexadecylamido), n’= 13 and DTPA-bis (octadecylamido), n’=15
OH
HOOH
DTPA-BC14, R= C 14H29 
DTPA-BC16, R= C 16H33 
DTPA-BC18, R = C lgH37
Figure 8:- Amphiphilic chelating agents prepared by Kimpe et a l 
X. Zhao et al.25 synthesized amphiphilic ligands from alkyl ester of amino acids, namely
tyrosine and phenyl alanine. The ligands diethylenetriamine-N,N"-di(acetyl-L-phenylalanine
octadecylester)-N,N,N"-triaceticacid DTPA-BPO) and diethylenetriamine-N, N"-di(acetyl-L-
tyrosine octadecylester)-N,Nf,Nf,-triacetic acid (DTPA-BTO) were synthesized from DTPAA
with L-phenylalanine octadecylester hydrochloride and L-tyrosine octadecylester
hydrochloride respectively in pyridine (see Fig-9). Pyridine was used as solvent and as well
as the scavenger of hydrochloric acid.
c«2 c h 2
Figure 9:-DTPA based bisamides of L-phenylalanine octadecylester and L-tyrosine octadecyl ester 
Where R =H, DTPA-BPO; R =OH, DTPA-BTO
These long chain amphilic derivatives were mostly used to label liposomes. While, the alkyl
chain anchors the molecule to the lipid bilayer, the lipophobic DTPA on the surface is
exposed for chelation. Hnatowich et a l21 labelled with 67Ga and conducted bio distribution
studies, while Kabalka et al.72 labelled with Gd and utilised as MRI contrast agents for liver
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imaging. Further, X. Zhao et al.25 utilised the amphilic derivatives to produce lamellar
membrane liposomes as drug carriers for the liver. On the other hand, Kimpe et al.24 prepared
Gd complexes and subsequently incorporated them into mixed micelles to produce
supramolecular structures with decreased rotational motion.
c) DTPA based bisamides short chain alkyl amines
DTPA based bisamides o f higher alkyl amines and complexation with Fe (III)
In 1987, Quay et al.26 described the synthesis of DTPA bisamide (diamido acetyl diethylene 
triamine triacetic acid) and consequently complexed with Fe (III) chloride to produce, 
potential, low osmolality contrast agent. DTPAA was added in to 5 percent (v/v) ammonium 
hydroxide in water and the mixture was refluxed overnight to produce the amide derivative 
(diamido acetyl-diethylene triamine triacetic acid). The corresponding higher homologs of 
alkyl amines (dissolved in chloroform) were used to synthesize higher homologs of DTPA 
bisamides.
The paramagnetic complex has a prolonged circulation time due to its high stability (the 
stability constant not reported). They have pointed out that the amide contrast agent is less 
affected by enzymes degradation than simple ion-DTPA chelates (possibly due to increased 
molecular weight, which prevents immuno recognition27). In addition, the higher homologues 
of DTPA bisamides tend to be less polar and to bind more to serum proteins, increasing their 
circulation time further. It was reported that these agents will be appropriate for imaging the 
hepatobiliary system.
DTPA-bis propylamide and DTPA-propylpofyester
Sherry et al.2* synthesised DTPA-bispropylamide (DTPA-PA) (see Fig-10). 
Isobutylchloroformate and N-propylamine was added dropwise to a solution of dry 
acetonitrile, DTPAA and triethylamine. The product was obtained on an anion-exchange 
column. The same procedure was then used to prepare DTPA-propylester (DTPA-PE), except 
a large excess of n-propanol was added instead of n-propylamine.
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DTPA-PA; DTPA-PE;
D T P A -P AD T PA -A P D
F ig u re  10:- D TPA  based bisam ides an d  es te rs  p re p a re d  by  S h e rry  et al. inc lud ing  D T PA -PA 2 
D T P A -A P D  w as pu rchased  an d  p u rified  th ro u g h  a n io n  exchange ch ro m a to g rap h y .
Following Sherry, Konings et al.29 synthesized DTPA-Bis(ethylamide)dihydrate (see Fig-11). 
Instead of acetonitrile, they have used water as the solvent.
F igu re  ll:-S y n th e tic  p lan  fo r D T PA  based  b ise th y la m id e  fo llow ed by  K onings et aL
While Cacheris et al.30 followed Quay et al.26 procedure to prepare DTPA bisamide of 
methylamine, following year Geraldes et al.31 synthesized DTPA-bis (propylamide) as per 
the procedure mentioned by Sherry et al.2i Vander Elst et a l32 synthesized a series of DTPA 
bisamides by adapting Konings et al.29 procedure, reacting DTPAA with ammonia, 
ethylamine, n-butyl amine and bismethylamine (see Fig-12).
o
F igu re  12:- D T PA  bisam ides p re p a re d  by  V a n d e r  E ls t et a l , w h ere  R =-N H 2, - 
N H C H 2C H 3, N H -(C H 2)3-C H 3 a n d  N  (C H 3)2
In 1995, Geraldes et al.33 employed a slight modification to the procedure of Krejcarek 
and Tucker34 thereby synthesized a library of DTPA bisamides of alkyl amines. Synthetic 
procedure undertaken as follows: DTPAA was added to an ice cold, vigorously stirred
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solution of the amine. The reaction mixture was filtered and the crude product was
recrystallized. The procedure was untilised to synthesize DTPA-PA, DTPA-MA, DTPA-EA,
DTPA-BA, DTPA-HPA, DTPA-MEA, DTPA-NDMA, DTPA-MPEA, DTPA-BHEA and
DTPA from their corresponding amines (see Fig-13).
HO' OH
N N
.OH
O
,33
R,= R2 =  NHCH3 D T PA - M A 2
R j- R2 = NHC2H5 D T PA - E A 2
R,= R2 = NHC3H7 D T PA - P A 2
R,= R2 = n h c 4h 9 d t p a - b a 2
Ri= R2 = NHC7H15 d t p a - h p a 2
Rj= R2 = NHCH2CH2OCH3 d t p a - m e a 2
R1= R 2 = NH-N(CH3)2 d t p a - n d m a 2
R,= R2 = NHCH2CH2N(CH2CH2OH)2 d t p a - b h e a 2 
R ,= R2 = NH2 D T PA - A 2
R,= NHC3H7 R2 = OH D TPA -PA
R, = R2 = NHCH2CH2- N J 3  D TPA -M PEA 2
F ig u re  13:- D epicting various p re p a ra tio n s  o f  D T P A  b isam id es by  G era ld es  et al.'
The aforementioned bisamides were complexed with lanthanide ions and their lanthanide
• * 9Qcomplexes have been investigated for various purposes by these scientists. Konings et al. 
reported that the studies on their Gd complexes have proved the amide carbonyl oxygens play 
a prominent role in the metal ion coordination. Cacheris et al. have investigated the 
relationship between thermodynamics and the toxicity of Gadolinium complexes, while
1
Geraldes et al. studied the structural dynamics of Ln (III) complexes. In a separate research 
project, Geraldes et al investigated the effects of replacement of the carboxylates with
amide groups. They have determined the efficacy of the resulting Gd (III) complexes as
contrast agents. The efficacy of these potential agents was studied through the determination 
of their stabilities and relaxivities. Vander Elst et al?2 prepared Dysprosium complexes of 
their bisamides and investigated the possibility to act as potential negative contrast agents, on 
the basis of high field effect on the water protons.
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DTPA based mono and bis and Tris alkyl amides
In line with Geraldes et al , a decade later, Jaszberenyl et al. also investigated the effect of 
replacement of a carboxylate with an amide group and its impact on the water exchange rate 
of the gadolinium complexes. Following the procedure o f Geraldes et al.31, they, however, 
have synthesized DTPA-N, N-bis [bis (n-butyl)]-N-methyl-tris (amide) (see Fig-14) instead 
of DTPA bisamide. Since the amide donor group does not bound to the metal as strongly as 
carboxylate, steric crowding becomes less prominent. This in turn leads to lowering the water 
exchange rate. In line with this, they have found that the gadolinium complex of the trisamide 
derivative have slower water exchange rate compared to gadolinium complex of the bisamide 
derivative. Investigations also revealed that the rate of water exchange of bis and tris amide 
derivatives are reduced in comparison to [Gd (DTPA) (H2O)] ". Activation volumes justified 
a dissociative interchange and a limiting dissociative mechanism
NHCH3
.OH .OH
HO,
A cetic
an h y d rid e
OH
NHCHj
o
n -b u ty lam in e
O
NHCH3
o , ^  -O h  o ^  ^ o h
N N
(n-Bu2)N J  L   . N(n-Bu2)
O O
Figure 14:- Synthetic scheme depicting the synthesis of DTPA based Mono ethylamine
propylamide 
DTPA based bisamides bearing aromatic amines
Apart from aliphatic amines, aromatic amines also employed to produce DTPA based 
bisamides. In 1995, following the method of Konings, Bligh et al.36 synthesized a series of
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DTPA bisamide complexes containing, methylene phenyl, and ethylene phenyl side chains
along with isopropyl and isobutyl. (see Fig-15).
■OH
HOOH
Figure 15:- A representative diagram to show the DTPA bisamides of iso propyl, 
methylenephenyl and ethylenephenyl. L1; R-Pr1. L2; R-Bu1, L3; R-Bz, L4; R-Phenyl ethyl
Yun.Ming et al.37 also followed the procedure of Konings et a l29 and synthesized three 
DTPA bisamides derivatives of benzyl amine, isopropyl amine and tert-butyl amine 
(see Fig -16).
Figure 16:- Depicting DTPA based bisamides of isopropyl amine, tert-butyl amine, Benzyl 
amine R: CH (CH3>2, C (CH3)3, and CH2C6H5 
As aforementioned, Bligh et al. earlier published their work on non-ionic, bulky chelates.
Four years later, in an extended series of preparation they have produced DTPA-bisamides
containing isopropyl, isobutyl, cyclohexyl, 2-norbomyl, methylnephenyl, ethylene phenyl and
2-ethylhexyl side chains.38 See Fig-17.
o
OH
.OH .OH
RHN NHR
r  Abbreviated name
isopropyl DTPA-B(iP)A
isobutvl DTP A-B(iB)A
cwlohexvl DTPA- B(iCH)A
2y-nortomyl DTPA-B(NB)A
methylenephenyl DTPA-B(meP)A
ethylenephenyl DTPA-B(etP)A
2-ethylhexyl DTPA-B(etH)A
Figure 17:- Series of DTPA based bisamides synthesized by Annie Bligh et al.
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Feng et al.39 prepared a series of DTPA bisamides. Among these DTPA-BIN (see Fig-18)
thought to be potential, low osmolality hepatic contrast agents.
OH
° % ^ OH ° % ^ ° H
c h 3  n
I
.N
h 3 c '
N CH3
IVL
'CH3
O O
(a)DTPA- BDMA 
O
'OH
O
N CH2 CH3
'CH2 CH3
(b) DTPA- BDEA 
O
HO-
N
HNHO.
ONH
(c) DTPA- BIN
Figure 18:- Depicting the DTPA bisamides of prepared by Feng et aL 
Bligh et al. carried out a comparative study of the nuclear magnetic relaxation dispersion
(NMRD) profiles for their Gd (III) complexes. Later, they have explored the chemistry of
their Gd (III) chelates for their target specific ability and relaxation enhancement on water. On
the other hand, Yun.Ming et a l31 measured the stability and selectivity constants with metal
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ions such as Gd (III), Zn (II), Ca (II), and Cu (II) to evaluate the possibility of using the
complexes of their bisamides as potential MRI contrast agents.
c) DTPA based alkoxyalkylamides
Aliphatic and aromatic alkoxy alkyl amines was also employed to synthesize DTPA based 
alkoxyalkyl amides.
Based on aliphaticalkoxy amines
Webber et al.40 in their patented research described the synthesis of DTPA based 
alkoxyalkylamides.,,Bis[N-(2-methoxyethyl,)-carbamoylmethyl] diethylenetriamine-N, N’, 
N"-triaceticacid (see Fig -19) was prepared by a stirred suspension of DTPA-bisanhydride in 
isopropanol with 2-methoxyethylamine.
This method was also used to prepare other alkoxyalkylamides by reacting methoxy
propylamine, methoxybutylamine, ethoxyethylamine, ethoxy propylamine, ethoxy butyl
amine with DTPAA (in the stoichiometric ratio of 1:2).
r  n °  n
T 1 II 1Ri C— H2 C ^  CH2 ----£  Rl
N — A  N
Ri C— H f /  CH2 ----C R,
S Ho o J
Figure 19:- Representative diagram of DTPA alkoxy amide prepared by Webber 
where R, represents the alkoxy amines.
In their patented research, Delaire et al.41 reported a similar synthesis of DTPA alkoxyalkyl 
amides but modifying the synthetic conditions. These modifications are suitable for large 
scale preparations of MRI contrast enhancement agents as claimed by Delaire et al.41 DTPAA 
was reacted with the primary or secondary amines; alkyl (mono, di and polyhydroxy) and 
alkoxy amines. Contrary to Webber’s procedure they have added co-solvents to this reaction 
mixture (mostly they have used mixture of IP A /acetonitrile).
DTPA-bis(methoxyethylamide) (MEA), DTPA-bis(methylmethoxyethylamide) 
(MMEA) and DTPA-bis-(hydroxyethylmethoxyethylamide) (HEMEA) were synthesized by
A*JH.Imura et al. They have reacted DTPAA with appropriate amines according to the 
procedure described by Webber et a l40 See Fig-20.
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F ig u re  20:- D T PA  based  alkoxyalky l am id es  p re p a re d  by H .Im u ra  et al., w here  
R = H  (M EA ), R = C H 3 (M M E A ), R =  C 2H 4 0 H  (H E M E A )
Webber et al.40 measured the Ti and T2 relaxivities of the gadolinium complex of the DTPA 
bisamide, which were 4.69 and 4.40 mm'V^at 10 MHz, 37 °C) respectively, while H.Imura 
et al.42 investigated the thermodynamic parameters. Thermodynamic parameters such as 
entropies and enthalpies are valuable information in understanding the role of ligand structure 
in paramagnetic complexes (especially, when investigating complexes useful for MRI). 
H.Imura et a l42 attributed the large, positive entropy changes to the bonding between the 
carboxylate groups and that of Ln (III). Negative enthalpy values have been attributed to the 
coordination of the nitrogen donors and the amide groups. They also found that two amide 
groups replace two water molecules upon complexation with Ln (III).
Based on aromatic alkoxy amines
• i lYun-Ming-Wang et al. reported the synthesis of DTPA bis amide derivatives of 
adamantanamine, 2-methoxybenzylamine and 2-methoxyphenethylamine. They have once 
again used the procedure of Konings et al. (with slight modification to that they have done 
in the previous year) (see Fig-21).
F ig u re  21 :- D T PA  b ased  b isam ides a d a m a n ta n a m in e , m ethoxybenzy lam ine 
an d  2 -m eth o x y p h en e th y lam in e
Later, Yun-Ming Wang et al.44 synthesized diethylenetriamine-N,N,N-triacetic-N,N-bis(2- 
methoxyphenethylamide) (see Fig-22). In fact they prepared DTPAA as described by 
Eckelman et al.19 and have reacted with 2-methoxyphenethylamine, according to the
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procedure described by Konings. They have used DTPAA and amine in 1:3 stoichiometric
molar ratios, instead of 1:2 used by Konings.
F ig u re  22 :- D T PA  based b isam ide o f  d ie th y le n e tr ia m in e -N , N , N -triace tic -N , N- bis
(2 -m eth o x y p h en eth y lam id e)
Yun-Ming-Wang et al.43 in their previous project utilised their bisamides to study the 
interaction of those bisamides with metal ions such as Gd (III) and its competing endogenous 
cations (Zn (II), Ca (II), Cu (II)) towards producing a potential MRI contrast agent.
In the present project,44 however, they have utilised their bisamide to prepare 
complexes of gadolinium and its interaction with bovine serum albumin (BSA). They 
suggested that the observed relaxivity increase may be assigned to the ability of the methoxy 
functional group to support network hydrogen bonded water molecules in the second 
coordination sphere of the Gd (III) ion, nearer to the surface of the BSA. This is further 
justified by the possibility to exclude the change in the coordination number of the metal ion 
(upon interaction of the complex with BSA). They also investigated the 170  NMR shifts of the 
dysprosium complexes
F igu re  23:- D TPA  based  b isam ide o f  d ie th y le n e tria m in e -N , N , N -triacetic-N , N- bis
(2 -m eth o x y p h en eth y lam id e)
d) DTPA based Phenyl amides
DTPA based bisamide o f benzyl amine as a chelating agent for MRI contrast agent
Aime et al.45 attempted to produce a low osmolality paramagnetic contrast agent, which was
reported in 1997. They synthesized bis (benzylamide) diethylenetriaminepentaacetic acid
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(BBA-DTPA) and its Gd (III) and Lu (VI) complexes. DTPAA and benzyl amine was reacted
together in DMSO at room temperature. Acetone was used to remove excess DMSO during
the work up. Among the three factors (high relaxivity, thermodynamic stability and water
solubility), water solubility is drastically reduced by the introduction of hydrophobic
substituents. DTPA-Bisphenylmethyl amide was found to increase the water solubility of the
paramagnetic chelate than DTPA-Bisphenylamide (i.e. from 0.049M-0.08M at 25 °C).
F ig u re  24:- D TPA  bisam ides o f  benzy l am in es a n d  m e th y l benzyl am ine  
w here  R  = C H 3, R = P heny l, R = P h en y l m ethy l
DTPA-bis (benzylcarbamoylmethyl) amide derivative
The prominent role played by yttrium in the field of radio immunotherapy attracted the 
attention of David Parker46 and his colleagues. Therefore in order to carry out investigations, 
they also synthesized N,N”-bis(benzylcarbamoylmethyl)-N,N,N”-diethylenetriaminetriacetic 
acid (see Fig-25). Synthetic procedure followed could be summarised as follows. DTPAA 
was reacted with benzyl amine, using pyridine as solvent. Precipitate obtained upon pH 
adjustment (3.5) was further washed with diluted hydrochloric acid. The obtained crystal 
structure of yttrium complex revealed the amide carbonyl ligation occurs in a distorted mono­
capped square-antiprismatic structure. This also indicated only one water molecule bound to 
the metal.
OH
F igu re  25: - D T PA  b isam ides o f  m ethy l b en zen e  syn thesized  by D avid P a rk e r  et aL
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DTPA based bisamide o f (3-aminophenyl) boronic acid
Aime et al.41 investigated paramagnetic probes with regard to their application in clinical 
chemistry (determination of analytes concentration). These paramagnetic probes could 
influence the relaxation properties of the solvent water protons. This in turn is dependent on 
the degree of interactions of these probes with the analytes. Therefore this interaction 
facilitates the determination of analytes concentration (10-4-10"5 M). They have synthesized a 
suitable functionalized derivative of the DTPA-gadolinium complex. They have prepared 6- 
(carboxymethyl)-3,9-bis((N-3-boroxyphenyl)carbamoyl)methyl)-3,6,9-tria-undecanedioiacid. 
DTPAA was reacted with (3-aminophenyl) boronic acid sulphate in DMSO. Stability constant
17 —1measured was 1.1 x 10 M
They measured the proton relaxation times of solutions of bisamide (0.56 mM) 
comprising variable concentrations of human serum albumin at various degrees of glycation 
(measured by fructosamine method).
A good linearity between the relaxivities and albumin fructosamine concentration also was 
reported. This in turn justifies the ability of the method to probe and determine gylcated 
proteins.
F igu re  26:- D TPA  based  b isam id e  o f  (3 -am inopheny l) bo ron ic  acid 
The Ti relaxivity reported by Aime et al. for the Gd complex of this DTPA based bisamide of
(3-aminophenyl) boronic acid is slightly less than (4.6 mM'*S'1 (at 20 MHz, 25 °C) that of
their previously reported gadolinium complex (Gd (III) DTPA-BBA), which has enjoyed
4.78 raNT'S'1 (at 20 MHz, 25 °C).
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DTPA based bisamide o f isoniazid
More recently, in an attempt to decrease the side effects associated with hyperosmolality and 
to improve the tissue- and/or organ-specificity of the paramagnetic chelates, Zhang et al.48 
prepared a novel DTPA based bisamide. Taking into consideration, that isoniazid is a very 
useful medicament to treat tuberculosis and its excellent solubility in water they have 
designed and synthesized a novel ligand from DTPA and isoniazid. DTPAA was reacted with 
isoniazid in pyridine. The novelty of the ligand was justified by its high Ti relaxivity (6.08 
mM'1S'1 (at 20 MHz, 25 °C) high thermodynamic stability (102084) and also by its high 
affinity for serum proteins (upon protein binding, T i relaxivity was 9.09 mM'1S'1 (at 20 MHz, 
25 °C)).
F igu re  26:- S ynthetic  schem e o f  D T P A  b ased  b isam id e  o f  Ison iaz ids 
DTPA based bissulphonamides
In 2000, Scozzafava et al.49 had prepared a series of DTPA based bissulfonamides 
(see Fig-27). They have shown that the Zn complexes of these derivatives have topical 
antiglaucoma properties. The method used was as follows. DTPAA was added to a solution of 
4-(2-aminoethyl)-benzene sulphonamide dissolved in anhydrous dimethylformamide. The 
mixture was stirred at room temperature for 4 h. Then it was poured in to large excess of 
dichloromethane and the solid obtained was filtered and washed with dichloromethane and 
acetone. The crude product was purified by HPLC.
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F ig u re  27:- A L ib ra ry  o f  D T P A  b ased  S u lp h o n am id es
3.1.7 Creating DTPA functionality- A Retro synthetic approach
The most commonly used method for attaching DTPA chelates to other molecules involves 
the reaction between the cyclic bisanhydride and an amine residue on the target molecule. The 
stability constant, K, of the resulting carboxamide-derivatized metal chelate can be lower than 
that of the parent carboxylate by several orders of magnitude. For instance Gd(DTPA) is more 
stable than Gd(DTPA-BMA) by a factor of 102 9 at pH 7.4. Another disadvantage of the 
carboxamide-derivatized metal chelate is their reactivity towards water in the aqueous 
solutions, in which the anhydride and bio molecule are frequently coupled. To circumvent this 
challenge, large excess of the anhydride must be used. More over, the bisanhydride contains 
two identical reactive groups and should be viewed as a potential cross-linking reagentsoand 
also leads to denaturation of the antibody.
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A plausible solution to these difficulties is a well-characterized metal chelate bearing a
reactive functional group, such as an isothiocyanate, through which the chelate, with its full
complement of carboxylates, may be attached to another molecule.
The potential utility of radioisotope conjugates (in both the detection and treatment of
neoplastic disease) leads to the discovery of many synthetic approaches, specifically linking
radionuclide to Immunoglobulin. Further this is best achieved by the use of “bifunctional”
chelating agents (hence, molecules possessing both an array of metal binding groups (i.e., a
chelating function) and an additional moiety through which the chelating portion of the
molecule may be covalently linked to a protein (i.e., a protein-reactive function)). Most work
to date has employed DTPA as the bifunctional chelator, methods having been developed;
seek to use one of the five carboxymethyl groups in forming an amide bond to the antibody
while the other four remain available for metal binding. Bifunctional chelating agents that
incorporate a unique protein-reactive site should avoid a potential cross linking problems.
There are several such systems known to date. Tracing back the history of
synthesizing analogues of DTPA, initially leads on to the work of Sunberg et al.51. They have
synthesized EDTA derivative bearing a p-amino phenyl substituent, the details of which had
been discussed in Chapter 2.
3.1.7.1 DTPA analogue through backbone substitution
Prior syntheses of functionalized DTPA analogues have two kinds of sub strategies. First is to 
place a p-nitro benzyl group at the methylene of a terminal acetic acid. Second is to have it on 
the diethylenetriamine backbone.
3.1.7.1.1 Substitution in the Central Nitrogen
I. Through central acetic acid arm with amino acids
The central acetic acid group of the parent DTPA structure would bear the functional group. 
By placing the branching group on this central acetic acid, certain symmetry would be 
retained in the ligand arms. In addition, depending on the selection of amino acid, it is 
convenient to have various functionalities.
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DTPA analogue from  L- cysteine
For instance, Choi et al synthesised a DTPA analogue which is derived from L-cysteine via 
N-dialkylation, using a bromide equivalent to 2, with R = t-butyl groups. The reaction method 
was very long, and is shown in scheme 2(see Fig-28). Compound 6 was obtained as pale 
yellow oil. From 6, the t-butyl and t-boc groups could be removed, or further functionality 
could be added. In this case it was attached to biotin.
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Scheme 1 :Reaction pathway o f  thecysteine based DTPA. Reagents and conditions; (a) 
BrCH2C 00tB u /K 2C 0 3/DM F/RT,48 h; (b)NBS/PPh 3 /CH 2 Cl2/0 °C, 2 h; (C) (B oc)2 0 /  
TEA/ CH3 OH;(d) NBS/PPh3 /CH 2 Cl2  /0  °C; (e) Cysteinm ethylester/NaO CH 3 /CH 3 OH/ 
RT; (f)Compound 2, phosphate buffer pH = 8 /RT.
O
H
t-B oc-N
A Y *V " N J
V  V  \° A  
° k  0
H,N
N °  ° ^  
°Y~NJ V
\ °  v  vy.
° y  °
N. O^ .OH
H2N -^
< y V
OH y >  Vj^OH  
OH O
Biotin-N O
N C y O H
V A  k^
OH k ^ O  k ^ O H  
OH O
Scheme 2:Hydrolysis and biotinylation o f  the DTPA derivatives. Reagents and conditions;
(g) C-HC1/70 °C /Ihr; (h)3M  HCl/Ethylacetate/RT,30 h; (i) Biotin/TBTU/TEA/CH 2 Cl2/RT 
and 2.C-HC1/70°C.
Figure 28:- Synthetic scheme depicting the preparation of biotinylation of the DTPA
Derivatives
Potential Multimodal Imaging Agents
DTPA analogue from L-phenylalanine
Syed et al.53 have chosen a different strategy for backbone, by modification of DTPA. It was
based on the stereospecific displacement of triflate group of a 2-hydroxycarboxylic acid 
ethylester with amino group of p-nitro-L-phenylalanine methyl ester under complete inversion 
of configuration. Further these derivatives have not been prepared in enantiomerically pure 
form.
Fig-29 and Fig-30. The stepwise synthesis of 10, (see Fig-29) invokes the freedom of 
selection for carboxyl protecting groups. This will in turn facilitate deprotection and any 
further modifications. The position of this substituent can have important effects on 
confirmation and stability of the resulting metal chelate.
approach. Anelli et al. synthesized DTPA analogue, starting from L-glutamic acid and 
L-lysine. They have discovered using such methodology, and suitable protections, 
conveniently yield DTPA Pentaesters. The following is a brief account of their methodology. 
1-tert-Butyl 5-benzyl diester reacted with bromide 2 to afford hexaester. The isolation of 16 in 
fair yields is related to the easy lactamization of both 15 and the monoalkylated intermediate.
Therefore, Williams and Rapport54 devised a strategy to produce DTPA analogues in
pure forms, from amino acids. They have proposed the N-alkylation strategy as depicted in
1 .h n o 3/h 2s o 4
2. BnOH/TsOH'
L-phenylalanine
12
R = p-nitrobenzyl
HO 1. DMF/KHCO3
2. BrCH2C 0 2R '
X
NBS/Ph3P
,  13a R= Bn, X= Br 
13b R= Bu‘,X= Br
F ig u re  3 0 :-P re p a ra tio n  o f b rom oderiva tive . 
a n d  alcohol derivative .
14a R= Bn, X = OH 
14b R= Bu‘,X = OH
R'-R^R3-  Bn
F igure  29:- A lkylation s tra teg y  devised by 
W illiam s an d  R a p p o rt
DTPA analogue from L-glutamic acid and L-lysine
Five years later, after Williams and Rapport, Anelli et al.55 came up with an exciting
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The dialkylation of 15 was carried out in homogenous phase, eliminating the need for two-
phase conditions (as proposed by Rapport et al.) and proved to be the best. The cleavage of
the benzyl ester protection of 16 by hydrogenolysis yielded the monoacid pentaester 17. On
the other hand, to obtain a DTPA pentaester with a free amino group, commercially available
N6-Cbz L-lysine was esterified in tert-butyl acetate to afford 18. Subsequent dialkylation with
bromide 2 afforded protected pentaester 19. Removal of Cbz moiety by hydrogenolysis
yielded the amino pentaester 20 (see Fig-31). Pentaesters 17 and 20 can be easily reacted with
substrates containing amino or carboxylic functionalities respectively and subsequently, the
tertbutyl ester groups can be removed using routine methodologies. It was further established
by Rapport, that there was no racemisation observed under the reaction conditions which they
developed for the dialkylation of amino esters.
COOtBu
COOtBu
COOtBu
15R=COOBzl 
18 R= NHCbz
COOtBu
tBu<
tBu<
COOtBu
'COOtBu
16 R=COOBzl— |
17 R=COOH b 
19R=v
20R=. X NHCbz SNH?
(a) 15, EtOH/H2 0 ,  pH 8 ; forl8  MeCN/pH 8  phosphate buffer;
(b) H2 ,5% Pd/C,EtOH;(c) H2 ,5% Pd/C,MeOH.
Figure 31:- DTPA analogue prepared by versatile bromoderivative.
II. Directly substituted central nitrogen in the backbone
In 2005, TimStorr et al.56 had been attracted by the usage of NO scavengers in cancer 
treatment. As such, they have designed a DTPA analogue which could satisfy the above 
objective. Following a similar synthetic strategy to that developed by Williams and Rapport, 
they have synthesized a DTPA analogue bearing an ethyl group on the central amine. Two 
equivalents of compound 21 were reacted with ethylamine to afford the protected form of
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DTPA analogue. The standard TFA hydrolysis of the tert-butyl ester groups afforded
compound 24 (see Fig-32).
MsOV \
1.RNH2,CH3CN
k 7c o 3
2.TFA
\
21
22 R=Et 
25 R=Bu 
28 R=Bn
&
< /  \ Im M HCl
TFA
•OH
OH
24R=Et
27R=Bu
30R=Bn
23 R=Et 
26R=Bu 
29R=Bn
F igu re  32:- C en tra lly  fu nctionalised  D T P A  an a lo g u e
3.1.7.1.2 Substituted Terminal nitrogen
I. Substitution through terminal acetic acid arm
Westerberg et al.51 synthesized a p-isothiocyanatobenzyl moiety attached at the methylene 
carbon atom of one of the carboxymethyl arms. They have initially started with o-nitrophenyl 
pyruvic acid. The reductive alkylation and subsequent carboxymethylation steps, ended up in
o-nitro benzyl analogue. Upon reduction of the nitro group, the product obtained as a six- 
membered lactam. Thereafter, to overcome this problem, they reinitiated the synthesis, 
starting with p-nitrophenyl pyruvicacid. This was obtained by acid hydrolysis of the 
azalactone, which was in turn obtained from the reaction of p-nitrobenzaldehyde with 
acetylglycine. Intramolecular condensation during the carboxymethylation, leading to the 
formation of a lactam also proved to be a problem. In order to circumvent these problems, the 
secondary nitrogen atom of diethylenetriamine was first protected with a 
diethylacetamidemoiety which was eventually hydrolyzed to form the fifth carboxymethyl 
arm, through the alkylation and subsequent reduction steps. The reduction of the nitro benzyl
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substituted chelators and the subsequent transformation into the ultimate protein-reactive
forms were carried out according to a known procedure.51 (see Fig-33)
NEt2
ho^ °  c A ,
“NH,
OH
NH2
no2
Br2 CH2COOH
° y 'oh h° y °  ° v °L J  H2 ,Pd/C Y N J
N ^  N   N N
V  V
OH I OH
NH2 NO?35 ,wz 34
F igu re  33: -P- iso th iocynato  o f  benzy l g ro u p  a tta c h e d  to  te rm in a l ca rb o x y l a rm  o f
D T P A  an a lo g u e
CQ
In the following year, Keana et al. have investigated a more convenient route to synthesize 
DTPA analogue. They have synthesized this DTPA analogue to be utilised as a potential 
contrast agent. Initially, pentamethyl ester was prepared by reacting DTPA with SOCI2 in 
methanol. To which aromatic moiety was introduced through the addition of lithium 
diisopropyl amide (LDA), benzyl bromide and HMPA. Thereafter, nitration and the 
subsequent conversion to aniline moiety were carried out along with the conversion of ester 
groups in to their lithium salts. After which amine group on the aromatic moiety was 
converted to isocyanate group (see Fig-34). Subsequent complexation with gadolinium 
trichloride yielded the derivative in the form of a sodium salt.
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OR
CK O^R
•0  °^V -0R -OR
n( ' N / n)v //Nsn
OR
OR OR
n = 1, R = H (DTPA) 
= 0, R = H (EDTA) 
a I « n = l ,  R = Me 
= 0 R = Me
I n  0 , 
36 n  1,
^  37 n 
38-43
OR
0'Li+
o o-Lr % ^ OLi+
_  38n =  1, R = Me:R' = H 
39n =  0 R = Me:R' = H 
40 n = 1, R = Me:R' = N 0 2  
"41 n = 0 R = M e:R '= N 0 2
42n = 1, R = Me:R'= NH 2  
”43n = 0 R = Me:R’ = NH 2
44n=l O'Li 
45n=0
4 6 n =  1 
47n = 0
48M=Bi (III) 
49M=Gd (III)
N=C=S
N=C=S
(a) SOCl2/ MeOH; (b) LDA, benzyl bromide/HMPA; (c) H N 0 3 /H 2 S 0 4; (d)H2/Pd 
(e) LiOH/H2 0 ;  (f) SCCl2 /MeOH; (g) MC13, 2 equiv o f  NaOH
F igu re  34:- D TPA  analogues p re p a re d  by  K e a n a  et aL, P -iso th iocynatobenzy l
te rm in a l C a rb o x y l a rm
Laurent et a l59 discussed two methods for inserting a Bz group onto the 2-position of DTPA. 
The first method involved reductive amination of a protected diethylenetriamine derivative 
with a a-keto acid and the second method is the mono-deprotection of protected DTPA, 
followed by alkylation. The first method involves producing the DTPA from a terminally 
Boc-protected diethylenetriamine. The central N atom of the DTPA backbone is alkylated and 
then reductive amination is carried out (see Fig-35a). The product is then alkylated with 
2-bromoacetic acid and undergoes ester hydrolysis under alkaline conditions to give ligand 
50. An issue found with this method was that the complex mixture of products, required
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purification by HPLC. Therefore they have devised a second route which is similar to the
method used by Keana et al. (see Fig-35b).
a)
Boc'
H.NL Cl
Boc
O.
_ ^ -N E t2
r
COOH
CF3COOH R=Boc
CONEt2
R=H
HOOC N 
HOOC
m
' S
Ph
50 k
N COOH 1.BiCH2COOH
HI
HOOC^
NaBH3CN
" r k
COOH 2 .N a O H ,A
PhJ
O Ph 
.NH2
51 1^
CONEt2
b)
ROOC^ N'
ROOC^
SOCl2
MeOH
COOR
'N COOR 
^CO O R
Base
-78°C
H,COOC
J  52
H3 COOC ©
COOR
,—  DTPA R=H 
!_► 53 R=Me
HC1 54R=Me
50R=H
ROOC N ' 
HOOC,
Bnl
^COOR
N COOCH3
kCOOCH3
»oc J
Ph
N COOR 
^CO OR
F ig u re  35: - D epicting  tw o d iffe ren t a p p ro a c h e s  h an d led  by  L a u re n t et a l (a , b) fo r 
in se rtin g  B n g ro u p  in th e  2- position  o f  D T P A
11. Substitution through Terminal carboxylic arm
Arano et al.60 synthesized the monomaleimide derivative of DTPA (MDTPA, compound 64 
in Fig-36) according to the procedure outlined in Fig-36. The synthesis of the compound 
requires the selective reactivity of only one of the five carboxylate groups.
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XOOBu*i  r
• N ^ . C O C F ,  o_ „  B li'O O C ^N
.COOBu
Bu*OOCJ 55 BifoOC J
N COCF3
56
kCOOBu*
Bu*OOC^N'
ButoOC^
COOBu1
NH
k.57 ^COOBu* 
XOOBu*
^COOBu*
Bu*OOC^ N N N ^ 'COOCH2C6H5 
Bu*OOC^ 58 kCOOBu1
B uta N ^  
Bu*OOC^ 5 9
‘N COOH 
^COOBu*
Reagents:(a) CF3 COOC2 H5; (b) BrCHjCOOBu1, iPr2 NEt;(c) BrCH 2 COOBul, NaH;(d) NH 2 NH2, 
ButOH:(e)BrCH2 COOCH2 C6 H5, /Pr2 NEt; (f) Pd/C, H2.
Bu*OOC^N'
BukDOC^
r
59
COOBu1
N ^C O O H  g _ ButO O C '^ N '
kCOOBu1 Bu*OOCJ
60
COOBu1
N COO-N
kCOOBu* $
o
o
N-CO-OCH3 +  BOC^ ' N ' w / V n h 2  — —
[ 61 O
n ^ n h 2
62
COOBu1
Bu*OOC'
Bu*OOC
1^1
COOH
Bu*OOC O 
63
O COOH 
64
'COOH
COOH
Reagents:(g) dicyclohexylcarbodiimide, N-hydroxysuccinim ide;(h) N aH C 0 3 ;(i) CF3 COOH;
(j) /Pr2 NEt;(k) CF3 COOH.
Figure 36:- Synthetic scheme depicting the synthesis of mono maleamide derivative 
DTPA analogue bearing two identical groups targeted fo r  sialic acid
Frullano et al.61 produced a potential contrast agent which could detect sialic acid. For which 
they have successfully synthesized the ligands 70 and 71 (see Fig-37), which are both 
composed of a central lanthanide-chelating unit flanked by two identical groups designed to 
interact with sialic acid. Ligand 70 was synthesized from tris-(2-aminoethyl) amine (TREN). 
Two of the three amine functions of this compound were protected with tert-butoxycarbonyl 
(Boc) groups by a known procedure62 which gave compound 65. Treatment of 65 with 2- 
methylthio-2-imidazoline hydro iodide by refluxing in ethanol, followed by deprotection of
66 with HC1 afforded 67. The boronic acid function was introduced by reductive amination of
67 with 2-formylphenylboronic acid and sodium borohydride, which led to a mixture of mono 
and bis-substituted derivatives of 67. The mixture was then separated by ion exchange
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chromatography. 70 was obtained by condensation of 68 with DTPAA in ethanol. The bis-
Boc-protected precursor of ligand 71 was synthesized by a published procedure.63
Deprotection by treatment with TFA gave 69 almost quantitatively. Ligand 71 was obtained
by reductive amination of 69 with excess 3-formylphenylboronic acid and sodium
borohydride.
NHBOC NHBOC NH
r-1 - L .  r ’ j u  r '
H N '^ \ ^ N' ^ V‘NH2 HN"~v ' ' N " N H  H2N ^ N — ^ N H
boc BOC AHN N HN N
65 66 67
(i):Relux with 2-methylthio-2-imidazoline hydroiodide in ethanol, (ii):deprotection with HC1 37%
NHCOB
I
OH
HO Y° o*S °Y oh
/ s  .N . ,  ,
N ^  NH
/  V -fy 0 H )2
HN.
68
NH2 69 NH2
OH
HO. .O  O . .OHY °  °y c
n/Sv' N's/ ^ n
H V Y° H
Nr N r NH r NYNV-NH I J  I J  HN-^
N Ns r*
HN .NH
(ho)2by L J y b(OH)2
70
OH
hoY ° o^ S °y oh
O ^ J  Y °
^NH
HN^ Q  <p KyNH
B(OH)2 (HO)2B
71
F ig u re  37 :- D T P A  p re p a re d  w ith  b o ro n ic  ac id  to w a rd s  de tec ting  sialic acid
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III. Through direct substitution o f the term inal nitrogen 
DTPA analogue from  Tren
In 2003, Couchet et al.64 have synthesized a bifiictionalised DTPA analogue by means of a
synthetic procedure containing three-step sequence. The reductive amination of 
diethylenetriamine with 2,2-bipyridine-5-carboxaldehyde was carried out. Thereafter 
trialkylation of the secondary triamine followed with deprotection of t-buyl ester groups, 
yielded the bifunctionalised ligand (see Fig-38). Alternatively, they have used the DTPAA to 
prepare the same ligand. They investigated the luminescence properties of the europium 
complex in aqueous media.
nitrogen of the diethylene triamine backbone, in that, 2,6-di(hydroxymethyl)pyridine was 
used to initiate the synthesis. The reaction pathway is shown in Figure-39. 
2,6-di(hydroxymethyl)pyridine was monooxidised and reacted with 1, 4, 7-triazaheptane in 
dichloromethane to give a diimine 75. This was reduced with NaBPLt in refluxing ethanol,
bromoacetate under basic condition to produce 77, and then 78 was produced with
1) R-CHO
2) NaBH4
R R
tBuOOCCH2Br
CF3 COOH
OH
F ig u re  38 :- B ip y rid in e  fu n c tio n a lised  D T P A  ana logue  
DTPA analogue from  2, 6- di (hydroxymethyl) pyridine
Artali et al.65 reported an alternative strategy to incorporate functionality to the terminal
leading to the isolation of the derivative 76, which was then alkylated with t-butyl
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trifluoroacetic acid, followed by evaporation in vacuum and treatment with diethyl ether to
induce precipitation of the ligand.
/= N  
HO N = /
OH tBu
HO HO N=<HOO NHN
BrCH2COOtBu (  
K2 C 0 3  NMP 60°C NH
, 1)TFA 
2)Et20
OH tBu
NH
HO HO N=<HO
OH tBu
78 77 76
F igu re  39 :-S yn thetic  schem e d ep ic tin g  th e  p re p a ra tio n  o f  1, 4, 7 - tr iaz ah e p tan e
d eriv a tiv es
3.1.7.1.3 Direct substitution ethylene carbon in the backbone
Despite the superiority of these bifunctional contrast agents (BFCAs) in terms of metal ion 
retention, their widespread use has been limited. This is more likely for reasons such as, 
complex separations involved in their synthesis and could be also because of the difficulties 
encountered in synthetic scale up. Under such circumstances, in 1991, Cummins et al.66 
proposed a synthetic route, which was not only convenient, but also yielded high yields of end 
product. They have claimed that this procedure could yield multigram quantities of the 
product. The procedure initially introduced for 1B-DTPA, later was extended to synthesize
l-(paminobenzyl)-4-methyl-DTPA (1 B4M-DTPA). It is recommended to have a closer look 
on the synthesis in Fig-40.
t^NH2
CHCI3 ,Reflux CH2 C12
Na2 S 0 4
75
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R
n o ,^  H
te  e , 3n  N02Y ^ , °V N' -  -  1 )BH 3
n h 2h c i  n h 2  I. 2 ) H C 1
N h A r  ^ ^  NH2  3)NaOH
7 9  8 0 R  =  H
84 R = M e
But02C —CH2 R 
n o 2,  ^ n h c h 2c h r n h 2 n o 2 N .s' ^s' N(CH2C 0 2tBu)2 
BrCHoCOOtBu  ^ M i l
NH2 N(CH2C 0 2t-Bu)2
81 R= H H 2  /  8 2  R= H
85 R= M e a/Pd/C 8 6  R= M e
H2N
83 R= H 
87 R= MeHCl(aq)
h o 2c — CH2 R
8 8  1, 1B-H 5 DTPA- 4HC1 R =  H
89 2, 1B4M-H 5 DTPA-4HC1 R = M e
F ig u re  40 :- S yn thetic  schem e fo r  D T P A  a n a lo g u e  syn thesized  by  C u m m in s
a n d  co -w o rk e rs
It has been a long-accepted tenet of coordination chemistry that the most stable complexes are 
formed when the coordination number of the metal is fully saturated by ligands. In line with 
this fact, Brechbiel et al.61 in 1991 examined the importance of ligand structure features for 
retarding the release of yttrium in-vivo. They introduced the following modification to their 
previous ligand (see Fig-41). A methyl substituent was introduced to the carbon 
backbone, along with p-nitro benzyl group.
A notable aspect here is the substitution of 1,2-diaminopropane for 1,2-ethylenediamine 
in the aminolysis of methyl I-nitrophenylalaninate, followed by borane reduction of the 
resulting amino amide to give principally, precursor dien intermediates. The procedure is 
quite lengthy to be discussed. Fig-41 speaks for the procedure.
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CH3(H)
3HC1
91
.c o 2h
c o 2h
(a) E t3N , 1,2-diam inopropane; (b) B H 3.TH F, E tO H /H C l; (c) B rC H 2CO OH , KOH; 
(d) H 2, Pd/C , C12CS.
R
NH
NH a,b
OtBu
92 R= />-N02Bz, R,= Me 
96 R= Me, Rj= p - N 0 2Bz 
100 R= H, Rj= />-N02Bz
93 R= p -N 0 2Bz, R,= Me 
97 R= Me, Rj= ;?-N02Bz 
101 R= H, R x=  />-N02Bz
d. e
r  'i c°2h r "i
co2h c o 2h c o 2h c o 2h
94 R= /?-N02Bz, Rj= Me 
98 R= Me, R,= p -N 02Bz 
102 R= H, Rj= jo-N 02Bz
c o 2h c o 2h co 2h c o 2h
95 R= p-SCNBz, R,= Me 
99 R= Me, R!= p-SCNBz 
103 R= H, R,= /j-SCNBz
(a) TFA; (b) THF/ EtOH, EtOH/ HC1; (c) BrCH2 C 0 2 H, KOH; (d) H2, Pd/ C;
(e) C12 CS.
F ig  41 :-S yn the tic  schem e d ep ic tin g  th e  len g th y  p ro c e d u re  followed by
B rec h b ie l et aL
3.1.7.1.4 DTPA analogues based on confirmationally constrained structures
In an attempt to enhance the complex stability, the branching of the ethylene diamine
backbone of DTPA could be effected through the introduction of rings in to the ligand. This 
in turn imposes conformational constrains on the specific portion of DTPA. These constrains
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provide pre-organisation of the ligand’s donor groups, such that it will reduce the entropy of
formation of the metal complex. Further, constrain serves as a steric barrier to
decomplexation. It may be expected that macrocyclic ligands could provide the greatest
degree of conformational constraint. They, however, do not have structural flexibility to
accommodate variety of metals as they possess a cavity of fixed dimension. This fact justifies
the innovative approach taken by the scientists to produce confirmationaily constrained
DTPA analogues.
/. Based on Am ino Acids
DTPA analogue from  trans-4hydroxy-proUne
It is also possible to produce functionality from 4-hydroxy-L-proline. Williams and Rapport68 
in 1994, prepared another DTPA analogue. This time they started with trans-4hydroxy- 
proline. Through a series of synthetic steps they have produced 109 (see Fig- 42).
H
r 3o . MsO/
I U jiflJ  \ NaN3^ / \ 4g  ^ / \
\  , \  /  ^  \  /Pr2NEtN . C 0 2R2 N ^ C 0 2B u‘ N ^ C 0 2Bu‘ ‘B uO j C  N
Rl I I I
N . 'v ____ . CO-,1
C 0 2Bu* 
105
104a R1 = H R2, R3  = H 
104d R1 = C 02Bn R2, R3  = H 
104e R 1 = C 0 2 Bn, R2  = tBu, R3  = H 
104f R 1 = CH2 C 0 2 Bu‘, R2= tBu, R3  = H 
104g R 1 = CH2 C 0 2 Bul, R2= tBu, R3  = H
^C 02Bu*
106a R = N 3  
106b R = NH,
O 2BII
107
CO-iBu*
C 0 2Bu‘
H2, Pd/C
BrCH2 C 0 2 But
/Pr2NEt
C 0 2Bn
TfQCH?CO^Bn 107a,
109 108a R=H
108b R=CH2COOBu‘
Figure 42:- Synthetic scheme depicting the preparation of DTPA analogue 
Starting from 4-hydroxy proline.
DTPA analogue from  Serine and Proline towards confirm ationaily constrained analogues
Pickersgill et al.69 produced DTPA analogues. These differ from the pyridine containing
DTPA ligands, as the smaller cyclic ring (5 carbons rather than 6) on the backbone leads to a
more confirmationaily constrained ligand. The major synthetic steps involved in the synthesis
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are; activation of triflate, low temperature alkylation with benzyl glycolate and finally the
deprotection of the pentabenzyl esters (see Fig-43).
OH
HO2C N' 
HOzC '
HO
h o 2c  N 
HOjC
^/COzH
^^)-^C02H
110
c o 2h
112 ^  CO,H
rc o 2h
h o 2c
HOzC
^ V V - co2h
J *>J  V
v— c o 2h
114
, c o 2h
h o 2c  n
c o *H h o , J
r^
py--co2H
N
^  CO,H
HO. ,C O zH
^Y^V-,bco2H ho2c'/Vs'n'
J
h o 2c
113
r
c o 2h
N
^  CO,H
HO
HNI
Tr
NH,
HO,
r
Tr
,NH2
( - ) - l  15a (+ )-115b
(-)-U5a, *Pr2NEt
CH2C12, -10°C 9 v 0O 2Bn
COB
11 3
(+ )- !  15b , /Pr7NEt
CH2C12,-10°C
RO
V >  C 0 2Bn'—K1
HN
1
Tr BOC
116R = H
RO^
HN^
Tr
W  C 0 2Bn
TBDPS,NEt3 
DMAP,CH2C121_^117 R=TBDPS
BOC
TBDPS,NEt3 I 120 R=H 
DMAP,CH2Cl2L ^ i21  R=TBDPS
TBDPSO
H,N
TFA,CH2C12, Et3SiH TFA,CH2C12, Et3SiH
118
lvo -NH
C 0 2Bn
TBDPSO
H,N
lvo -1—• kILJ C 0 2Bn122  NH
TBDPSO
Tf0CH2C02Bn, /Pr2NEt,CH2Cl2 
-78°C to-10°C
C 0 2Bn
Bn02C N 
BnOzC
TBD SPO ,
TfOCH2C02Bn, zPr2NEt,CH2Cl2 
-78°C to-10°C
C 0 2Bn
C 0 2Bn B n 02C N
-C O ,Bn B n 02C
J
119 123
j)^ C 0 2Bn
N
^ — C 0 2Bn
F ig u re  43 :- C o n firm a tio n a ily  c o n s tra in e d  D T PA  analogues synthesized by
P ick e rs  gill et aL
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II.Based on Piperidine or Azepane ring
7ftIn the following year, Chong et al. proved that confirmationaily restrained DTPA analogues 
could be achieved from piperidine ring or an azepane ring. Further, substitution of either the 
piperidine ring or an azepane ring with an amino group of the DTPA is expected to potentially 
increase complex stability and hepatobiliary clearance of the system. They have measured 
relaxivities of the gadolinium complexes as well. Initially 2,6-pyridinedicarboxylic acid was 
converted to cis-2,6-bis-(methoxycarbonyl)piperidine, this was then reacted with benzyl 
bromide under basic conditions to yield 124, which then underwent base promoted reaction 
with LiBFLt in THF to yield N-benzylated diol.
The hydroxyl groups of this diol were converted to their respective chloride by SOCI2 to 
yield 125. The treatment of 125 with NaN3 in DMSO yielded the ring expanded diazide 126, 
which was then through a series of conversions, converted to triamine derivative, which then 
was alkylated with t-butyl bromoacetate to provide 127. Then 127 (Fig-44) was deprotected 
with HC1 (g)/dioxane. A notable aspect in this synthesis is the ring expansion. This was 
attributed to the formation of aziridinium intermediate.
,cXXC02CH3 rQ> rQv
Dm /"m Dm 1 NU Rn I
128 R=H
F igu re  44:—T riam in e  d e riv a tiv e  b ased  on  p ip e rid in e  r in g  p re p a re d  by  C hong  et a l
3.1.8 DTPA based amide derivatives bearing chromophores:
A Novel Approach.
Keeping in line with the aforementioned BFCA’s, we have successfully synthesized new 
BFCAs. These ligands have been synthesized by utilising both major strategies mentioned 
above. In making these ligands, we have paid special attention towards incorporating 
chromophores in to the diethylene triamine backbone. The chromophore was incorporated in 
the form of naphthalene moiety. The details will be discussed in the following sections.
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3.2 Results and Discussion
3.2.1 Ligand design and Synthesis of DTPA analogues
3.2.1.1 Symmetric Naphtha derivative
3.2.1.1.1 Ligand Design
As part of satisfying our goal of producing dual purpose contrast agent, we intended to 
develop bifunctional chelating systems. These systems were developed such that they ensure 
high thermodynamic stability of the chelate which in turn will ensure very high tolerance 
under in-vivo conditions.
To meet these criteria, our initial attention was directed towards DTPA for reasons 
explained earlier in this chapter (sec Section 3.1). It was then thought to synthesize, DTPA
71based mono amide by mixing DTPAA with ethylene diamine in 1:1 stoichiometric ratio. 
The approach is not as straight forward as it appears. As commonly encountered and widely 
reported72, all the attempts ended up with a mixture of mono and bis amides. Further, efforts 
to purify the mixture through column chromatography were not successful, as experienced
73and reported in aforementioned literature (however, a very recent publication, claimed to 
solve this longterm difficulties).
The article published by Choi et al.74 attracted our attention. They described the 
procedure of synthesizing DTPA analogue through N, N—Bis[(tert-butoxycarbonyl)methyl-2- 
bromoethylamine 1 (see Fig-1).
N
1
F ig u re  1:- N ,N -B is[(te r t-b u to x y ca rb o n y l)m e th y l-2 -b ro m o e th y lam in e  (B rom oderiva tive)
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This has allowed us to synthesize new multidentate ligands. DTPA based monoamides could
be prepared from DTPA analogues rather than through DTPAA. Therefore we have decided
to utilise the strategy of synthesizing DTPA analogues from ‘scratch’ (see Section 3.5.2).
This has triggered our synthesis to produce amine functionalised DTPA analogues, having the
functionality in the central nitrogen of the ligand. Employing a retro synthetic approach and
the stoichiometric ratio (1:2 ) commonly used, we found that by reacting one equivalent of
amine functionalised precursor and two equivalents of bromoderivative could produce the
desired analogue of DTPA (see Fig-2). The procedure reported by Anelli et al.15 were
employed to synthesize 2. Yield was 28%. The shifting of the t-butyl peak and the doublets of
para amino benzyl amine in the proton NMR spectrum, confirmed the success of the reaction.
The estimated purity was 99%. The scaling up, however, was not successful. When the benzyl
amine reactant was increased from 2.8 mmol to 3.7 mmol, the *H NMR spectrum of the crude
product indicated the presence of excess para amino benzyl amine, which could not be
removed by column chromatography.
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OH
NH,
NaOH, RT,
V
n h 2
t f a ,c h 2c i2
lh, RT
n h 2
HO.
N
OH OH
Figure 2: - Schematic representation of the successfully synthesized 
Centrally functionalized DTPA analogue
3.2.1.1.2 Ligand Synthesis
Synthesis o f N-Boc protected am ine functionalised DTPA analogue
It was then decided to synthesize centrally functionalised DTPA analogue with ethylene 
diamine (EDA). The need for protection of one of the amine groups of the EDA was realised, 
as there is a possibility for polymerisation. Since N-Boc protection is widely used in peptide 
chemistry, BOC protection with ethylene diamine was carried out (see Fig-3).
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Synthesis o f N-Boc-1,2-diaminoethane, tert-Butyl N-(2-aminoethyl)carbamate
The procedure employed could be summarised as follows. Di-tert butyl di carbonate dissolved 
in chloroform was added to the stirring ethylene diamine solution in chloroform, drop wise. 
After stirring for 2 h, the suspension was filtered and solvent removed. The residue was 
extracted with ethyl acetate and washed with brine. Upon drying over MgSC>4, the oily 
product was isolated. Yield was 38%. The distinct coupling of the triplets appeared on 2.75 
and 3.1 ppm (J = 5.9 and J = 5.7 Hz respectively) in the lH NMR spectrum confirmed the 
success of synthesis coupled with a distinct peak for t-butyl group which was shifted to 
slightly upfield (1.54 ppm). These values were consistent with the chemical shifts reported by 
Essein et al.76 Further, carbonyl stretching vibration of the ester at 1732 cm' 1 also supported 
the success of synthesis.
H 
\
N C
3
Figure 3:- N-Boc protected ethylene diamine 
Challenges encountered in the synthesis o f bromoderivative: Introducing a m odified procedure 
The procedure mentioned by Choi et al. was employed initially.74 They first synthesized, 
N,N-Bis((tert-butoxycarbonyl)methyl)-2-ethanolamine (alcohol derivative 4, see Fig-4) 
through the alkylation of ethanolamine with tertiary butyl bromoacetate in DMF. This was 
then utilised as follows. N-bromosuccinmide (NBS) was added portion wise to the dissolved 
solution containing a mixture of 4 and triphenyl phosphine (PPI13) in dichloromethane. After 
stirring for 2 h solvent was removed. Upon addition of diethyl ether, semisolid residue was 
formed. This was then triturated followed by flash chromatography to yield pure bromo 
derivative 1 (see Fig-1).
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4
Figure 4:- N, N-Bis ((tert-butoxycarbonyl)methyI)-2-ethanolamine 
(Alcohol derivative)
When the procedure was adapted to form 1, however, it could not yield the desired results. 
The proton NMR spectrum of the crude product indicated no signs of bromination as the 
couplings of the triplets belong to the ethylene backbone were absent. Therefore, in a 
continuous search we came across the procedure reported by Williams and Rapport.54 
This was found to be, however, similar to that of Choi et al. When attempted, although the 
procedure helped to obtain the desired product, it could not be considered as a successful 
reaction. It is because of two reasons. Firstly, the product prepared as such, is not sufficiently 
pure. Secondly, the yield of the product was unacceptable (i.e.<10%). These observations 
prompted us to review the procedure being used. As a suitable initiative to solve the problem,
mm
we began our search for the mechanism of bromination utilising NBS/PPI13. Song et al. 
interesting findings on Aziridinium salts (see Fig-4) gave us an idea, yet it does not provide 
any information on the role of triphenyl phosphines (a recent publication outlines the role of 
PPh3 in bromination78).
They proposed that the 6 -amino alcohol reacts with the phosphonium salt (formed 
through the reaction between NBS and PPI13) to yield an intermediate this then subsequently 
undergoes rearrangement to form aziridinium cations, along with the removal of 
triphenylphosphine oxide. They have attributed the salt formation due to steric hindrance 
caused by the substitution in the backbone.
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Br'
R
Route aRoute
R '-1- butyl group
Figure 5:- The proposed mechanism for bromination by Song et ah 
Where R -benzyl, nitro benzyl, propyl groups
It was thought, however, that, instead of allowing the bromination to take place in situ, it may 
be wise to prepare the phosphonium bromide first, by the portionwise addition of NBS to the 
dissolved solution of triphenyl phosphine in dichloromethane (successful preparation of the 
phosphonium bromide is indicated by the formation of sticky, semi solid-triphenylphosphine 
oxide). The prepared phosphonium bromide was then added in to the solution of alcohol 
derivative in dichloromethane dropwise. The rest of the procedure (see Fig-5) was followed 
as reported by Choi et al. The product was characterized by proton NMR spectroscopy which 
indicated the essential coupling of triplets (J = 7.4 Hz) belonging to the ethylene backbone.
"Y_ 2 \
DMF, 0°C
k 2c o 3
c h 7c i , .o °c
Figure 5:- Scheme representation of the modified procedure for bromide synthesis
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The reaction was carried out according to a known procedure. 1,2-Diamino-N-tert- 
butyloxycarbonylethane was dissolved in 95% ethanol/water mixture. The pH was adjusted to 
10 with NaOH. To which was added, Bromoderivative 1 dissolved in 95% ethanol dropwise. 
After 18 h of stirring, the ethanol was removed. Following acidification, the aqueous solution 
was extracted with dichloromethane. It was washed with water and dried over MgSC>4.
The crude product was purified by flash chromatography (diethyl ether: Hexane-1:5) 
and the pure protected ligand was isolated as a yellow oil. The yield, however, was less than 
15%. As a matter of curiosity, it was deprotected with TFA/DCM to obtain the pure ligand 
and characterized by the lH NMR spectroscopy (see Fig-6). The NMR spectrum indicated the 
absence of t-butyl peak, and the other peaks were slightly shifted towards down field, while 
retaining the symmetry of the molecule.
NaOH, RT,
NHBOC
TFA,CH2C12
O H O H
5
Figure 6:- Schematic representation of the attempted centrally substituted DTPA analogue
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Introducing N-(2-Am inoethyl)-l, 8-naphthalimide as a suitable chromophore
Although, the product 5 obtained in high purity (99%), the yield was <25%. As a suitable 
alternative, it was thought to introduce N-(2-Aminoethyl)-l,8-naphthalimide 6 (see Fig-7), 
in to the diethylene triamine backbone. Moreover, naphthalimide moieties are considered to 
be good chromophores. Naturally, we thought this could be a good precursor to be reacted 
with 1, which in turn would yield a functionalized DTPA analogue with strong chelating 
ability (through the provision of extra donor atoms).
It was also believed, through the nature of the synthesis, that the functionality will be 
positioned on the central nitrogen atom of the DTPA backbone. This will in turn support the 
stability of the chelate through the provision of extra donor atoms.79 Therefore, all four 
carboxylate arms would be free to be involved in coordination. Hence we first synthesize, N-
O A
(2-Aminoethyl)-l,8-naphthalimide 6 as per the procedure reported by Licchelli et al (see 
Section 2.1.1)
The crude product was sufficiently pure for alkylation with bromoderivative 1
6
Figure 7:- N-(2-Aminoethyl)-l, 8-naphthalimide 
Overcoming challenges in alkylation
Alkylation proved to be challenging, in terms of selecting the right solvent and the relevant 
temperature. For the solvent, we have selected dimethylformamide (DMF) (after having 
unsuccessful attempts with chloroform). Two reasons dominated in the selection process. As 
the alkylation mechanism is expected to proceed through S n 2 , it was thought a polar aprotic 
solvent could be the best selection, as it is known to facilitate Sn2. It was also found that 
reaction requires heating, in order to facilitate work up; DMF, which has a relatively low 
boiling point, was selected against the other alternative (DMSO).
,o
o
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Initially, N-(2-Aminoethyl)-l,8-naphthalimide was reacted with N-Bis[(tert-butoxycarbonyl) 
methyl-2-bromoethylamine 1 in the stoichiometric ratio of 1:2 in DMF. The *H NMR 
spectrum of the crude product, however, was not promising enough. Here we thought of the 
possibility of DMF being decomposed slightly. As such we thought to use a moderate 
temperature that was 65 °C. The compound 1 and amine functionalized naphthalic anhydride 
were dissolved in anhydrous DMF and heated to 65°C. The ]H NMR spectrum of the crude 
product indicated the alkylation. It also indicated the need for further purification. We opted 
for column chromatography.
Thin layer chromatography carried out first, proved that 5% Dichloromethane 
/Methanol would be the ideal solvent mixture. The purified protected ligand (see Fig-8) thus 
obtained, subsequently underwent deprotection.
Figure 8: - t-butyl protected symmetric naphtha ligand 
The protected ligand was characterized by NMR spectroscopy, IR spectroscopy and Mass
spectrometry. Chemical shifts were assigned by comparision to previously publish data.74,79, 
80 The deprotection was carried out by refluxing the protected ligand at 2M HC1 for two hours 
as reported by Vogt et al.sl The deprotected ligand L 11 (see Fig-9) was isolated in good yield
(90%).
H O H O
Figure 9-Symmetric deprotected ligand
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The absence of peak related to t-butyl group, which has appeared on 1.40 ppm, indicated the
success of deprotection, while the other protons give rise to only a negligible chemical shifts. 
Characterisation through IR  spectroscopy
Table l, it is evident, that there is a significant frequency shift takes place towards the finger 
print region upon complexation with lanthanide metal ions (Gd (III) and Eu (III)). This could 
be attributed to the participation of amide oxygen in coordination.
As expected the magnitude of the shifts between the complexes of Gd (III) and Eu (III), 
however, is more or less the same. Further, it was rather surprising, no frequency shift was 
observed for Yb (III) complex, although the mass spectrum revealed the molecular ion.
Table 1:- A comparison of frequencies obtained for different vibrational modes 
of IR for the Symmetric naphtha ligand along with its starting materials and also 
complexed forms_______________________________________________________
vibration
modes
inIR
Frequencies observed for starting material and the protected unprotected
forms of the ligand (cm1)
Bromo
derivative
Naphtha-
EDA
derivative
Protected
Symmetric
Ligand
(L10)
Deprotected
Symmetric
Ligand
(L11)
Lanthanide 
complexes of 
Symmetric naphtha 
ligand
Gd Eu Yb
N(C=0)
Amide
1662 1654 1655 1623 1622 1655
N(C=0)-Ester 1737 “ 1739 “ “
N(C=0>Acid - “ - 1695 1729 “
N(O-H) - “ - 3429 3424 3383 3401
N(N-H) - 3346 3414 - “ “ -
Characterisation through mass spectrometry
The molecular ions for the complexes of the symmetric ligand (L11) of Gd (III), Yb (III), Eu 
(III) and Nd (III) were observed.
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3.2.1.2 Asymmetric Naphtha
3.2.1.2.1 Ligand Design
Having succeeded in synthesizing a centrally fimctionalized DTPA analogue, our attention 
was directed towards the second sub strategy (see Section 3.5.2); to synthesize a DTPA 
analogue, fimctionalized in the terminal nitrogen of the diethylene triamine backbone.
In order to satisfy this purpose we have selected triethylene tetra amine (TRIEN). This was 
then reacted with 1,8 naphtha anhydride to produce Naphtha-TRIEN derivative (see Fig-10).
0
7
Figure 10:- Naphtha-TRIEN derivative synthesized in this project 
3.2.1.2.2 Ligand Synthesis 
Synthesis o f  Naphtha- TRIEN derivative
The same conditions were employed as that has been used for L1 initially; the naphthalic 
anhydride was dissolved in excess triethylene tetra amine and refluxed. Solvent was removed 
through distillation. The !H NMR spectrum of the crude product, however, was not promising 
enough. We then opted for heating the reaction mixture to 120 °C. The 'H NMR spectrum of 
the crude product was more promising (as the triplets of TRIEN relatively more visible in the 
latter, compared to the previous attempt). To purify further, we dissolved the crude product in 
dichloromethane. The mixture was filtered and the filtrate was evaporated. This was then 
dissolved in toluene. The toluene was decanted and the NMR spectrum was satisfactory. 
Alkylation o f naphtha derivative o f  TRIEN  & Lim itations
After the preparation of the precursor, it was decided to carry out the alkylation as per the 
conditions used for the symmetric naphtha derivative. The crude product suggested the need 
for further purification, as the excess naphthaderivative was visible in the *H NMR spectrum. 
Therefore, it was then decided to attempt the alkylation with 1:5 ratio rather than 1:4 (as we 
thought, excess tertiary butyl bromoacetate will ensure complete alkylation). The !H NMR
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spectrum of the crude product suggested the success of the reaction. The need for hither
purification, however, was also felt from the proton NMR spectrum. The thin layer
chromatography indicated the best solvent mixture (5% DCM/Methanol) for column
chromatography. Unfortunately, the yield realised upon flash chromatography was very low
(<20%). In spite of the low yield, the protected ligand was then deprotected (see Fig-11-13).
Resonances were assigned by comparision to previously publish data.66
dm f ,k2co3
60°C
2MHCI
Reflux
3hr
Figure 11:- Scheme representation of the synthesis of Asymmetric naphtha ligand
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o
L12
Figure 12:- The synthesized protected asymmetric naphtha iigand
o
.OH
OH
O
L13
Figure 13:- The synthesized Deprotected Asymmetric Naphtha ligand 
Characterisation through IR  spectroscopy
From Table 2, it is evident, that there is a significant shift in the frequency of amide stretching 
vibration occurs towards the finger print region upon complexation with Gd (III). Similar to 
symmetric ligand L11, the amide oxygen coordination to the gadolinium ion could be reasoned 
for the above observation. The poor yield of the ligand as aforementioned has put up on 
limitations on investigation. Therefore only Gadolinium complex was prepared.
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Table 2:- A comparison of frequencies obtained for different vibrational modes of IR for the 
Asymmetric naphtha ligand along with its starting materials and also its Gadolinium completed
form
Observed
vibration
modes
ofIR
Frequencies observed for starting material and the protected , unprotected 
forms and also the Gd complex of the ligand (cm'1)
Tertiary
butyl
bromo
acetate
Naphtha-
TRIEN
derivative
Protected
Asymmetric
naphtha
Ligand
Deprotected
Asymmetric
Naphtha
Ligand
Gadolinium 
complex of the 
Asymmetric 
naphtha ligand
v(C=0)
Amide
- 1659 1648 1654 1644
v(C=0>
Ester
1731 1732 - -
v(C=0 >■ 
Acid
- - - 1738 1728
v(0-H) - - - 3427 3403
v(N-H) - 3416 3414 - -
Characterisation through mass spectroscopy
The molecular ion of the complex of Gd (III) was visible in the mass spectrum.
3.2.2 Novel synthesis of DTPA based bisamides
3.2.2.1 DTPA based bis amide of N-(2-Aminoethyl)-l, 8-naphthalimide
3.2.2.1.1 Ligand design & Synthesis
Following the success of EDTA bisamides, it was thought to synthesize DTPA bisamides of 
selected precursors. Auxiliaries were selected such that they could act as luminescent sensors. 
As such, naphthalimides is of great importance. This ligand will be dealt with in detail in 
Chapter 4. The synthetic procedure was exactly the same modified procedure used to 
synthesize EDTA bisamides of 4-aminomethyl pyridine. Ligand was obtained in a good yield 
(45%) (see Fig-14).
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L14
F ig u re  14:- D T P A  b isam id e  o f  N -(2 -A m in o e th y l)- l, 8 -n ap h th a lim id e
3.2.2.2 DTPA based bis amide of 4-amino methyl pyridine
3.2.2.2.1 Ligand design & Synthesis
Initially, the same synthetic procedure used to prepare EDTA bis amide of 4-aminomethyl 
pyridine was employed. The precipitate thus obtained, contained 25% of starting material 
(excess of 4-aminomethylpyridine). This was concluded from the proton NMR spectrum, 
which indicated the ratio of 1:4, between the doublet of L15 and that of the doublet of the 
amino methylpyridine. Recrystallisation with hot methanol and ethanol also failed, it was 
then thought to remove the material under very high vacuum.
The removal of starting material by high vacuum, however, yielded little success with 
removal of only 3% of excess 4-amino methylpyridine from the crude product. It was then 
thought to purity the ligand by continuous washing with acetone for a prolong period of time 
(7days). The method adapted for this purpose was soxhlet extraction. This has yielded 
substantial results, yielding a 92% pure ligand (see Fig-15). It should be noted, that despite 
the extended period used for Soxhlet extraction, purity of the ligand could not be improved 
further (as the trace amount of 4-amino methylpyridine could not be removed in its entirerity.
L15
F ig u re  15 :- D T P A  bis am id e  o f  4- am in o  m ethy l p y rid in e
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3.3 Experimental Section
General Experimental: Reagents were obtained from commercial sources and used as received 
unless otherwise noted. Solvents were dried and purified under N2 by using standard methods 
and were distilled immediately before use, specifically dimethylformamide, was distilled 
using anhydrous calcium hydride. All compounds were prepared under N2 unless otherwise 
mentioned. The NMR spectra were obtained using a Bruker ARX 400 at 20 °C in CDCI3 
unless otherwise noted. Mass spectra were performed on a micro mass Platform II system, 
operating in Flow Injection Analysis mode, with the electrospray method. Infrared spectra 
were recorded with a JASCO FTIR-410 spectrometer, between 4000 and 250 cm' 1 as KBr 
pellets. UV/Vis spectra and measurements were recorded with a JASCO V-570 spectrometer. 
Synthesis of DTPA bisanhydride
DTPA (5.0 g, 12.72 mmol) was suspended in pyridine (8  mL) and acetic anhydride 
(7.0 g, 68  mmol) was added dropwise to the stirring solution. The reaction mixture was 
allowed to stir for 24 h at 65 °C. The resulting anhydride was filtered off and washed 
thoroughly with freshly distilled acetic anhydride and freshly distilled diethyl ether. The 
pale-cream powder was then dried under vacuum until constant weight was obtained. The 
product was characterised by infrared spectroscopy and measuring its melting point. 
Yield 4 g, 88%. IR (KBr disc) (cm1): 2940(br), 1820(vs), 1770(s), 1629(s); Melting point: 
181-183°C.
3.3.1 Synthesis of Napthalinic anhydride derivatives
3.3.1.1 Synthesis of N, N —Bis (tert-butoxy carbonyl) methyl -2-ethanolamine (4) 
Alkylation74
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The procedure was used as reported by Choi et al.74 except for slight modifications. To tert-
butyl bromoacetate (17.02 ml, 116 mmol) dissolved in DMF (30 ml), potassium carbonate
(12.514 g, 125 mmol) was added. The reaction mixture was cooled down to 0 °C and
ethanolamine (2.98 ml, 49.4 mmol) added dropwise for 5 min. The reaction mixture was
stirred at 0 °C for 30 min and then allowed to stir overnight at room temperature. After an
addition of concentrated NaHCC>3 (100 ml) and diethyl ether (150 ml), the organic layer was
separated and washed with concentrated NaHCC>3 (50 ml) and subsequently with brine
(200 ml). The solvent was removed under reduced pressure to yield the product as pale yellow
solid. Yield 14.2 g 42%; ‘H NMR (400 MHz; CDC13): 8H 3.65 (t, 2H, J = 14.92 Hz,
NCH2OH), 3.40 (s, 4H, NCH2COO), 2.85 (t, 2 H, J = 3.92 Hz, NCH2), 1.46 (s, 18H, (CH3)3).
13C NMR spectrum and Mass spectrum were not obtained as it is a known compound.
3.3.1.2 Synthesis of N,N-Bis[(tert-butoxycarbonyl) methyl-2-bromoethylamine (l)75
N
PPI13 (4.3404 g, 16.53 mmol) was dissolved in dichloromethane (25 ml), subsequently added 
NBS (2.988 g, 16.78 mmol) portion wise and the mixture was allowed to stir at 0 °C (until the 
colour of the solution changes from yellow to light brown). The mixture was transferred to 
Alcohol derivative 4 (6  g, 20.74 mmol), dissolved in dichloromethane (25 ml), dropwise at 
0 °C. After which, the reaction mixture was allowed to stir over night. The solvent was 
removed and to the resulting crude product was added diethyl ether. Upon which observed the 
formation of a sticky solid. The mixture was triturated and filterd. Filtrate was evaportated 
and the crude product was flash chromatographed (Hexane: Diethylether - 5:1). The product 
was obtained as colourless oil. Yield 2.0 g, 28 %; *H NMR (400 MHz; CDCI3) Sh (ppm) 3.45
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(s, 4H, NCH2COOC (CH3)3), 3.41 (t, 2H, J = 7.4 Hz, BrCH2), 3.11 (t, 2H, J = 7.4 Hz,
BrCH2CH2N), 1.44 (s, 18H, COOC (CH3)3).
13C NMR spectrum and Mass spectrum were not obtained as it is a known compound.75
3.3.1.3 Synthesis of N-(2-Aminoethyl)-l, 8-naphthalimide (6)
O - ( 0 r *f,— ^ N---CH\ ---------- f  Q
To 1,8-Napthalinic anhydride (2 g, 10.09 mmol), was added freshly distilled ethylene diamine 
(15 ml, 224.30 mmol) and allowed it to reflux overnight. Then the solvent was removed 
through distillation and high vacuum. Thereafter, the crude product was dissolved in 
dichloromethane and filtered. The precipitate was washed with diethyl ether. After washing it 
thrice, the product was obtained as pale yellow precipitate. Yield 1.4g, 58%; *H NMR (400 
MHz; CDC13): 8H(ppm) 8.60 (d, 2H, J = 8.00 Hz, ArH), 8.30 (d, 2H, J = 8.00 Hz, ArH), 7.70 
(t, 2H, J = 8.11 Hz, ArH), 4.20 (t, 2H, J = 6 Hz, NCH2CH2), 3.00 (t, 2H, J = 6.65 Hz, 
NCH2CH2NH2); ESI-MS (+ion): found m/z 241.0971, calc.241.0977 for [(6) H]+.
13C NMR spectrum and Mass spectrum were not obtained as it is a known compound.80
33.1.4 Alkylation of Napthalic anhydride derivative with N,N-Bis[(tert- 
butoxycarbonyl) methyl-2-bromoethylamine (L10)
To N,N-bis[(tert-Butoxycarbonyl)methyl-2-bromoethylamine 1 (1 g, 2.84 mmol) was added 
K2C03 (3.4 g, 87 mmol) and previously synthesized 6 (0.34 g, 1.42 mmol). Thereafter, DMF 
was added and the reaction mixture was gently heated up to 65 °C and allowed to stir
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overnight. Then the solvent was removed. The *H NMR spectrum of the crude product
indicated impurities. The crude product was flash chromatographed (5% MeOH: DCM
mixture). The pure product was obtained as yellow oil. Yield 0.62 g, 54%; LH NMR (400
MHz, CDC13): 8h (ppm) 8.50 (d, 2H, J = 7.27 Hz, Ar), 8.10 (d, 2H, J = 8.13 Hz), 7.70 (m,
2H), 4.30 (m, 2H), 3.40 (m, 8H,), 2.85 (br s, 8H), 1.40 (s, 36H); 13C NMR (400 MHz; D20):
5c 170.70, 163.4, 133.22, 130.63, 127.19, 121.53, 80.88, 45.43, 52.45, 55.10, 27.10; IR (KBr
disc) (cm1): 3440(br), 2977(s), 2931(w), 1736(s), 1702(w), 1661(vs), 1628(w), 1591(s); ESI-
MS (+ion): found m/z 783.4578, calc 783.4544 for [(L10) H].+
33.1.5 Hydrolysis of Alkylated Napthalinic Anhydride derivative (L11)
To L4 (0.12 g, 0.153 mmol) was added 2M HC1 (10 ml, 323 mmol) and the reaction mixture 
was refluxed for 2 h. Then the solvent was removed under high vacuum and to give the 
product as pale yellow solid. Yield 0.072 g, 84%; lH NMR (400 MHz, D20) 8h (ppm) 8.00 
(d, 2H, J =6.79 Hz), 7.92 (d, 2H, J = 8.41 Hz), 7.40 (t, 2H, J = 6.94 Hz), 3.7 (m, 4H), 3.40 (s,
8H), 2.90 (m, 4H), 2.80 (m, 4H); 13C NMR (400 Hz, D20 ) 8c 172.25, 168.72, 135.45, 135.65,
131.78, 131.59, 130,76, 127.09, 126.58, 119.92, 55.77, 55.34, 52.31, 50.81, 37.01; IR (KBr 
disc) (cm 1): 3430(br), 2963(w), 1695(s), 1655(vs), 16259w), 1588(s); ESI-MS (+ion): Found 
m/z 557.16, calc 557.00 for [(L11) H].‘
3.3.1.5.1 Complexation reaction of L5 with Gd (III) Chloride
Initially two reactants, namely L5 (28 mg, 0.05 mmol) and GdCk. 6H20 (18.0 mg 0.05 mmol)
were added to two different vials. The ligand was dissolved in ethanol 10 ml, and heated 
slightly to ensure complete dissolution. Then GdCb was dissolved in distilled H20, again 
heated to ensure complete dissolution. Thereafter the vial containing the metal salt solution
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was kept over the mixer, and the ligand solution was added dropwise. The instantaneous
formation of the precipitate was observed. After the complete addition of the ligand to the
metal, the mixture was stirred for two days; care was taken to ensure to prevent any light
interaction with the mixture, by covering the system with Allufoil. Then the solvent was
evaporated via rotavaporator and high vacuum to give a yellow precipitate, which is the
complex. Yield 84%; IR (KBr disc) (cm1): 3425(br), 1729(w), 1625(s), 1408(s); ESI-MS(-
ion): found m/z 712.0898, calc 712.0890 for [(L5)Gd]. UV/Vis [X™*, nm (sM, M 'W 1)] in
H20: 235(17,658), 274(4128), 344(6279).
The complexation reaction of L with Eu (III) chloride, Yb (III) chloride and Nd (III) chloride 
were carried out as described for complexation with Gadolinium. Except in the case of Nd 
(III) chloride it has to be dissolved in DMF, instead of water
3.3.1.6 Reaction with Napthalinic anhydride and Triethlylenetetraamine (7)
To 1,8-napthalinic anhydride (1 g, 5.05 mmol) was added triethylene tetra amine (4.5 ml, 30 
mmol) and allowed it to reflux overnight. Solvent was removed through distillation. 
Thereafter the cmde product was dissolved in dichloromethane and filtered. The filtrate was 
evaporated and the lU NMR spectrum for the filtrate and that precipitate recorded. To purify 
further, it was decided to wash the precipitate in toluene and the toluene washings was 
evaporated to obtained the product as a dark brown sticky solid. Yield 0.7 g, 42%; lH NMR 
(D20 , 400 Hz) 5n(ppm) 8.5 (d, 2H, J = 8.53 Hz, ArH), 8.10 (d, 2H, J = 8.14 Hz, ArH), 7.70 (t, 
2H, J = 8.00 Hz, ArH), 4.35 (t, 2H, J = 5.8 Hz, NCH2CH2NH), 2.95 (t, 4H, J =12Hz, 
NCH2CH2NH), 2.80 (t, 2H, J = 8.00 Hz, NHCH2CH2NH), 2.7 (t, 2H, J = 10 Hz, 
NHCH2CH2NH2), 2.6 (m, 4H); IR (KBr disc) (cm1): 3416(br), 2964(s), 2822(w), 1699(s),
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1660(vs), 1625(w), 1590(s), 1439(s); ESI-MS (+ion): found m/z 349.15, calc 349.17 for
[(7) H].+
3.3.1.7 Alkylation of Napthalinic anhydride derivative (L12)
To tertbutylbromoacetate (2.27 ml, 15.58 mmol) was added K2CO3 (10 g, 72.46 mmol) and 
previously synthesized 7 (1.011 g, 3.10 mmol). After the addition of DMF (20 ml), the 
reaction mixture was gently heated up to 65 °C and allowed to stir overnight. Then the solvent 
was removed. As it was discovered from the *H NMR spectrum the crude product contains 
impurities, it was decided to flash chromatograph the material (Methanol: DCM). Product was 
obtained from eluents which were collected upon eluting with 10% MeOH: DCM solvent 
mixture. Solvents were removed through rotavaporation and high vacuum. Yield 0.25 g, 20%;
NMR (CDCI3, 400 MHz) 5H 8.50 (d, 2H, J = 7.13, ArHa), 8.10 (d, 2H, J = 7.98, ArHc), 
7.70 (t, 2H, J = 7.73, ArHb), 4.2 (m, 2H), 3.4 (s, 8H), 2.9 (m, 2H), 2.8 (m, 2H), 2.7 (m, 2H),
2.6 (m, 4H), 1.4 (s, 36H); 13C NMR (400 MHz, CDC13,): 8c 169.03, 163.06, 132.84, 130.55, 
130.15, 125.88, 121.66, 79.85, 55.02, 54.82, 51.92, 51.77, 50.92, 37.17, 27.08, 27.00, 27.14, 
26.91; IR (KBr disc) (cm'1): 3467(br), 2973(s), 2360(s), 1733(vs), 1648(s), 1595(s); ESI- 
MS(+ion): found m/z 783.45, calc 783.45 for [(L12) H].+
33.1.8 Hydrolysis of Alkylated Napthalinic Anhydride derivative (L13)
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L12 (0.12 g, 0.15 mmol) was introduced to a round bottom flask and 2M HC1 (10 ml, 324
mmol) added and the reaction mixture was refluxed for 2 h. After 2 h solvent was removed
through rotavaporation and high vacuum. Yield 0.07 g, 58%; *H NMR (400 MHz, D2O) 8h
(ppm) 8.00 (dd, 4H, J = 8.8 Hz, other constant not determined, ArHa,c) 7.45 (t, 2H, J = 26 Hz,
ArHb), 3.00 - 4.25 (m, 18H); IR (KBr disc) (cm1): 3428(br), 29649w), 2532(w), 1738(s),
1702(w), 1654(s), 1590(w); ESI-MS(+ion): found m/z 559.2057, calc 559.2040 for [(L13)
H].+
3.3.1.8.1 Complexation reaction o f L13 with Gd (III) Chloride
Complexation was carried out in a similar maimer described for L11. Yield 85%; IR (KBr
disc) (cm1): 3404(br), 1728(w), 1644(s), 1408(s); ESI-MS(-ion): found m/z 714.23, calc 
714.11 for [(Ll3)Gd], UV/Vis [Xmax, nm (sM, M 'cm '1)] in H20: 235(6752), 267(1679), 
345(2309).
3.3.2 Synthesis of DTBA Bismaides
3.3.2.1 Synthesis of DTPAbisamide of Amine functionaiized naphtha derivative (L14)
OH
To DTPA bisanhydride (0.308 g, 0.816 mmol) dissolved in dimethylformamide (10 ml) was 
added N-(2-Aminoethyl)-l,8-naphthalimide 6 (0.413 g, 1.72 mmol) dissolved in 
dimethylformamide (10 ml), dropwise. After the complete addition, the reaction mixture was 
allowed to stir over night at room temperature. Then dichloromethane (50 ml) was added to 
the reaction mixture. The precipitate formed was filtered and was washed initially with 
acetone and subsequently with acetonitrile. Yield 0.38g, 45%; JH NMR (400 MHz; 
DMSOck): 5(ppm) 8.4 (d, 2H, ArHa, J = Hz), 8.35 (d, 2H, ArHc, J = Hz), 8.15 (s, 1H, NH),
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7.75 (t, 2H, ArHb, J = 2.7 Hz) 10.00 (s, 2H, NH), 7.50 (d, 4H, (m, 2H, NCH2), 3.40 (m, 2H,
NCH2CH2), 3.30 (s, 2H, NCH2COOH), 3.1 (s, 2H, NCH2COOH), 2.6 (s, 2H, NCH2CH2N);
13C NMR (400 MHz; D20 ) 8c: 173.00, 171.23, 163.95, 134.40, 131.4, 130.8, 127.67, 127.38,
122.36, 57.63, 55.35, 52.26, 37.08; IR (KBr disc)(cm‘‘): 3436(br), 2963(s), 1699(s), 1660(vs),
1627(w), 1585(s).
3.3.2.2 Synthesis of DTPAbisamide of aminomethyl pyridine (L15)
DTPA bisanhydride (0.364 g, 1.018 mmol) was dissolved in dimethlyformamide (7 ml) 
completely and was added 4-Aminomethyl pyridine (0.22 g, 2.036 mmol) completely 
dissolved in dimethlyformamide (7 ml), drop wise. After the complete addition, the reaction 
mixture was allowed to stir at room temperature overnight. Then dichloromethane was added 
to the reaction mixture, a great deal of precipitate was formed, which was filtered and washed 
firstly with acetone and subsequently with acetonitrile. Yield 0.15g, 25%; *H NMR (400 
MHz; D20  with K2C03, Me4Si); 8.42 (d, ArCH6, J  = 6.51 Hz, 2H), 7.50 (d, ArCH2, J  = 6.30 
Hz, 2H), 4.45 (s, NHCH2, Ar 2H), 3.65 (s, 2H, NCH2CH2COOH), 3.30 (s, 2H, NCH2COOH), 
3.15 (s, 2H, NCH2CH2CONH), 2.70 (s, 2H, NCH2CH2N); 13C NMR (400 MHz; D20  with 
K2C03): 179.26 (CO), 175.30 (CO), 148.99, 148.78, 122.63, 59.36, 58.69, 53.46, 41.98; IR 
(KBr disc) (cm1): 3438(br), 1712(w), 1666(s); ESI MS+ion: found m/z 574.2645: calc. 
574.2625 for [(L1)H]+.
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Utilising, retrosynthetic approach, two new DTPA analogues have been synthesized. 
Chromophore bearing, central nitrogen substituted, DTPA analogue has been synthesized for 
the first time. The Symmetric naphtha derivative of N-(2-Aminoethyl)-l,8-naphthalimide has 
four free carboxylic acid groups. This will favourably enhance the stability of the gadolinium 
chelate, while providing binding site for blood proteins (such as BSA). This will in turn 
potentially enhance the relaxivity. Two novel DTPA bisamides were synthesized.
It is also envisaged, that the pyridine N in the DTPA biamides of 4- 
aminomethylpyridine could act as donor atom for /ac*-Re(CO)3(Bpy)Cl. This rhenium 
complex possess a very short emission life time (<10 ns). This has been attributed to the non 
radiated quenching of the exited state through the bound chloride ion. Interstingly, when the 
chloride was replaced with pyridine nitrogen, the life time is significantly enhanced (by two 
orders of magnitude).
These investigations clearly support the fact that the gadolinium complex of the DTPA 
bisamide of 4-aminomethyl pyridine could be a potential dual purpose contrast agent.
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Chapter 4: PART A 
Relaxivity Measurements
A.4,1 What is Relaxivity? Or Why is it Important?
The relaxivity of a paramagnetic contrast agent could be defined as the ability of a 
paramagnetic chelate of ImM concentration in solution, to enhance the relaxation rate of 
surrounding water protons. The factors contribute to the relaxivity and their effects are yet to 
be uncovered fully. Throughout history, however, scientists have travelled a long way to 
probe the factors affecting relaxivity.1
A.4.1.1 The factors defining relaxivity
Optimisation ofparameters o f the relaxivity
Most of the commercially available contrast agents are efficacious only at high 
concentrations; 0.1 mM (with the exception of gadobutrol, which could be administered in 
higher dosages, see Fig-1). Naturally, enhancement of sensitivity is an issue. Paramagnetic 
chelates with high relaxivities could be detected in lower doses or enhance contrast at 
equivalent doses in relation to compounds with lower relaxivity. According to the standard 
theory of ‘Solomon-Bloembergen-Morgan’, it was predicted that it should be possible to 
produce contrast agents with relaxivities, more than 50 times higher than those that exist in 
current usage.2
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Therefore, with the advancement of NMR imaging, two major approaches have been
undertaken to enhance relaxivities. Firstly, through the optimisation of parameters those are 
governing the relaxivity of the water protons (such as water exchange rate, rotational 
correlation time) and secondly, through linking the gadolinium complexes. For instance, 
gadolinium chelates appended to a polyamide dendrimer (giving rise to Gadomer), reported to 
posses high relaxivities ( l6.5 mM’1s'1 at 40 °C, 0.47 tesla per Gd). To optimise rotational 
correlation times, macromolecules are employed. These macromolecules employed in the 
covalent or non-covalent binding could be ranging from natural molecules like DNA3, 
proteins4, lipids,5 and have been widely reported in many reviews.
Defining ‘Relaxivity ’
In mathematical terms relaxivity could be defined, as the degree of change in the relaxation 
rate of the water protons, after the administration of the contrast agent, normalized to the 
concentration of the paramagnetic chelate (see Eq-1).
r, = A(l/T 0 (l)
[M]
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‘Relaxivity of the solvent water protons is a complex, multifaceted phenomenon. In typical
in-vitro or in-vivo studies, initially, the water protons situated in close proximity to the
paramagnetic metal ion are relaxed. This relaxation effect is then translated rapidly to bulk
water in the vicinity. Ti relaxation of water protons induced by the Gd (III) ion takes place
mainly through a dipolar mechanism. To explain this mechanism, water could be divided in to
three categories. Firstly as ‘inner sphere water’, where oxygen atom of the water molecule is
directly coordinated to the paramagnetic centre. The water molecules involved in the
hydration of the complex belongs to the second category, ‘second sphere water’. The
residence time of the second sphere water molecule will be finite and will be longer than the
translational diffusion of the bulk water. Third category is known as ‘outer sphere water’.
This is the bulk water in the vicinity. According to the contribution of these different
categories of water protons to the overall relaxation process, the mechanism could be
classified in to three major categories. Firstly, as ‘Inner sphere mechanism’and secondly as
‘Outer sphere mechanism’ finally as 'Second coordination sphere mechanism’.
Inner sphere mechanism
This is most significant and widely studied contribution to the relaxivity. Gd (III) has a high 
magnetic moment (7.9 BM) due to seven unpaired electrons. Therefore high relaxivity is 
produced by the fluctuating dipole created by the interaction of the electron spin of the 
paramagnetic centre with that of the nuclear spins of the water protons. This fluctuating 
dipole could facilitate the spin transitions and spin relaxation.
To understand this dipole, it could be characterised in terms of a time constant, known as the 
correlation time (l/rc). There are four different correlation times that have been identified and 
named according to their origin of contribution. Firstly, rotational diffusion of the complex 
contributes to the fluctuating dipole, this is known as the rotational correlation time (l/rR) and 
secondly, residence time of the water proton in the inner coordination sphere (l/rm) (residence 
time is also referred to as water exchange rate between the inner or 2nd coordination sphere 
and the outer coordination sphere).
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The rest of the contribution arises from electronic longitudinal relaxation rate (1/Tie) and the
transverse relaxation rate (1/T2e) (also see Eq-4).
The parameters influencing Inner sphere Mechanism
To understand the complex process. Peter Caravan proposed the following diagram7 
(see Fig- 2).
-H
Gd;N-
O'
H B ulk w ater
H
„ / 0\ H
O H
/
H
2nd Sphere w ater
F igu re  2 :- D iag ram m atic  re p re se n ta tio n  o f  th e  p a ra m e te rs  in flu en c in g  in n e r sp h e re  m echan ism .7 
According to the figure, there are q water molecules in the inner coordination sphere with Gd-
H distance of r, residency time rm. Further gadolinium ion is denoted by a large vector due to
its high magnetic dipole, which is indicated by spin S. These spins undergo longitudinal and
transverse relaxation, described in terms of Tie and T2e, respectively. Moreover, assuming the
complex tumbles isotropically, the rotational diffusion could be attributed towards rotational
correlation time. This is denoted by t r . Also we must take in to consideration the second
sphere water with a distance of r’od-H, its residence time could be denoted by rm\ ft is evident
that the influence of these parameters to each other could not be ascertained by measuring the
relaxivity alone. Through the relaxivity measurement, however, some of the parameters could
be determined indivually, and thereby other parameters could be simulated. The contribution
of the inner sphere water, to the relaxivity could be described by the following equation
s </ |H ,Q |
1 ( G m - T n . )
Tim is the proton relaxation time of water protons in the inner coordination sphere. Clearly, to 
optimise relaxivity, one must lower the Tim and rm, while increasing the q. It is obvious that 
the concentration of the water can not be altered.
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Hydration Number (q)
Although the concentration of the water molecules could not be altered, it was discovered that 
it is possible to adjust the number of water molecules in the inner sphere. So as to say, the 
hydration number could be altered. This could be achieved by creating more vacant sites for 
the oxygen atom of the water molecules. There is, however, an inherent risk involved in 
carrying out this exercise. When the coordination sites around the metal ions get reduced, it 
compromises thermodynamic stability of the complex. This will result in increased toxicity. 
The second trade-off in increasing the q is the possibility of coordination with other ligands 
(such as phosphate and carbonate which are endogenous anions). This will in turn, displace 
the water molecules and lead on to reduction in relaxivity.
The estimation of hydration number could be carried out through X-ray crystallography
O
and luminescence life time measurements (on isostructural Eu complexes). ENDOR 
spectroscopy is also employed presently to determine the hydration number. This technique 
basically correlates the difference in the intensity of the ENDOR spectrum taken in both D2O 
and H2O of the complex. The hydroxy pyridinione compounds reported by Raymond et a l9 
stand in testimony of a successful optimisation of hydration number.
They have determined the q value as 2 and the complex was found to be thermodynamically 
stable, coupled with the resistance to anion coordination.9 
The water proton relaxation rate ( TIm)
From Eq-2 it is clear, water proton relaxation time of the bound water should be short as 
possible. Tim is greater than rm with regard to first generation contrast agents. Further, Tim is 
the limiting factor for relaxivity of these contrast agents.
Therefore an understanding of the factors influences Tim will be helpful to comprehend the 
role of other parameters affecting the relaxivity of a contrast agent. Following equations will 
provide the necessary foundation (see Eq-3 and Eq-4).
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‘•m *■ K * ic
(4)
The terms in the equation are:
The distance between the bound water and that of Gd (III), rGdH, the electron Larmor 
frequency ©s (cos = 658vH), proton Larmor frequency ©h and correlation times of rci and tC2 
related to longitudinal relaxation and transverse relaxation respectively.
longitudinal and transverse relaxation influences the inner sphere water proton relaxation. 
Gadolinium -water distance
paramount importance if it could be reduced some how; it will lead to significant 
enhancement in relaxivity (see Eq-3). It is, however, virtually impossible to alter this 
parameter.
Rotational correlation time
As aforementioned, the contribution to the correlation time arises through the three factors, 
namely rotational diffusion, electronic relaxation and water residence time.
The commercially available MRI scans, however, operate at 1.5 Tesla. At this field, the 
correlation time is predominantly attributed to rotational diffusion. A simple monomeric Gd 
complex will have tr of 0.1ns on average. The attachment of proteins, however, will increase 
the tumbling time resulting in enhanced relaxivity.10
Rotational diffusion could be determined by number of techniques, such as EPR, fluorescence 
and NMR spectroscopy. A huge amount of work has been undertaken to optimise the 
rotational correlation time11 there by increasing the relaxivity.
As from the above equations, it is evident that the factors affecting correlation times related to
Literature values ranging 2.7-3.1 A have been obtained indirectly from fitting of NMRD data. 
It is possible to directly measure this parameter through ENDOR spectroscopy. It will be of
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Electronic relaxation time
This is a complex phenomenon and depends on the field strength of the magnetic field. 
Similar to the rotational correlation time, ‘electronic relaxation time’ also needs optimisation. 
This is because at low fields (0.1 Tesla), electronic relaxation time is very high and 
predominantly contributed to correlation time. At high fields, however, electronic relaxation 
will be declining to an extent where at some point it becomes slower than the rotational 
motion
1 IT ,C. UT2c »  1 /tr ; T u  *  t cI. 7%c % t , 2 
at low field ( <  0.1 T)
1/7’,c  1/7%, «  l / t R; rR % rcl % tc2
at high field (6„  >  1.5 T)
Water residence time or Water exchange rate
The relaxation effect experienced by the bound water molecule in the inner coordination 
sphere is transmitted to the bulk solvent through the exchange of water molecules. This is 
characterised in terms of water residency time or sometimes called water exchange rate. 
Water exchange is an inevitable factor which determines the relaxivity. This parameter 
influences the relaxivity directly as well as through the influence exerted on the proton 
relaxation time (sees Eq-2 and Eq-4).
There is an intense need, however, to optimise the water exchange rate. The relaxivity 
of a Gd based contrast agent could be limited; if the water exchange rate is too slow as the 
relaxation effect is transferred poorly to the bulk.
On the other hand, if the water exchange rate is very high, relaxivity will be reduced as 
the water molecule does not remain coordinated to the Gd (III), long enough for it to be 
relaxed. The water exchange rate could be directly measured through 170  NMR transverse 
relaxation rate measurements.
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A.4.1.2 Influence of Temperature and Field strength in the
measurement of Relaxivity
Given that temperature influences the rate of water exchange and rotational diffusion, it is 
evident that temperature changes will have profound effect on relaxivities. Therefore it is a 
must to report relaxivity data with the appropriate temperature used. The appreciable 
temperature could be 37 °C due to the fact, it is the physiological temperature. Field strength 
also equally influences the relaxivity data. The high field strengths are increasingly used in 
today’s clinical practice. This in turn increases the tissue relaxation times. Therefore long 
tissue relaxation time and high resolution scans lead on to long acquisition times. The use of a 
contrast agent, however, significantly reduces the acquisition time.
To estimate the efficacy of the contrast agent, prior to the in-vivo imaging studies, a 
detailed investigation will be carried out in-vitro. In this respect, the investigations carried out 
with Fast field reflexometry are of paramount importance. Therefore following section will 
give a brief introduction to this very important technique.
A.4.1.3 Principles o f NMR spectroscopy underlying the Magnetic
Resonance Imaging
The subatomic particles, electron, proton and neutron all possess spin of a half by nature. This 
spin could be positive or negative. Within an atom any of their arrangement will ensure a 
combined value of zero or multiples of Vi. In an applied magnetic field, bearing field strength 
of Bi, a particle with a net spin can absorb a photon of frequency u.
This u is dependent on the gyro magnetic ratio, which is a characteristic constant for a 
particular nucleus. For instance Yh = 42.58 MHz / T.
i) = yB (5)
A proton, because of its inherent spinning, generates a magnetic field, thus has a magnetic 
moment vector. When the proton is subjected to an applied magnetic field, the spin vector of 
the particle gets aligned with the applied magnetic field. This alignment could be parallel or 
anti-parallel. Hence, the spins with a high energy configuration will be aligned along the
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direction of the magnetic field, while the spins belong to the lower energy configuration will
be aligned in the opposite direction of applied magnetic field. If the system is subjected to
radio frequency (RF) radiation at this stage, it may lead on to transition of the low energy
proton to the high energy spin state. This transition is possible only if the energy of the photon
absorbed by the proton overcomes the energy barrier of the two spin states (i.e energy
difference between low and high energy spin states). The frequency in relation to the energy
of the photon responsible for this transition is known as ‘resonance’ or ‘lamor frequency’.
This is influenced by another factor, planks constant (h = 6.626xl0'34 Js). See Eq-6.
E = hu (6)
Combing equations (5) and (6) leads to the expression:
E = hyB (7)
The slight excess of spins in the lower energy level, N*, compared to the higher energy level, 
N, is reflected in expression (4):
N/N* = e_E/kT (8)
Where E is energy difference of the high and low energy spin states; k is Boltzmann's 
constant (1.3805x1 O’23 J/Kelvin); and T is the temperature in Kelvin. The ratio N/N* will 
decrease as the temperature decreases. As the temperature increases, the ratio of the difference 
in population between energy states will eventually become zero. That is to say ratio N/N* 
achieves unity.
The observed signal intensity in MRI arises due to the difference in energy absorbed by 
nuclei which undergoes transition from low to high energy spin state and that of the energy 
released by the nuclei due to their simultaneous transition taking place from high to low 
energy spin states. In other words, signal intensity is proportional to the population difference 
between the high and low energy spin states.
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In short, sensitivity of MRI is a consequence of the energy exchange taking place between
the spectrometer and that of the spins at a particular frequency. ‘Targeting’ proton is justified 
by its natural abundance (i.e. 99.985%) and also because of its biological abundance (a typical 
biological tissue contains more than 60% of water).
Tj * Longitudinal/Spin-Lattice’ Relaxation
The net magnetisation vector arises from the population difference in the two spin states, 
aligned parallel to the externally applied magnetic field Bi. This vector is known as 
equilibrium magnetisation (denoted by Mi). The vector solely composed of longitudinal 
magnetisation component (Mz) and there are no transverse components (Mx and My) 
involved.
When this nuclear spin system is subjected to RF radiation of a frequency equal to that 
of the energy barrier between the two spin states, net magnetisation vector will be altered and 
it will acquire a transverse component.
At the same time, clearly, nuclei will be rotating around the z axis at a frequency equal 
to that of the frequency of the photon that induces transition between the two energy states. If 
the magnitude of the RF radiation is of sufficient intensity, then the spin system will be 
saturated. Therefore the net magnetisation vector comprises entirely the transverse 
component, inducing the Mz to become zero.
When the applied radiation is removed, however, the spin system relaxes back to the 
initial equilibrium state. This induces the recovery of the longitudinal magnetisation to its 
initial equilibrium value. This process is illustrated by a time constant. This time constant is 
known as spin—lattice relaxation time, denoted by Ti. The variation of Mz as a function of 
time t (after initial displacement) could be depicted through the following equation.
MZ = M,(1 - e ™ )  (9)
Therefore, after time Ti, the longitudinal magnetisation will have returned to 63% of its initial 
value (see Fig-3).
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63%
F igure  3:- A g raph ica l rep re se n ta tio n  o f  e q u a tio n  9, show ing  how  th e  recovery  o f the longitud inal
m agnetisa tion  follow s an  ex p o n en tia l process.
T2 ‘Transverse/Spin-Spin’ Relaxation
The transverse component of the net magnetisation vector is designated as Mxy and is 
perpendicular to Bo. The pattern of* growth of T2 is a complex phenomenon. The explanation, 
however, could be attempted as follows.
The rotation around Bo by the nuclei together, creates interaction of the local magnetic 
fields produced by the spinning protons. This will lead on to the cumulative loss in phase with 
time. The process of the recovery of transverse magnetisation vector to its equilibrium state is 
best described by a time constant. This time constant is known as the spin-spin relaxation 
time, T2 and could be illustrated by the following equation. Also see Fig-4.
MXy(t) = MXY(0)e-,/T2 (10)
37%
F igure 4:- A g rap h ic a l rep re se n ta tio n  o f  eq u a tio n  10, show ing  how  the  recovery o f the 
tra n sv e rse  m ag n etisa tio n  follow s an  exponen tia l process.
The spin-spin relaxation is also caused by the magnetic field inhomogeneity experienced by 
the nuclei, in-vivo. Further, the various chemical environments in which protons are located 
also causes the dephasing of the transverse magnetisation vector. Therefore, the overall decay 
of the transverse magnetisation could be attributed to both these factors. This is illustrated by 
the following equation.
1 6 6
1/T2* -  1/T2 + l/T2inhomo
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(11)
Where T2* indicates the overall transverse magnetisation vector. T2 indicates spin-spin decay 
without these contributing factors, T2inhomo indicates the decay resulting from magnetic field 
inhomogeneity.
A.4.1.4 Fast Field-Cycling Relaxometry
Significance and Applications
Field cycling relaxometry is an exclusive technique among the various NMR techniques (see 
Fig-5) available. Field cycling relaxometry allows one to cover several decades of frequency 
by utilising the same instrument.
There are various applications of the field cycling relaxometry in the literature that 
could be discussed; bio polymers, investigations regard to biological tissues, liquid crystals
I ^
and lipid bilayer investigations to name a few.
Due to its versatility to determine Ti decay over a range of field strengths, however, it 
has emerged as the powerful tool for characterisation of molecular dynamics, especially in 
complex media.
More precisely it has provided the basis for Fast field cycling MRI and has provided 
advantage an over the fixed field MRI scans, with regard to specific tissue imaging.13
1 0 1 10'
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transverse relaxation, 
residual spin couplings
10 rad  H;
conv. relaxometry
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F ig u re  5 :- D ep ic tin g  th e  v a r ie ty  o f  N M R  te ch n iq u e s  av a ilab le  o ver a ran g e  o f 
a n g u la r  fre q u en c ie s  a n d  tim e
A. 4.1.4.1 General Aspects o f Practical Application o f FFC
During a fast field-cycling relaxometry (FFC) experiment carried out in a relaxometer, one 
measures the spin lattice relaxation time of a sample as a function of external magnetic field. 
This external magnetic field is cycled through a range of discrete field strengths.
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Although, spin-lattice relaxation time is the most commonly measured parameter, spin-spin
relaxation times are also measured by FFC, to obtain further information occasionally.
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Digital acquisition module
F igure 6 :- Schem atic  rep re se n ta tio n  o f  th e  ty p ica l field cycling re laxom eter 
A.4.1.4.2 Basic principles o f FFC
As aforementioned, FFC is used to obtain, nuclear magnetic relaxation profiles. This is 
possible by employing two different methods, namely pre-polarised sequence (PPS) and non­
polarised sequence (NPS).
Pre- Polarised Sequence used in low fields (When Br «B p)
When compiling NMRD profile, during the PPS phase, initially a strong magnetic field is 
established, Bp. This will polarise the nuclear spin system as in a typical NMR experiment. 
Thereafter, the instrument switches the magnetic field of the higher flux density, Bp towards 
lower flux density, Br. The magnetic field will remain in this low flux density for a known 
period of time, x (as far as, Stellar Spin master FFC-2000 relaxometer is concerned, switching 
on to high flux to low flux density is achieved, by modifying the current in the magnetic coil.
There are instances, however, where mechanically the sample will be shifted onto different 
field strengths, for eg;-sample shuttling technique). At this stage, the magnetisation lies
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parallel to the externally applied magnetic field and its value initially equal to the equilibrium
magnetisation of the polarisation field (see Eq-12).
M(0) = Mz(0) = M0(Bp) (12)
Once the magnetic field is changed to low flux density, the nuclear spin system started to 
relax towards the new orientation of the magnetisation (Mo(Br). The magnetisation now 
evolves, and could be depicted in a mathematical form (see Eq-13) and is called the Bloch 
equation.
Mz(x) = M0(Br) + [M0(BP) - Mo(Br)]exp{ - x/Ti(Br)}' (13)
Following this relaxation process (after the relaxation interval), the remaining magnetisation 
could be determined by switching the magnetic field to a higher flux density Bd (Bd should be 
higher than Bp). Subsequently, the sample is subjected to RF radiation tuned to a preset 
frequency, irrespective of the relaxation field. Following the 90° RF pulse, the signal is 
detected through free induction decay (FID). One distinct advantage to be noted is that 
acquisition time for FID will be in milliseconds. This brings the possibility to keep the 
detection field period (time remaining in Bd) to be kept as short as possible. This will in turn 
improve the duty cycle.
In order to switch back the net magnetisation vector to Mo(Bp), the field is now 
reverted to polarisation field, bearing flux density Bp. The field will remain at this flux density 
for an extended period of time, after which the process will be repeated. So as to say, the 
second cycle begins. This could be illustrated in Fig-3.
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Figure 3:- G rap h ica l rep re se n ta tio n  o f  th e  v a r ia tio n  o f  m agnetic  field s tren g th  d u rin g  a p re-po larised
sequence
Non-Polarised sequence used in  high fields: where Br —► Bd
A pre-polarised sequence is suitable in experiments where the relaxation flux density Br, is 
considerably lower than the polarisation field Bp. The accuracy of the data, however, is 
compromised when the difference in magnetisation vector, AMzeff of the high and low flux 
densities becomes sufficiently small. This has brought up the essential need for a non­
polarised sequence, especially where Br becomes high that it approaches Bp
Non polarised sequence begins, without the initial polarisation phase of the nuclear 
spin system. Thus the relaxation curve is produced through a typical inversion recovery 
method. An 180° pulse rotates the net magnetisation vector down to the -z  axis, thereafter the 
net magnetisation undergoes spin lattice relaxation, which returns the net magnetisation 
vector to its equilibrium value along the +Z axis. The resulting relaxation curve will be 
starting from zero or quite close to zero. The relaxation curve is then of the type:
^ d e t e c t e d  ( t )  =  M  »  .  A M / f f  e - ^ l  ( 1 4 )
F I D
t
F igu re  4 :- G ra p h ic a l rep re se n ta tio n  o f  a non-po larised  sequence, ind icating  the 
absence o f  p o la risa tion  field Bp,
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The major advantage of FFC relaxometry is its capability to be cycled incrementally over a
range of relaxation flux densities. An important consideration when analysing relaxivity data
is the contribution of the diamagnetic component arising from the medium in which the
sample dissolved in to (pure water).
rap = ra - r^  per mM (15)
Where p = paramagnetic, d = diamagnetic.
The reference rate in a diamagnetic solution corresponds to the absence of a paramagnetic 
Gd-L complex and is denoted by:
Tod = 1/Tod (a = 1,2) (16)
The relaxivity, ra (s'1 mM'1), of a paramagnetic compound such as a contrast agent is thus 
defined as a paramagnetic relaxation enhancement (PRE) of added Gd-L complex:
ra = r„p/ [GdL] (17)
Due to the large magnetic moment of the Gdm centre resulting from its electronic spin S=7/2, 
the observed relaxation rates Ra increase markedly with the concentration [GdL] (mM) of the 
Gd-L complexes added to the solution.
A.4.2 Results and Discussion
A.4.2.1 Manganese and Copper complexes of EDTA bis amino
methyl pyridine (Mn-L4 and Cu-L4)
An Overview o f M anganese Complex (M n-L4)
The lH NMRD profiles of compound Mn-L4 and free Mn-(II) each at two different 
temperatures are illustrated in Fig-1. Lowering the temperature of the sample induces 
enhancement in the relaxivity, this is expected as relaxation rates are inversely proportional to 
the diffusion coefficient.14
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At 30 MHz, the relaxivity of Mn-L4 (at 37 °C) is 3.52 mM'V1, which is comparable to the
performance of commercially available, gadolinium based contrast agents Magnevist® and
Dotarem®.
At the same time it is still markedly higher in comparison to Teslascan® (the only 
clinically approved manganese based contrast agent at present) 1.88 mM'V1 (at 20 MHz, 37
°C).
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F ig u re l:-T h e  *H N M R D  profiles o f co m pound  M n -L 4 an d  F re e  M anganese in 20 °C  an d  37 °C 
F ig u re  reveals th e  effects o f  changes in te m p era tu re .
Fig-2 and Fig-3 depict the representative titration results, in this case L4 added to ImM 
solution of Mn (II) at 20 °C and 37 °C respectively. The sharp break in the L4 titration 
indicates that the association constant is relatively high.
Further, high relaxivities observed before the sharp breaking point at 1 mM 
concentration of the ligand is due to the free Mn (II) ions, which has higher number of 
coordination sites for the inner sphere water molecules. The complex stability is reflected by 
the consistency in the relaxivity, even in higher ligand concentrations and. also clearly, a 1:1 
complex is formed.
1trM_H2O_20C 
1mM_H20_37C 
1 mM_1 rrM_L1 _H2O_20C 
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F igure  2 :- T itra tio n  o f  L 4 in to  a  lm M  so lu tion  o f  M n (II) a t  20°C
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F igure  3 :- T itra t io n  o f  L 4 in to  a 1 mM  solu tion  o f  M n (II) a t 37 °C 
The NMRD profile obtained upon addition of lmM of L4 in to 1 mM of Mn (II) in PBS 
and distilled water are depicted in Fig-4. The relatively low relaxivities obtained in PBS 
buffer in comparison to that in distilled water, may be attributed to phosphate ions binding to 
the complex, thus displacing the inner sphere water molecules.
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Therefore the decrease in number of inner sphere water molecules could have resulted in
relatively low relaxivity. This concept of anion binding and its influence on the relaxivity is
well documented.15
Alternatively, the relatively low relaxivities obtained in PBS buffer in comparison to 
that in distilled water, may be attributed to the increased deprotonation of the ligand in high 
pH. This will contribute to increased binding of Mn (II) with the ligand. This will in turn 
result in slightly less, free Mn (II) ions in solution. This has reflected in relatively low 
relaxivity.
&i
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Figure 4:- The *H N M RD profiles o f  com pound  M n -L 4 in d istilled  w a te r  (Top) and  P hosphate  B uffer
S olu tion  (PB S) (B ottom )
An overview of the copper complex - Cu-L4
The Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) was shown to be a valuable PET 
hypoxia marker for some tumour types.16 Indeed, recently EDTA bis amide of sulphonamide 
was also proposed as a PET hypoxia marker. 17These observations prompted us to investigate 
the complex formation of Cu (II) with L4 as to estimate its potential to be used as PET 
imaging agent. The !H NMRD profile of compound Cu-L4 in two different temperatures 
(20 °C and 37 °C) is illustrated in Fig-5. Lowering the temperature of the sample induces 
enhancement in the relaxivity as observed and reasoned for Mn-L4.
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The notable feature, however, is the relatively low relaxivities experienced by Cu-L4 (see Fig-
6 and Fig-7), when compared to Mn-L4 under similar conditions. In fact relaxivity of naked
Cu (II) in water is 8.14 mM‘1S'1 as against 0.90 mM'1S'1 enjoyed by naked Mn (II) in water.18
The observation is mainly attributed to the relatively long electronic relaxation time
experienced by Cu (II) ions in comparison to its Mn (II) counterparts. Interestingly, the
titration of the metal with ligand does not display the clear inflexion point at the 1:1 ratio as
displayed by the Mn species. This is surprising as copper binds to ligand more strongly than
Mn (II). Thus this is perhaps suggestive of equilibrium of a dimeric species and a monomeric
species with high concentration of ligand enforcing the monomer. If the dimeric species has a
higher relaxivity than the monomer (as one might expect), then the titration data would effect
the progression of free metal to dimer to monomer with a gradual reduction of water
molecules coordinated to the metal and a continual reduction in the relaxivity. The absence of
this behaviour with Mn reflects the weak binding of a second Mn (II) ion to the ligand.
</>
i
i
-2.00 -1.50 -1.00 -0.50 0.00 0.50 1.00 1.50
Field Stienyth (Loy voiles)
F igure 5 :- T he ‘H  N M R D  p rofiles o f  com pound  C u -L 4 in 20 °C  an d  37 °C , revealing  the
effects o f  changes in te m p e ra tu re .
1 .70
1 .55
1.40c
1 .2 5
1.10 -I
0.95*  
0 .8 0  ■ 
0 .6 5  •
x CuCI2_1mM_1mM_L1_20C 
♦ CuCI2 1mM 1mM L1 37C
175
Potential Multimodal Imaging Agents
2.50
2.00 J
y>
i  1.50-
I  1.00 H
ce
0.50 -\
0.00
0.00
2.50 i
2.00 -
&
i  1.50 I
I
1.00  -
0.50 -
0.00
A.4.2.2
♦ 30.00 ■ 12.33 5.06
*5.06 % 2.08 ♦ 0.86
+ 0.35 -0.14 -0 .06
0.02 0.01
0.50 1.00 1.50 2.00 2.50 3.00
Concentration of the Liijaiul (M)
3.50 4.00
Figure 6:- Titration of L4 in to a lmM solution of Cu (II) at 20 °C
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Figure 7:- Titration of L4 in to a lmM solution of Cu (II) at 37 °C
M anganese and Iron com plexes o f EDTA bis amino methyl 
sulphonic acid (M n-L6 and Fe-L6)
An Overview o f the Manganese Complex -  Mn-L
r-_______J . 6The H NMRD profile of compound Mn-L at two different temperatures is illustrated in 
Fig-8. Lowering the temperature of the sample induces enhancement in the relaxivity, as
observed and reasoned for Mn-L and Cu-L .
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The relative increase, however, is considerably larger than for Mn-L4. A notable observation
is that the relaxivity is similar to the relaxivity profile of the free manganese ion. This clearly
indicates the presence of free Mn (II) ions in large amount in the solution, a clear indication of
very low percentage of complexation of L6 with Mn (II).
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The variation of relaxivity as a function of pH at a constant temperature is depicted in Fig- 
11 a. The relaxivity remains constant up to pH 7.1, however further increase in pH resulted in 
enhanced relaxivity. As the solution is made increasingly acidic, the relaxivity is considerably 
enhanced due to progressive dissociation of the complex. The relaxivity of free Mn (II) ions is 
ca. 8.0 ±0.1 mM'V1 (20 MHz, 37 °C). Further when the pH is lowered, carboxylates gets 
protonated and no longer coordinated to the metal centre. This frees more Mn (II) ions. These, 
free Mn (II) ions will have relatively higher number of coordination sites for inner sphere 
water molecules. Therefore due to increased hydration number (q), enhancement in the 
relaxivity is observed.198
x  0.
 0.  0.
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An Overview on the Iron complex ( Fe-L6)
NMRD profile of compound Fe-L6 in two different temperatures (20 °C and 37 °C) has
been illustrated in Fig-12 and Fig-13. Initially, relaxivity is high due to free Fe (III) ions. 
These free Fe (III) ions have relatively higher number of coordination sites for the inner 
sphere water molecules but not as high as Mn (II). It is worthy to note that the ri relaxivity of 
the coordinatively saturated Fe(EHPG)’ was found to be ~1 mM’1 S’1. It was also reported that 
the water proton relaxation occurs only via outer sphere mechanism in this complex.196
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A  decrease in relaxivity is observed until it reaches its minimum value around 0.6mM. This
may be attributed to the complex formation, resulting in the decrease of inner sphere water
molecules. Further, above 0.6 mM, an increasing trend in the relaxivity is observed. This is
possibly due to the low electronic relaxation time of Fe (III), which is the main contributor to
correlation times (rC) 20 The low correlation time will in turn contribute to shorter longitudinal
water proton relaxation time and may be reflected in the increasing trend in the relaxivity.
Another possible explanation could be the formation of binuclear complex. This binulear
complex of Fe (III) will have slower tumbling rate compared to its mononulcear complex.
Reduction in tubling rate at low field strengths (less than 1.5 Tesla) leads to increase in
relaxivities.
Further, lowering the temperature, results in a relatively exponential increase in 
relaxivity. This may be attributed to the cumulative effect caused by the decrease in 
temperature and also through the contribution of low electronic relaxation times of the free Fe 
(III) ions.
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A.4.2.3 Collective overview
C om pounds M n L4 and  M n L6: O verv iew
While the comparative relaxivities of compounds Mn-L4 and Mn-L6 are only slightly higher 
(see Table-1), the introduction of substituents on the pyridine ring (in L4) allows us to 
envisage ligands bearing functional groups capable of noncovalent or covalent interactions 
with slowly moving substrates such as proteins or polysaccharides.
This could lead to contrast agents with longer rotational correlation times and 
consequently much higher relaxivities or increased specific tissue affinity. Further, the 
introduction of sulphonic acid groups (in L6) may have contributed to the relatively higher 
relaxivities. This may be reasoned as follows. In solution, anions like phosphate or carbonate 
binds with the metal ion, there by reducing the water exchange rate, as they block the area. 
Anionic sulphonic acid groups inhibit the formation of ternary complexes, thus contributing 
to higher relaxivities. Moreover some second sphere mechanisms might contribute to the 
higher relaxivities, resulting from sulphonic acid moieties. On the other hand, the sulphonic 
acid moieties are acid groups. They may not allow the complexation. This will in turn free 
more Mn (II) ions.
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Therefore, these free, Mn (II) ions might contribute to relaxivity enhancement by the
provision of increased coordination sites for the inner sphere water molecules.
Table 1: !H NMRD Relaxivity profile output data0 for compounds Mn-L4, Cu-L4, Mn-L6 
______and Fe—L6 (Collected at a relaxation field of 30 MHz, lmM, 37°C)_____________________
Compound T\ Relaxation time/s ri Relaxation rate/s'1 % Error ± Error (Rl)
Mn-L1 0.284 3.52 2.45E-01 8.62E-03
Cu-L1 1.717 0.58 2.24E-01 1.30E-03
Mn-LJ 0.182 5.50 3.38E-01 1.86E-02
Fe-LJ 1.243 0.80 3.50E-01 2.82E-03
Table 2: A selection of known ligands with accompanying relaxivities for their Mn (II)
and Cu (II) complexes
Ligand Temp (°C) freq (MHz) ri ( s 1 mM1) ref
Tesla Scan 37 20.0 1.88 21
Lumenhance 37 10.0 20.90 22
FerriSeltz - 16.0 1.60 23
Another important observation is related to the reduced significance of temperature change on 
relaxivity. As aforementioned, relaxation rates are inversely proportional to the diffusion 
coefficient and while this is clearly still a feature of the NMRD profile of the nitrate-free 
compound, the reduced temperature effect could be a consequence of enhanced water 
exchange rates.
Impact on Water Exchange Rate
It has been reported, water residence time is being dominated mainly by four factors. They are 
as follows: The charge on the complex, solvent accessibility, steric constraints at the binding 
of the water molecules and the mechanism of water exchange. Out of these four factors, 
solvent accessibility and steric constraints may be attributed to the relaxivity enhancement of 
the ligands in question.
The presence of hydrophilic groups is known to change the access of bulk water 
molecules towards the coordinated inner sphere water molecules (through affecting the water 
accessibility surface) and thereby contribute to the change in water exchange rate. This will 
have a pronounced affect in the relaxivity.24
The relatively high relaxivities observed in the case of Mn-L6 may be partially 
attributed to the presence of sulphonic acid groups as the hydrophilic group.
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On the other hand, relaxivity enhancement observed in Mn-L4 could be attributed to the
presence of pyridine moieties, which has contributed to the steric constraints. The steric
constraints are also known to contribute to relaxivity enhancement through fast water
exchange rate. It has been found that introduction of pyridine-N-oxide pendant arm induces
rapid water exchange rate.25
Further, it was reported that the polyamino carboxylates undergo water exchange 
through dissociative process. The steric compression around the bound water site is crucial for 
such dissociative processes as it facilitates leaving of the inner sphere water molecules.
This will result in increased water exchange rate. Therefore it could reasonably 
concluded that the increased steric compression due to the presence of pyridines induces 
relaxivity enhancement through the increased water exchange rate.26,27
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tem pera tu re . pH  o f  th e  sam ples w as a d ju s te d  to  7-8 to  re p re se n t physiologically re levan t conditions.
A.4.2.4 Sym m etric naphtha derivative o f N -(2-A m inoethyl)-l,8-
naphthalim ide (L 11)
Fig-15 depicts the lH NMRD profile of Gd complex of the symmetric naphtha derivative (see
Fig-15). As is seen, the relaxivity of the lmM concentration of the complex is significantly
high (i.e. 8.8 mM'1S'1 at 30 MHz, 25 °C).
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Reproducibilty of the results were ensured by repeating the whole synthesis and repeating the
measurements under the same conditions (8.5 m M 'V1 at 30 MHz, 25 °C). Furthermore, the
Free Gd (III) was not detected in the sample, by means of xylenol orange as indicator.
Most of the polyamino polycarboxylate scaffolds used as commercial contrast agents 
have relaxivities in the range of 4-5 m M 'V1 (at 30 MHz, 25 °C). Acyclic DTP A analogues 
reported to date also have comparable relaxivities to those of commercially available contrast 
agents based on polyamino polycarboxylates. Exceptionally higher relaxivities were reported 
by Raymond et al.28 for their HOPO based contrast agents. (7-13 mM'V1). As such, to the 
best of our knowledge, this is the highest value reported for a ligand of this nature.
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F igure 15: R e p ro d u c in g  id en tica l e x p e r im e n ta l co n d itio n s w ith  th e  sam e sam ple over an  
ex tended  tim e  p e rio d  co n firm e d  th e  h igh  s ta b ility  o f  th e  com plex.
Experimental
NMRD acquisition:
The 1/7) NMRD profiles were obtained on a Stellar Spin master* FFC-2000 relaxometer, 
typically covering a continuum of magnetic fields from 2.4 x lO’4 to 0.72 T (corresponding to 
a proton larmor frequency range 0.01-30 MHz). Technical details are available in the 
reference manual available upon request from Stelar .
* www.stelar.it
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A Spin master Variable Temperature Controller (VCT) allowed the setting and monitoring of
the sample temperature at two different temperatures, 20°C and 37°C with a resolution up to
0.01 °C. The temperature gradient over the sample region was dependent on the air (nitrogen)
flow and the installed temperature. The temperature in the probe head was measured with a
Fluke 52 k/j digital thermometer with an uncertainty of 0.5 K. The temperature inside the
probe was controlled by circulation of perfluoroalkanes. Each sample was allowed to
acclimatise to the desired temperature for 15 minutes prior to data collection. The
reproducibility in Ti measurements was within less than 1%.
The Mn (II), Cu (II) complexes complexes were prepared in a sample tube by mixing
equimolar amounts of either MnCl2.6H20 (99.99%; Aldrich) or CUCI2.H2O (99.99%; Aldrich)
and the ligand in doubly distilled water to the required concentration. A slight excess (5%) of
ligand was used and the pH was adjusted by adding NaOH (each 0.1 M). PBS was used to
represent the physiological environment.
Titration Method
In a typical titration experiment, a solution containing 4mM of the ligand was added on to the 
solution containing lmM of metal ions in appropriate amounts, such as to provide final 
concentration of the ligand ranging from 0.2 mM - 2 mM.
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Chapter 4: Part B 
Potentiometric Measurements
B.4.1 Evaluation of Potential Contrast Agents
B.4.1.1 Need for evaluation of contrast agents
As aforementioned in “Chapter 1” , the potential contrast agent must meet the criteria of 
maintaining high stability, while improving the relaxivity enhancement to appreciably higher 
standards. In short, successful preparation of a potential contrast agent means incorporating 
both these properties to their optimum values.
Tolerance to Toxicity
Safety/Toxicity has been evaluated by acute toxicity (L D 50) , sub chronic toxicity, local tissue 
tolerance, cardiovascular pharmacology, mutagenic potential, absorption, distribution, and 
metabolism and excretion studies.29 As aforementioned, these synthetic complexes are 
composed of relatively toxic components (i.e., metal ion and ligand, loosely bonded together) 
and subject to dissociation. The future development of radio or magneto pharmaceuticals 
inevitably relies on in-vivo affinity of these components for each other. The in vitro 
measurements of stability of these synthetic complexes have been considered as a step in the 
right direction. The stability constant measurement is one such parameter, among the number 
of parameters that are being used for this purpose. As such, a brief account on stability 
constants will not be out of place.
B.4.1.2 Protonation Constants and Stability Constants
The development o f the theory o f  stability constants throughout the ages
Throughout history, the estimation of stability constants has provided means for, 
understanding the degree of association of a ligand towards metal ion in solution. The initial 
interest in stability constants dates back to the early nineteenth century. This was initiated by 
Von Euler30 and Bodlander.31
186
Potential Multimodal Imaging Agents 
Their efforts, however, could not precede beyond the empirical formulae and overall stability
constants. N. Bjerrum32 and J. Bjerrum33 later made significant advances in this field that
serves as a basis for the present day, more detailed analysis of the complex systems. This also
paved way for the introduction of stepwise hydrolysis constants and step wise stability
constants. The numerous reports published in this field follow the same principles or basic
criteria. They are, constant ionic medium, high degree of accuracy (both during the
measurements as well as during interpretation), broad range of mass balance equations
utilising very complex algebraic manipulations. The theoretical background for these complex
calculations was initially provided by Rossotti and Rossotti.34
It was only two decades ago, however, significant advancements took place in this
field and eventually they have lead on to advantageous implications. A notable advancement
is the advent of tailor made computer programs. These programs, comprising computational
methods, accelerated the processing of equilibrium data and thereby gave rise to more precise
stability constants. One such program, known as “ Hyper Quad” designed by Peter Gans et
iff
al. , was of tremendous significance with regard to this project
Furthermore, the arrival of two stability constant databases has added lustre to this 
field. The significant aspect of these databases is the provision of a comprehensive selection 
of stability constants from literature, coupled with more detailed information on experiments. 
This information is crucial for drawing conclusions from the reported data as well as for 
comparative purposes.
B.4.1.2.1 What is meant by Stability Constants9?
The constant corresponding to stability constant arises from the ratio between the products of 
the activities of product species to that of the product of the activities of the reacting species 
in solution, at the point of equilibrium. This could be interpreted in mathematical terms by the 
following equation (see Eq-1)
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xX+jY ^  p P + q Q
=  a pP . a ^
a x  * a Y
The species in the equilibrium either concerned with product or reactant will have their 
individual Gibbs free energies. This will pave the way for a quantitative description of the 
reactvities of all the species involved. The difference in these Gibbs free energies could be 
directly measured in terms of stability constant measurements.
Ionic strength and Stability Constants
A  significant factor that needs to be considered when estimating stability constants is the ionic 
strength of the solution in consideration. It is quite impossible to measure the ionic activities 
of the complex ionic species while the reaction proceeds. Therefore in order to eliminate the 
problem, a non reacting electrolyte could be introduced far in excess of the reacting ionic 
species in consideration. This will in turn facilitate the control of ionic strength and thereby 
equate the activities of the ionic solutes to that of concentrations. This procedure used to 
determine stability constants, while maintaining constant ionic strength through the 
supporting electrolyte, has been adapted as standard practice. Clearly, it brings practicality. So 
as to say, the activity terms in Eq-1 could now be replaced with molar concentrations (see 
Eq-2).
„  m o ] ’
A  =  — ------------------ (2)
[X]*. [Y f
It also has an added advantage in that any concentrations obtained from the 
pontentiometric measurements could be correlated with that of the measurements obtained by 
other means (eg:-absorbance techniques). Moreover, the results could be directly applied to 
mass balance equations used for the estimation of stability constants and protonation 
constants.
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Importance of measuring Protonation Constants
In the solution, there is a competition between the metal ions and protons for the ligand sites. 
Therefore it is imperative that the measurements for protonation constant should precede the 
measurements for stability constants. The protonation constants for the potential ligands could 
be defined as follows.
LH+ + H+^LH?+ : K. =
[L][H+]
[L'Hf+1
[LH+][H+]
L'H5+ + H+ ^  LHf+ : K3 = L^H3J[L'Hf+] [H+] etcetera ^
The expected number of protonation constants depended upon two factors, namely 
the nature of the ligand and the number of potential sites available for protonation. With the 
subsequent addition of base (as aliquots) to the reaction solution, the ligand in consideration 
will become increasingly deprotonated. As a result, the dynamic equilibrium will be reverted 
to its original forms.
The significance o f Stability Constants
All of the usages of stability constants lie on a common platform. This may be further 
explained by taking into consideration a system having species which are held together by 
weak bonding interactions. Through the variation of concentration or by variation in pH, it is 
possible for a reactive species to exist in many various forms. The knowledge of stability 
constants is useful to understand these vital dynamic equilibria in solution. The knowledge 
obtained of these equilibria (through stability constants) is found to be of immense use in 
various fields as wide as analytical, biological, industrial and coordination chemistry research 
itself.38 In addition to the role of evaluating MR image enhancement agents, there are other 
practical applications that could be discovered in the literature.
189
Potential Multimodal Imaging Agents 
The field of ‘Molecular Recognition39 extensively uses stability constants to determine the
extent of host-guest interaction (see Fig-1). For example, Liu et a/.40 have utilised stability
constants to assess the stability of anions (oxalate, fumarate, sulphate etc) to determine the
extent of host-guest interactions. The usage of stability constants is inevitable in the
development of chemo sensors and luminescent probes.41 M.A. Santos et al.42 have used
stability constants measured through potentiometry, to evaluate Al-decoporating agents used
in the treatment of Parkinson diseases. Attracted by the role of arylazo derivatives of
benzimidazole and barbituric acid in biochemistry, Amrailah et a l43 have evaluated formation
constants of binary systems (where, selected amino acids acted as primary ligands and aryl
benzo derivatives acted as secondary ligands with regard to Cu (II), Zn (II) and Cd (II)).
Furthermore stability constants for complexes of haemoglobin and myoglobin with dioxygen,
CO, CN‘, facilitate the treatment of early stages of CO poisoning.44 The determination of
stability constants are useful in the preparation of silver cleaning solutions (as the silver
cleaning solution contains ligand with a higher affinity for Ag (I) than the tarnish) and also in
various Fe (III) complexing agents in rust removers.
R .
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HN
HO,
HO
HO HO
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1,3,5-T ris(t-octy lureidom ethyl)-2 ,4 ,6-trie thylbenzene ( la )  (3—G lu co se  ((3-G lc)
Figure 1:- ‘Molecular Recognition’ is a rapidly developing field, where the role of stability
constant determination is inevitable.
There are many other areas, where usage of stability constants is of great importance.
Environmental science45, waste management45, agriculture46, behaviour of 
radiopharmaceuticals in blood plasma47 are such areas to name a few.
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B.4.1.3 Complex formation and Chelate Effect
A metal ion does not exist as isolated ion in solution; rather it would exist in combination 
with ligands (either solvent molecules or ions) or chelating groups. This leads to the 
formation of complex ions or coordination compounds. The Latin word ‘Chela’, meaning 
great claw, give rise to the term ‘Chelate’. In Coordination Chemistry, the term is used to 
refer to a molecule or ion containing two or more donor atoms. Linking two or more donor 
atoms with metal ions will result in greatly enhanced stability constants, as compared to their 
individual donor groups. Various investigations have been made in various perspectives to 
reason out this effect.
The conventional thermormodynamic explanation has attributed the chelate effect to 
increase in entropy associated with chelate binding in relation to binding of the separate 
monodentate donors. The increase in disorderliness has been related to increase in total 
number of particles generated upon displacement. The effect could be studied effectively with 
a suitable coordinating ligand along with its dimer. Schwarzenbach has studied EDTA 
complexes along with IDA complexes. He has reported the favourable entropy change that 
has resulted upon stabilization of the chelated species.
In addition to the thermodynamic explanation, the chelate effect could be explained 
in terms of kinetics. According to this theory there is a formation of the second M-L’ (where 
L’ indicate any donor atom) with respect to an unlinked second donor atom. Donor atoms 
constructing the flexible chelate are known to dissociate as rapidly as analogous unidentate 
ligands. As such in order to prevent this chelate dissociating in a similar rate to donor atoms, 
it could be assumed that rapid re-association also takes place. This fact supports the enhanced 
stability through associative Sn2 mechanism. Carter and Beattie have reported the 
kinetic chelate effect observed during the complexation of ethylene diamine with Pt (II) along 
with the monodentate ethylene diamine. They have confirmed the observed chelate effect as 
of kinetic origin by means of comparison with analogous substitution of ammonia.
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B.4.1.3.1 Hard-Soft Acid-Base Classification (HSAB)
In 1941, Sidgwick delivered a lecture to the Chemical Society ,which was later on published 
and titled as ‘Complex Formation’, where he has recognized the similarities in the affinities 
of some common ligands (such as cyanide and nitro) for a variety of acceptor ions and 
molecules. In 1958, Ahrland el al. 49 expanded the theory and proposed two well defined types 
of metal ions and ligands: class ‘a’ and class ‘b’ categories on the basis of trends observed in 
stability constants.
Class A consisted of fluoride, oxygen and nitrogen donor ligands while class ‘b’ 
consisted of other halides, sulphur and phosphorus donor ligands. The guiding principle was 
Tike ion-like ligand pairs’ (‘a’+ ‘a’, or ‘b’+ ‘b’) gave stable complexes, while the unlike pairs 
(‘a’+ ‘b’) gave complexes of lower stability. This was further modified and described by 
Pearson50 as the HSAB principle (see Table 1). In his own words: ‘Hard acids bind strongly 
to hard bases and soft acids bind strongly to soft bases’. Pearson has explained the phenomena 
in terms of various degrees of ionic and covalent interactions, electron correlation and 
solvation effects.
Table 1: A selection of metal ions and ligands classified into hard and soft categories
Hard Intermediate Soft
Metal Ions Mn2+, Sc3+, Cr3*, Fe3+ Fe2+, Co2+, Ni2+, Cu2+ Ag+, Pd2+, Pt2+, Rh+
Ligands r 2o , r o h ,  o h \  so42', cr B f, py r 2s, r 3p, co, c n \  r
The Irving- Williams Order
In 1948, H.Irving and R.J.P.Williams51 in a preliminary communication to ‘Nature’, reported 
an order of stability of complexes for a series of bivalent, first row transition metal ions. The 
order Mn < Fe < Co < Ni < Cu > Zn has been discovered to hold for the stability of nearly all 
such complexes irrespective of the nature of the co-ordinated ligand or of the number of 
ligands involved in coordination. They have provided theoretical justification in 195352 for 
the phenomena observed (see Fig-2).
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The order of stability has been attributed to two factors, namely reciprocal of ionic radii and
the second ionisation potential of the metals involved in the investigation. Furthermore, these
two factors increase monotonically across the series (from manganese to copper). This is to
say that, replacing a water molecule with a ligand of higher electron donating power will
increase the stability with the simultaneous increase in second ionisation potential. On the
other hand, replacement of a water molecule by a ligand bearing formal negative charge will
also result in enhanced stability due to increase in electrostatic interactions, which ultimately
decrease the cationic radius .
Irving and Williams also pointed out that entropy factors and stereochemistry might 
also have an impact in such stability order. They also noted the very high stability observed 
for Fe (III). Unusual, high stability was attributed to the changes that take place in the 
bonding orbitals due to the changes in the nature of ligand. In fact, stability constants are 
anomalously higher for copper complexes. This is now attributed to the Jahn-Teller effect 
(namely distortion from the, for example, octahedral geometries).
i / m f r , - £ 0 - 4
to
Hn Ft C t Ni Cu Zn
Figure 2: - Taken from Irving and Williams, J.Chem.Soc, 1953
B.4.1.4 Methods available for determining stability constants
B.4.1,4.1 Potentiometry
This is far the most convenient method for the determination of stability constants. For 
reasons of clarity, the theory behind the potentiometry will not be dealt in this chapter, except 
for highlighting the inevitable aspects. The method, however, could be briefed as follows:
It is based on the measurement of pH utilising a cell composed of two half cells. One of the 
two half cells is reversible to hydrogen ions, in that its potential changes as the hydrogen ion
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concentration is changed. The other half cell (known as reference electrode) will have a
constant potential throughout the experiment and it is used to complete the circuit. The
difference in the potential between the two electrodes will indicate the hydrogen ion
concentration. The most commonly employed electrode system will have a glass electrode in
combination with saturated calomel electrode as reference electrode.
B.4.1.4.2 Spectrophotometry
This is commonly used to directly observe (in the UV region or visible region) the mixtures of 
ionic species and molecular species at a known pH. Although relatively time consuming, it is 
useful for sparingly soluble substances. The method is active at very low pH and very high 
pH, unattainable by glass electrode. One important aspect is that the molecular species and 
ionic species should be able to absorb UV or visible light and must have their specific spectra.
B.4.1.4.3 NMR spectroscopy
This may be employed in circumstances where the substance could not be measured by UV 
spectroscopy (if UV spectra of the substance, does not change upon ionisation) and 
potentiometry (if the substance is too weak an acid or base or poorly soluble). A series of 
solutions of known pH will be prepared and the chemical shift results from the non­
exchanging proton (closer to the ionizing group) will be plotted against the pH. The 
requirement of high concentrations at which the NMR values are determined, imposes 
limitation on this method. Nevertheless, it is useful to define the region where the accurate 
pKa value lies.
B.4.1.4.4 Conductimetry
This is also relatively time consuming when compared to potentiometry and can not be 
considered as a versatile method. The method is based on the change in conductivity resulting 
from successive dilution with water to an aqueous solution of a moderately weak acid. 
‘Catalysis of Hydrolysis’ and ‘Thermometric titration’ are some other ancient methods which 
have been used with little success.
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B.4.1.5 Some Theoretical Aspects relevant to Potentiometric
Measurements 
Electrode Calibration Theory
The concentration of hydrogen ions in an aqueous solution under acid/base equilibria could be 
measured through the usage of hydrogen electrode or glass electrode. The hydrogen electrode, 
however, is rarely being used for this purpose, as it easily gets poisoned and often chemically 
alters the substance in question. Therefore glass electrode is considered ideal for the 
measurement of ionization constants. Clearly, essential requirement is therefore to calibrate 
the electrode response with respect to hydrogen ion concentration. Ideally the potential, E, of 
a glass electrode obeys the Nemst equation:
E =  E °+ 2 Ilo g e(H} (3)
where E° is the standard electrode potential, R is the gas constant, T is the temperature in 
Kelvin, F is the Faraday constant, and n = 1 in the case of the glass electrode.
From the above equation, it follows that the electrode response is proportional to the 
activity of the hydrogen ion. As aforementioned, the usage of a supporting electrolyte 
maintains the ionic strength constant with higher magnitude. This in turn prevents the 
obstacles encountered with the fluctuating activity coefficients. Thus the following equation 
will result thereof.
E =  E° +  sloge[H] (4)
Where the slope, 5 , ideally should have a value of around T/5.0399 mV. It further 
follows that, for a series of data points, E° and the slope factor could be estimated from the 
slope and intersect of the E vs loge [H+] plot respectively, if the hydrogen ion concentrations 
are known.
The titration is carried out using strong acid and strong base of known concentrations 
in a supporting electrolyte of high ionic strength. The titration vessel is filled with 2 mL of 
acid (HNO3 , 0.10 M) and 50 mL of the supporting electrolyte solution (NaNC>3 , 0.1 M).
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After addition of 0.05 mL of base (NaOH, 0.1021 M), the mineral acid concentration, Th, is
given by the following equation:
t  _  a H - v 0 + y b H - v
*H -  T 7 (5)
r0 +i?i+t?2
where a\\ is the concentration (mol dm'3) of acid of which Vo mL were added to the titration 
vessel, bn is the concentration (mol dm'3) of base in the burette (by convention given a 
negative sign), vi is the volume (mL) of background electrolyte solution added to the titration 
vessel, and v (mL) is the volume of base added from the burette. The uncertainty in the 
concentration of the base is treated with a coefficient gamma, y.
As conventionally, base concentration given a negative sign (as it is being added from 
burette), Th is positive at low pH, zero at the equivalence point and negative at high pH. Thus 
it is possible to estimate Th, by knowing all the relevant parameters and substituting the same 
in Eq-5. This in turn will facilitate the calculation of hydrogen ion concentration.
The hydrogen ion concentration can be determined from the mineral acid 
concentration, Th, while taking in to consideration of the self-dissociation of water, Kw- A 
reasonable agreement within the literature was noted for the value of -13.78 for log (Kw) 
under the specified conditions of 25°C, 0.1 M KC1.
[HzO]=Kw-[HMOH]; pKw=-ln(Kw) (6)
T„=[H]-KW-[H]1 (7)
(0 At pH values lower than 5, the second term in equation 7 is minute compared to the 
initial term and hence can be regarded as negligible; [H] =TH.
(ii) At pH values higher than 9, the initial term in equation 7 is minute compared to the 
second and can be regarded as negligible; [H] =Kw/ (-T h).
One inevitable concern is that the base solution may be contaminated with a slight amount of 
carbonate. The extent of impurity is determined as a percentage, via a Gran’s plot28 and this 
will be used to amend the alkali concentration.
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The parameters E°, s, y and pKw are determined by least-squares fitting of the observed
electrode potentials to the values calculated by equation 5.
Common Sources o f Errors and their minimisation: Ensuring Precision and Accuracy 
By nature, there is an inevitable need to maintain high degree of precision and accuracy,
throughout this technique. This brings the inevitable need to eliminate errors. These errors
have the potential to invoke adverse effects on the quality of results obtained. This in turn
justifies the need to eliminate any scope for error, throughout the entire experiment.
Upward Trend & Purity o f  the Sam ple
One of the most common errors could be observed is the upward trend of the pKa values (in 
titrating with alkali) during the progress of titration. This is usually due to impurity in the 
sample undergoing determination. Hence, that not so much of it is present as has been 
supposed. The impurity could be mainly due to water. In order to avoid this problem, it is 
imperative to dry under the same conditions preceded its determination. Analytical purity of 
the sample also needs to be ensured. ‘Upward trend’ has two other causes. It could be due to 
very fast nitrogen flow, which will be expelling some solution. Although accurate amount of 
material is present throughout the experiment, not all of it would have dissolved in solution. 
Needless to say, the presence of undissolved material can not yield any reliable pKa value. 
Standardisation o f  Reagents
One of the possible causes of error is due to inaccurate standardisation of reagents. Any kind 
of uncertainty in initial protonated ligand concentration would result in a marked error in the 
available hydrogen ion concentration. Very conveniently, Hyper Quad, however, has the 
feature to establish the true initial concentrations of both the ligand and hydrogen ions, 
through a lengthy refinement process. This will in turn minimise any possible errors due to 
inaccuracy in standardisation of reagents.
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Maintenance and Storage o f Glass Electrode
Another major source of error could arise from glass electrode itself. It is a must to ensure that 
the electrode is stored properly during and after the experiments, in line with the 
manufacturer’s specifications. When the electrode is not in use, it should be immersed in the 
supporting electrolyte containing roughly 0.001 M H+.
Unpredictable behaviour of the electrode may be experienced, if it comes in to contact 
with a heavy metal. Touching the metal temperature probe may give rise to considerable leaps 
in pH. This can be restored, however, by immersing the electrode in 0.1 M HC1.
Time required fo r  the system to reach Equilibrium
It is necessary to allow adequate time for the system to reach equilibrium, before any kind of 
data points can be recorded. In order to ensure this, two factors must be taken into 
consideration.
Firstly, there should be enough time for the system to physically adjust itself, to new 
conditions. Secondly, time also needs to be allowed for the varying reaction rates of different 
species undergoing dissociation. Equilibrium is assumed to be reached, if the pH has 
remained stable for 30 seconds, however, near the end-point of a titration, where the leap in 
pH value is observed, it may be necessary to wait for periods of ten minutes or more for the 
system to achieve the complete equilibrium. Further, achievement of equilibrium could also 
be noted from the first aliquot of base being added to the titration vessel.
B.4.2 Results and Discussion
Potentiometric titrations were carried out for EDTA based bisamides and DTP A based 
bisamides as well as for symmetric naphtha Ligand (synthetic analogue of DTP A) 
(See Fig-1). The protonation constants for all the water soluble bisamides were obtained. 
Specifically, EDTA based bisamides of sulphanilamide (L2), amino methyl pyridine (L4), and 
amino methyl sulphonic acid (L6) have been selected for potentiometric titration, due to their 
solubility in water.
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Figure 1:-Depicting the water soluble candidates of EDTA and DTPA based bisamides along 
with DTPA analogue selected for potentiometric evaluation
EDTA based bisamides of N-(2-Aminoethyl)-l, 8-naphthalimide (L1), para amino phenol (L3), 2- 
amino anthraquinone (L5), however, was found to be insoluble in water. Therefore titrations 
were not carried out for these ligands.
N N N N
/  \  0 0
Figure 2:-Depicting the insoluble EDTA based bisamides
B.4.2.1 Evaluation of EDTA based Ligands
B.4.2.1.1 Protonation Constants and Deprotonation Curves of EDTA bisamides
Among the EDTA based bisamides evaluated by potentiometric titration, EDTA bis amino
A  7methyl pyridine (L ) and EDTA bis sulphonamide (L ) gave good protonation constants. 
These values agreed with the literature values related to similar ligands.62'64 Best fits of the 
models between the measured and calculated titration data along with their protonation 
constants for L4, L2 and L6 are reported in Fig 3-4 and Table 1.
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The protonation constants obtained by potentiometric titration of the EDTA bisamides,
specifically for L4, L2, and L6 (see Fig-1) are depicted in Table 1. Depicted here are 6, 3, 2
stepwise protonation constants respectively and these number of protonation constants
corresponding to number of donor atoms actively involved in each ligand.
All constants were determined at 25°C and 0.1 M NaNO3.
Table 1: Thermodynamic Properties for the Ligands L4, L2 and L6
Quotient Constant L4 L2 L6
[HL]/[L][H] lo g  K hl 7.30 9.75 6.84
[H2L]/[HL][H] lo g  K h2L 6.20 6.62 0.74
[H3L]/[H2L][H] lo g  K h3L 5.40 5.25 -
[H4L]/[H3L][H] lo g  K h4L 4.80 - -
[H5L]/[H4L][H] lo g  K h5L 4.00 - -
[H6L]/[H5L][H] lo g  K h6L 2.40 - -
IpKa 30.10 21.62 6.84
B.4.2.1.1.1 Assignment o f  Protonation Constants
A review of the literature carried out with the aid of a stability constant database revealed 
many examples of protonation constants for fragments of an ethylene diamine backbone and 
carboxylate fragments. Further utilising such examples (see Table-2) meaningful 
comparisons can be drawn. EDTA bisamides of amino methyl pyridine (L4) and 
sulphonamide (L2) both have eight potential protonation sites. Only six and three maxima,
4 2however, were observed in the titration curves for L and L respectively.
Attributing Sequence to L 4
The pKa of the carboxylic acid groups are too acidic to be determined with this technique.54 
Among the remaining basic groups, the nitrogen sites of the ethylene diamine backbone are 
considered to be most vulnerable for protonation, due to their highest basic strength, pKa 
values reported from the literature also stand in testimony (see Table-2). Therefore, it is a 
reasonable assumption that the first two protonation constants for L4 are attributable to the 
protonation of the nitrogen sites of the ethylene diamine backbone.55
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Further, noted the marked difference in the Ki and K2 values of L4. The sequence of K*
values is Ki> K2 which relates to the build up of positive charge as the nitrogens are
successively protonated.
Statistical contribution to Kn should be favourable for initial protonation. So as to say, 
the statistical contribution for a reaction LH_i + H —► LH is dependent on the relative number 
of sites available for a new proton to attach.
Moreover, compared to EDTA, the replacement of two of the carboxylate arms in the 
parent EDTA structure with amide containing fragments (amino methyl pyridine) could have 
caused the decrease in log Ki values (i.e. 2.87 units). This may partially be due to the reduced 
inductive effect of the amide group in relation to that of carboxylate.56 Although, this is valid 
for the reduction of pKai, it does not hold for the signifant reduction in pKa2 values, which 
may be rationalized by the electrostatic effect due to the presence of two carboxylate groups 
instead of four in EDTA.
The first two protonation constants of L4 range from 13-6.2 (log units). Which is 
expected, considering the backbone nitrogen atoms of a structurally similar ligand, EDTA 
bisamide of 2-aminopyridine, displays a protonation constants ranging 6.82-3.49, depending 
on the experimental conditions involved. The third and fourth protonation constants could be 
attributed to either pyridine nitrogens or to the amide oxygens. Most likely target for 
protonation however, could be the nitrogen atoms of pyridine moieties than the amide 
oxygens. This is party justified, by the comparable range obtained for third and fourth 
protonation constants for L4 with that of pyridine nitrogens, Le range from 5.4-4.8 for L4 in 
comparison to 5.42-4.89 for pyridines, depending on the experimental conditions.
Further, a pyridinum cation is usually less acidic when compared to carboxylic acids. 
This is partly due to the resonance stabilisation of a carboxylate group, in contrast to a 
pyridine-N atom in which the lone pair on the N atom is not part of the aromatic Jl-system. 
Increased nucleophilicity of the amide oxygen in relation to pyridine nitrogen is well known.
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This has enabled the protonation of the amide oxygen relatively easy and has resulted in
comparatively low protonation constants 4.0 and 2.4.
Attributable protonation sequence fo r  L2
In the case of L , pKai, however, has to be attributed to the protonation of sulphonamide-N, 
rather than for the protonation of the ethylene nitrogens. This has been justified partly by 
pKai of 4-aminobenzene sulfamide, which is 0.73 units higher than that of the backbone 
nitrogen atoms of EDTA partly by the fact that the basicity of sulphonamide-N is 
considerably affected by the two highly electronegative oxygen atoms, rendering it less 
vulnerable for protonation. The observed value for pKai, 9.75 of sulphonamide-N stands in 
close testimony with the literature values and the aforementioned explanation.57
Consequently pKa2 attributable to the protonation of one of the nitrogen sites of the 
ethylene diamine backbone. Thus pKa3 is attributable to one of the oxygen of the peptide 
bond and the explanation given for L4 could hold for L2 as well. Further, the relative increase 
in pKa3 from 4.80-5.4 to 5.25 may be attributed to the electron withdrawing affect of 
sulphonyl moiety in contrast to the electron inductive effect of a methyl group in pyridine 
moiety. The summation of pKa values for individual ligands (ZpKa) provides us with a 
valuable insight in to the parameter called as overall basicity. While basicity is not the sole 
determining factor to be considered, when designing thermodynamically more stable 
complexes (since, for instance, electrostatic hard-soft interactions also plays a vital role), 
some of the scientists have succeeded in optimising the basicity of similar ligands, which 
facilitates the stability enhancement.
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Table -2: Tabulated data for the possible fragments obtained from stability constant data base
Binding
Species
Fragment or 
Moiety
Medium (Ionic 
concentration)
Log K 
Value(s)Method Temp/°C Ref
H+ KC1 (1M) 10.98
H+ No electrolyte 4.76
'O H
H+ 10.17
H+ 9.62
OH
calH+ NaCl (0.15M) 8.65
9.53H+
10.93H+
9.99H+
22.46
14.05
16.24Zn
H O H N -
679.16H+
H O
8.47NaCl (0.15M)H+s o 3h
B. 4.2.1.1.2 A  nalysis o f  Deprotonation Curves
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Figure 3:- Depicting the titration curves in the absence of metal ions for L4 (Left) and L2
(Right)
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Figure 4:- Depicting the titration curves in the absence of metal ions for L6
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B.4.2.1.2 Formation constants and Complexation Curves
Analysis of potentiometric curves (Fig 7, 8 and 9) by the software program Hyper quad 2006 
allowed the determination of various complex species in equilibrium and their formation 
constants are summarised in Table 4 and Table 5.
B .4.2.1.2.1 F orm ation constan ts
Table 4 depicts the stability constants obtained for Zn (II) complexes of L4, L2 and L6 and it 
could be noted here that the most basic ligand L4 corespondingly has the highest overall 
stability upon complexation, logKznL= 16.03.
This value is slightly less than Zn-DPDP, which has 18.95. It should also be mentioned 
here, this value is slightly higher than the manganese analogue of DPDP, namely Mn-DPDP( 
Teslascan®);commercially available contrast agent, in that an overall stability has been 
reported as 15.1.21
1 0 0  -
7  pH
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On the other hand, this value is several orders of magnitude lower than commercially
available octadentate, MRI contrast agents Gd-DTPA (Magnevist®) and Gd-DOTA
(Dotarem®), which have stability constants of 22.1 and 25.8 respectively. This may be
rationalized by the reduced chelate effect exhibited by the hexadentate ligand, leading on to a
thermodynamically less stable interaction.
Table 5 depicting the stability constants obtained for Cu (II) complexes of L4, L2 and 
L6. The overall stability constant obtained for Cu (II) complex of L6 is significantly lower 
than that of L2.
Once again the most basic ligand L4 has the highest overall stability upon 
complexation with Cu (II) as well, logKcUL= 28.74. This value is slightly higher than Cu- 
DPDP, which has 22.08.
On the other hand, this value is several orders of magnitude higher than Zn-DTPA 
BMA (Zn analogue of commercially available Ominscan®), which has 12.04.69 It will be 
interesting to note that the Gd (III) complex formed with EDTA-PA2 and EDTA-IPA2 has 
been reported to possess 10.3 and 12.79 respectively.
Table 4: Stability constants of ligands L4, L2and L6 with Zn11
Quotient Constant L4 L2 L6
[ZnL]/[Zn][L] log KZnL 16.03 9.69 -
[ZnLH]/[ZnL][H] log KZnLH 5.94 8.23 11.43
[ZnLH2]/[ZnLH] [L] Log KZnLH2 - - -
[ZnH.il/tZn3tH.!] logKZnH.! -7.89 -7.89 -7.89
Table 5: Stability constants of ligands L4, L2 and L6 with Cu11
Quotient Constant L4 L2 L6
[CuL]/[Cu][L] log KCuL 28.74 ^ f o ^ n t  1255
[CuLH]/[CuL] [H] log KCuLH 3.67
[CuLH2]/[CuLH][L] Log KCuL2 1.35
[CuH.i]/[Cu][H.i] log KCuH-i -6.29 - -6.29
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B.4.2.1.2.2 Analysis o f  Titration Curves
The best-fit models obtained from Hyperquad included ML and MLH for Zn (II) and Cu (II) 
of L4 and ML, MLH and MH.| for Zn (II) complex of L2. Inclusion of other species worsened 
the fit or was rejected during the refinement process.
Attempted modelling with Hyper Quad yielded no success with Cu (II) complex of L2. 
Modelling with 1:1 ratio led to unstable refinement and resulted in large ^-squared values 
conveyed a poor correlation between the calculated and experimental titration curves.
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Speciation Plots
The speciation diagrams of each ligand have been displayed below in Figures 10-11. These 
diagrams are in a form which represents the percentage of species in solution relative to the 
transition metal ion (for eg: - Zn (II)) across the entire experimental pH range.
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The speciation plot of L4 (Fig-10) reveals that the species ZnL begins to be formed at
approximately pH 4 unlike in the case of L2 (Fig-11), where it begins at pH 6. In contrast, this
species rapidly rises until pH 6, however, after which it gradually increases further to reach a
maximum around pH 10, at which point it has started to decline gradually.
The species ZnLH is formed at ca. pH 2 and gradually increases, in precise contrast to 
the species ZnL, until pH 4, whereupon it undergoes a sharp decline until ca. pH 6.5, after 
which it gradually declines.
Most important point is the cross over point. At roughly pH 6, ZnL surpasses ZnLH as 
the major species in solution. In contrast to L4, however, ZnL surpasses ZnLH at ca. pH 8, 
which is a basic condition, in L2. The presence of free Zn (II) ions declines rapidly as ZnLH 
begins to form, at around pH 4 in L4 it completely diminishes as the ZnL begins to form. In 
contrast, in L2, the presence of free Zn (II) ions sharply declines until pH 4, but does not 
begin to diminish completely until ca. pH 6, where it rapidly reaches negligible quantities in 
the now nearly basic solution. This is a crucial feature as far as toxicity is concerned. Toxicity 
caused by Mn (II) dissociation and trans metallation is widely researched and well 
documented.70 Further, observed the formation of hydrolysis product of zinc, which can be 
hydrolysed in media as high as pH 10.
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F ig u re  10:- S pecia tion  d ia g ra m  fo r L 4 in th e  p resence o f Z n n( N 0 3)2.6H20
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The speciation plot of L4 with Cu is presented in Fig-12. The species CuL begins to form at 
ca. pH 2 and rapidly rises until around pH 5, at which point it gradually increases to reach ca. 
pH 10, similar to ZnL in L4 after which it decreases gradually. On the other hand, the species 
CuLH gradually increases until pH 3 and sharply declines until pH 4, whereupon it gradually 
declines.
The point of cross over also to be noted here. At around pH 4, CuL surpasses CuLH as the 
major species in solution, which is a more acidic condition, in comparison to the zinc 
complex of L4.
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In the case of L4 (Fig-10 and Fig 12) and L2 (Fig-11) there are two major species formed 
during the course of the titration tending towards higher pH. These are successively MLH and 
ML, which could be represented by following equations.
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TMLH1 
P ll l ; [M]+ [L]+ [H]^MLH]; P m - ^ g  (J)
P u o ;  [M]+[L]?±[ML]; p110= [ 1mm (2) 
Evaluation of DTPA based ligands
On the other hand, with regard to DTPA based bisamides, it was found that DTPA bisamide 
of 4-aminomethylpyridine (L15) was readily soluble in water. The DTPA bisamide 
of N-(2-Aminoethyl)-l,8-naphthalimide (L14), however, was found to be insoluble in water. 
Potentiometric titration was not carried out for this ligand.
F igu re  13:- W a te r  in so lub le  D T P A  b ased  b isa m id e  o f  N -(2 -A m in o e th y l)-l, 8 -n ap h th aIim id e  (L 14)
B.4.2.2.1 Protonation Constants and Deprotonation Curves o f L15 and L11
B.4.2.2.1.1 Protonation Constants
DTPA bisamide of amino methyl pyridine (L15) has nine potential sites. There were only 
three maxima, however, were observed in the titration curve. Once again the review of the 
literature aided in the assignment of protonation constants.
Attributing Sequence to L IS
The pKa of the carboxylic acid groups are too acidic to be determined with this technique, as 
in the case of EDTA bisamides. Among the remaining sites, out of the three nitrogen atoms, 
the central nitrogen atom is often the primary target for protonation. It has been reported that 
the unprotonated form of the ligand will be capable of producing hydrogen bond rings 
inclusive of the amide hydrogens, the terminal hydrogens and the terminal carboxylate ions.
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Therefore addition of protons to the basic sites could only be possible through the destruction
of these hydrogen bond rings, which in turn justifies the marked preference for the first 
protonation at the central nitrogen atom. This has been reflected in the log Ki of 10.03 and the 
value tallies to a good extent with literature value. Further, it was also pointed out that the 
formation of amide linkages leads to the reduction of log Kj from 0.8-1.1 units and log K2 
value by 4.0-4.2 as far as DTPA bisamides based on alky amines is concerned. While the 
observation supports the first protonation constant observed in the experiment, it does not 
justify the slight reduction in log K2.
The second protonation occurs at one of the terminal nitrogen sites, simultaneously 
causing the proton attached to central nitrogen to migrate to terminal nitrogen. This happens 
in order to reduce the positive charge repulsion. This is possible through the destruction of 
hydrogen bond network.
T able 6: T h erm o d y n am ic  P ro p e rtie s  fo r  th e  L ig an d s L 15 an d  L 11
Quotient Constant
[HL]/[L][H]
[H2L]/[HL][H]
[H3L]/[H2L][H]
[H4L]/[H3L][H]
EpKa
Log Khl 
log KroL 
log K h 3L 
log KH4L 9.16
28.43
10.03
9.24
12.85
7.73
5.12
B.4.2.2.1.2 Analysis o f  Deprotonation Curves
0 1 2 3 4  5 6
Volume o f title (ml)
F igu re  14:- D ep ic ting  th e  tit ra tio n  cu rv e  o f  L 15in the  absence o f m etal ions
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B.4.3 Experimental Section
The potentiometric studies were carried out with a TIM840 autotitrator (Radiometer 
Analytical). A Metrohm combined pH glass electrode (Ag/AgCl) with 3M KC1 internal filling 
solution was used. Solutions were prepared using doubly deionised freshly distilled water 
(‘Boiled out water’). The electrode was calibrated with dilute standard acid and alkali 
solutions, thus defining pH = - log [H*] (pKw = -13.78). The electrolyte, NaNC>3 (0.1 M), was 
prepared in the form of a stock solution from analytically pure grade NaNC>3 obtained from 
commercial sources (Aldrich). The standard acid (HNO3) and standard base (NaOH) were 
also prepared to the same concentration as the electrolyte and were again obtained from 
commercial sources (Aldrich) free from any carbonate contamination which would have had 
the adverse effect of buffering the reaction mixture. The temperature of the reaction mixture 
was controlled by a thermostat which maintained a flow of water in a water-tight layer 
encapsulating the reaction cell at a constant 25°C (298K). The standard base was delivered in
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0.05 mL aliquots using an auto burette, which was a useful means of measuring identical
amounts quickly with negligible deviation from the desired volume. The solution was
constantly mixed by a magnetic stirrer bar at an appropriate speed (typically 2 0 0  rpm), fast
enough to thoroughly mix the solution but not so quickly as to disturb the electrode.
In a typical experiment, an aqueous solution (50 mL) was prepared containing the 
ligand (1 mM), metal nitrate salt (1 mM) and a known quantity of HNO3 (0.1 M). The ionic 
strength (7) of this solution was adjusted to 0.1 with 1M NaNC>3. The temperature of solutions 
(25 °C) in the covered, water-jacketed cell was kept constant by a Fischer Scientific BC10 
circulating bath. Upon reaching equilibrium, this solution was titrated with NaOH (0.1021 N). 
Each titration consisted of more than 80 data points spanning a pH range of 2-10.
The protonation constants of the ligands and overall stability constants of the metal 
complexes were calculated using the HyperQuad suite of programs, namely HyperQuad 2006
71and HySS 2006. The mathematical basis of which has been reviewed in the literature. Hyper 
Quad 2006, software’s selection of equilibrium models was dominated by critical evaluation 
of the least squares fitting results. This could be explained in terms of analysis of the 
weighted residuals and statistical parameters (%2 and a). The reported equilibrium constants 
are the mean average of two separate measurements. Immediately prior to this investigation, a 
trial experiment involving the known ligand tris(2-aminoethyl)amine (TREN, Fig. 4) was 
used as a control. The data matched, within statistical error, the comprehensive set of data 
from the literature.
n h 2
/  N
h2n  f  \ ^
n h 2
Figure 21: The ligand TREN. Literature protonation constants: 10.42,9.88,8.90. This work:
10.48, 9.70,8.40.
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Chapter 5 
Luminescence Measurements
5.1 Luminescence: An Introduction
The phenomenon of luminescence has dramatically expanded its horizon in the past two 
decades. It was initially considered as an important tool in biochemistry and biophysics. This 
emphasis, however, widens its scope. Presently this methodology (especially fluoroscopy and 
time dependence fluorescence) is dominating in the areas of DNA sequencing,1 medical
•y ' j
diagnostics, flow cytometry, biotechnology to name a few. Particularly, it has dramatically 
advanced in the area of cellular and fluorescence imaging, to the extent of single cell 
detection and imaging.4
To appreciate the importance of luminescence measurements with regard to new 
multidentate ligands, it is important to have an understanding of the phenomenon. The 
proceeding section is devoted to the principles underlying the phenomenon of luminescence.
5.1.1 What is luminescence?
In very simple terms, it could be defined as “ Emission of light from a substance” . This is 
possible because an electron that goes from ground state to the excited state upon excitation 
loses its excess energy in the form of photon, when the electron returns to the ground state. 
According to the type of excited state and the mode of excitation, it can be classified into 
three types of behaviour:
a. Fluorescence
b. Phosphorescence
c. Chemiluminescence
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Fluorescence
This type of emission takes place as result of a three step process, that occurs within 
molecules (usually poly aromatic hydrocarbons or heterocyclic molecules), which are known 
as chromophores (more specifically fluorophores).
These are also known as fluorescent dyes. Then the question arises, how do we relate 
fluorophores to the fluorescent probes? A Fluorescent probe is a fluorophore designed to 
respond to a specific stimulus or be localized within the specific site of a biological specimen. 
The process of fluorescence could be further explained by means of a simple electronic state 
diagram, known as Jablonski diagram (see Fig-1).
Step 1: Excitation
The light energy, supplied in terms of photons (hvExA) by an external source (incandescent 
lamp or a laser) will be absorbed by the fluorophore. This will result in the formation of 
excited singlet electronic state (Si’). This stage of luminescence distinguishes fluorescence 
from chemiluminescence, as the excited state is created by the chemical reaction in the latter. 
Step2 Excited-State Lifetime
The excited state could last for a specific period (1-10 nano seconds), within this period the 
fluorophore undergoes many conformational changes and may also interact with the 
environment in many ways.
These interactions have two different impacts on the excited state. Firstly, energy of the 
Si’ is partially dissipated, while yielding a relaxed singlet state, through which fluorescence 
emission originates. Secondly, not all the molecules initially excited by absorption (Step 1)
s ’— f—  .. s
s
■
c_
UJ
Figure:- 1 Jablonski Diagram explaining the process of fluorescence
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return to the ground state (So) by fluorescence emission. Other processes help to relax the
molecule and involve fluorescence resonance energy transfer (FRET) and intersystem
crossing. Further, ‘fluorescence quantum yield’ should also be defined. It is the ratio of the
number of photons emitted through fluorescence to the number of photons absorbed.
Step 3: Fluorescence Emission
When the fluorophore returns to its ground state (So), a photon of is emitted. Obviously, the 
energy of this photon is lower due to the partial dissipation of energy. Thus it has a longer 
wavelength than the excitation photon. The very difference in energy or wavelength could be 
represented by (hvEX-hvEM)- This give rise to another interesting phenomena, called the 
‘Stokes shift’. This Stokes Shift plays an active role in determining the sensitivity of 
fluorescence techniques. It is because it facilitates the detection of emission photons against a 
low background.
Fluorescence Spectra
The fluorescence process is on the whole assumed as cyclical. Except in the case of Photo 
bleaching or similar cases, where the fluorophore is destroyed in the excited state, the same 
fluorophore can be repeatedly excited and its emission detected. So many thousands of 
detectable photons may be generated by a single fluorophore. This fact, contributes towards 
the high sensitivity of fluorescence detection techniques.
When considering polyatomic molecules in solution, the discrete electronic transitions 
(hvEx and Iivem) are replaced by very broad energy spectra called the fluorescence excitation 
spectrum and fluorescence emission spectrum, respectively. When in the case of 
simultaneously detecting two or more different fluorophores, spectral bandwidths have to be 
considered. It could be generalised, excluding few exceptions that absorption spectra of single 
fluorophore species is identical to its fluorescence excitation spectrum. Moreover, the 
intensity of emission is proportional to the amplitude of the fluorescence excitation spectrum 
at the excitation wavelength (see Fig-2).
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W a v e le n g th
Figure 2:- Excitation of a fluorophore at three different wavelengths (EX 1, EX 2, EX 3) does not change 
the emission profile but does produce variations in fluorescence emission intensity (EM 1, EM 2 EM 3) 
that correspond to the amplitude o f the excitation spectrum.
Phosphorescence
In order to understand this phenomena, it is imperative to know about “ Intersystem 
crossing” . Intersystem crossing occurs when the spin of an excited electron is reversed. This 
is possible because the energy of the excited triplet state is lower than that of the energy of the 
excited singlet state. If the vibrational levels of these two different states overlap, the chances 
are more likely for this phenomenon to take place. For instance, the lowest singlet vibrational 
level may overlap with one of the highest triplet excited state vibrational levels.
Under such circumstances, a molecule in high triplet state vibrational level can collide 
with solvent molecules and lose energy. As a result it will relax to the lowest vibrational level 
of the excited triplet state. Then it may undergo a second intersystem crossing to the high 
excited singlet state vibrational level and eventually lose energy to come back to the lowest 
vibrational level of the ground state via vibrational relaxation (see Fig-3).
On the other hand, a molecule in the excited triplet state may not always be utilise 
intersystem crossing to return to the electronic ground state, instead it might lose energy by 
emission of a photon. An important fact to remember here is that triplet/singlet transition is 
much less probable than singlet/singlet transition. The lifetime of an excited triplet state could 
be up to 10s, whereas the lifetime of the excited singlet state ranges from 10'5 to 10"8s. 
Typically, for most fluorophores, phosphorescence is not observed, with fluorescence 
dominating the room temperature spectra. This is because, other radiationless transfers 
compete with phosphorescence, but it does become prominent at low temperatures or in high 
viscous media.
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Lowest Exited 
Ground State
Electronic State
Lowest Exited 
Triplet State
1. Absorption
2. F luorescence
3. P h o sp h o re sc e n c e
4. Vibrational relaxation
5. In tersystem  crossing
6. Internal conversion
 ►- P r o c e s s e s  involving p h o tons
R ad ia t ion le ss  t rans i t ions
Figure 3:- Depicting the possible physical processes, following absorption of a photon by a molecule 
Chemilummescence
Contrary to fluorescence, this is produced by the emission of the electronically excited 
species, created by a chemical reaction. This kind of luminescence could be encountered in 
biological systems, where it is termed as bioluminescence. Chemiluminescence, however, is 
not produced by many chemical reactions although it has some environmental significance. 
One appropriate example is the determination of nitric oxide:
NO + 0 3 —» N 02* + 0 2 
N 02* -» N 02 + hv (k = 600 - 2800 nm)
5.1.2 L ifetim e (o f lum inescence)
The time required for the luminescence intensity to decay from some initial value to 1/e of 
that value (e = 2.718). Lifetimes can be measured by phase fluorimetry (phosphorimetry) 
where the phase shift between the sinusoidally modulated exciting light and the emitted light 
is measured.
The aforementioned, brief introduction to the basic principles underlying luminescence has 
positioned us to know about its application. One such application is its usage in luminescent 
sensors.
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5.13 Luminescent Sensors
This is another specialised research field, in its own right. The wide range of applicability and 
its potentiality is inevitable in discussion. To put this in perspective, the growth of the field 
has been so rapid that it has outnumbered the publications (books, reviews, and journal issues) 
dedicated to sensors.5"10 The designs shed light on molecular switches11 as well as 
supramolecular photochemistry. This phenomenon of chemically induced switching of 
luminescence remains as spectacular a visual phenomenon that can be found in a laboratory.
Moreover, with the advancement of science there is a need to quantify chemical species 
of various kinds; especially in biological studies (systems responding to biologically relevant 
targets). This could be effectively achieved by the use of sensors. The active role enacted by 
coordination chemistry, from the stages of designing the luminescent sensors to the stage of 
characterisation is second to none.
Types o f Luminescent Sensors
According to the various mechanisms applicable to this switching behaviour (as it could be 
switched between ‘’on” and “ off ”  states), it gives rise to various types of sensors, such as 
PET systems,12 PCT systems,13 ICT systems, EET systems,14 and Eximer-Exiplex systems.15
Reporter—target interactions caused by the ion coordination could be of great help to 
cause this required switching behaviour. This could, however, be possible only if an 
appropriate photochemical process is brought in to action. Aforementioned quenching 
mechanisms (except PET) are considered to be not so ‘smart’ enough to respond to binding of 
the target species. Though there has been a great amount of effort exerted in the past to 
overcome this short coming, (such as the development achieved in EET), there is still much 
work to be done in this area.
Photo Induced Electron Transfer (PET)
The luminescent sensors based on PET mechanism (PET systems) are widely studied and 
thoroughly reviewed.16"18 The large, significant change in florescence intensity, which is 
commonly observed upon cation binding, is a unique advantage for PET sensors.
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The other important characteristic is the absence of shift in the fluorescence or excitation
spectra, which could prevent the possibility of intensity-ratio measurements at two different
wave lengths. This kind of sensor could be quantitatively designed and the observable
parameters could be predicted. These are prominent features of this PET mechanism.
5.1.3.1 Understanding PET
It is a well known fact that when molecules absorb light they transfer an electron to another 
system (exception-dye sensitized solar cell). Since the electron is getting transferred upon the 
absorption of light, it is known as Photo induced Electron transfer abbreviated as ‘PET’. 
Mechanism of PET
In spite of its broad usage and wide range of applications, the mechanism could be explained 
in simple terms. This could be approached in two ways. One is to utilise fluorophore-spacer-
receptor archetype and the other is making use of molecular orbital energy diagrams. Let us
10first consider the typical model introduced by A. P. de Silva et al. As it could be seen (see 
Fig-4) this model comprises three components.
a. Fluorophore/luminophore - Chromophore part of the system
b. Spacer -  bridge(non conjugated)
C. Receptor- Docking area for the analyte
PET____
Receptor
h v  EmissionAbsorbtion
Spacer
AnalyteEmissionAbsorbtion
SpacerFluorophore
Fluorophore Receptor
Figure 4:-Depicting the fluorophore-spacer-receptor model suggested by A.P.Silva et al. 
For an Off- On- type sensor, figure depicts the ‘switch-on’ of fluoresce binding of the 
analyte, which inhibits PET from the receptor to the fluorophore.
224
Potential Multimodal Imaging Agents
Here, one could consider the fluorophore and receptor as analogous to a donor and acceptor
system. The switching behaviour could be interpreted in terms of ‘On’ and ‘Off states of the
sensor.
Background understanding
Before we try to understand the model in detail, let us focus our attention on each 
components of the model. Here the fluorophore is the component which absorbs light; this 
could either donate the electron from the excited state to the receptor or accept an electron 
from the receptor in its ground state to fill the vacancy. Thus it is obvious, that the receptor 
could accept/donate electron from/to the luminophore (fluorophore).
The last one is the spacer that connects these two together. This could be a virtual 
component or may be absent altogether. Further, the transfer of electrons becomes viable only 
if it is energetically feasible, a thermodynamical condition discovered by Weller.19
Further, it is a known fact that excited states of the fluorophore (which arises upon 
excitation by the light source) are better oxidising agents/reducing agents than their ground 
state counterparts. Consider a situation where the fluorophore is a reducing agent and the 
receptor is an oxidising agent. Also consider the fact that, the energy level of the HOMO of 
the fluorophore, lies below the energy level of the LUMO of the receptor. Then electron 
transfer will not be possible as it is not energetically feasible. Through light excitation, 
however, if we create a F* excited state, where the energy level of the LUMO of the 
fluorophore is higher than that of the LUMO of the receptor, then the electron transfer is 
thermodynamically feasible.
The typical question that needs to be addressed is, how does the analyte (target species) 
affect this process? It is quite straightforward now. If the receptors energy levels could be 
tweaked in the presence or absence of an analyte (for eg: - a metal ion), then the presence of 
the analyte may turn on or off the luminescence. Thus, the presence of an analyte enhances 
the luminescence or quenches the luminescence. This forms the basis for all the PET sensors.
225
Potential Multimodal Imaging Agents
In the “ on” state of the sensor, the excitation of the fluorophore gives emission. It is because
the PET is inactive upon the arrival of the analyte. For instance, if we assume the analyte is
H+, then the hydrogen ion draws the electron towards itself on the basis of electrostatic
interaction. As a result, the oxidation potential of the target species bound receptor will
increase to an extent that the thermodynamic conditions become unfavourable for PET to take
place. The excess energy is released in the form of luminescence.20
In the “ off” state”  of the sensor, in the absence of an analyte, thermodynamics favour
the electron transfer from the receptor to the fluorophore or in some cases from fluorophore to
the receptor. This concept forms the basis for “ Off-On-type” PET sensors.
In contrast, reversed, “ On-Off-type”  PET sensors have also been designed and
developed. In that, the “ off ”  state of the sensor is attributed to the activation of PET due to
favourable thermodynamic conditions arise upon complexation.
5.1.3.2 Kinds o f  PET sensors on the basis o f  modulating factor
A review of the literature revealed that there are many sensors available or in the process of 
development for main group elements, transition metal cations, lanthanides and actinides. 
There are PET sensors that have developed to target a range of anions, such as acetates, 
phosphates, some halides, and amino acids.21, 22 Organic compounds as target species, also 
have drawn attention from PET sensor designers.23 Further, some physical properties were 
also the target for PET sensor development. For instance, in the early 21st century, pH sensor 
development based on PET mechanism started receiving significance.24’25
This project is, however, concerned on developing cation sensors. Therefore we shall now 
focus our attention towards cation sensors.
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Cation Recognition: A PET perspective
Why is it necessary?
Cation recognition is of utmost importance to many scientists (including chemists, biologists, 
clinical biochemists, environmentalists and especially among the PET Sensor designers).
Some of the main group elements (e.g. sodium, potassium, magnesium, calcium) are of great 
biological importance. As they tend to regulate many biological processes. Conduction of 
nerve impulses, regulating muscle contraction, regulation of cellular activities, is just to name 
a few of these processes.
Further, there are some enzymes containing metal ions, along with proteins as part of 
their constituents (metallo enzymes). There are various metal ions influencing the regulation 
of these metallo enzymes. In medicine, in the treatment of psychological diseases, for instance 
manic depression, it is important to regulate serum levels of lithium. Furthermore, 
regulating the level of potassium in the serum, is very important in the treatment of high 
blood pressure. To elaborate further, once could consider the adverse impact of heavy 
elements (e.g. mercury) and the toxicity caused by these elements to living organisms.
As prevention is better than cure, their early detection will help to save many lives.
The nature of the cation-controlled, photo induced processes brings variety in to the type 
of cation sensors available for this purpose. They could be based on photo induced electron 
transfer, photo induced charge transfer, excimer formation or disappearance and so on. The 
classification gets subtle with the type of complexing moiety (podands, crown ethers, 
cryptands, calixarenes etc), which has been used in each type of mechanism.
So vast and potent are the cations in day to day life, it is no surprise that there were many 
methods introduced to recognize and monitor these cations. Flame photometry, Atomic 
absorption spectrometry, ion sensitive electrodes, electron microprobe analysis, and neutron 
activation analysis, are a selected few examples, out of the many analytical methods 
introduced so far to serve the purpose. They, however, are expensive and often require 
samples of large size. Further none of these techniques allow continuous monitoring.
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Contrary to the above, fluorescent sensors are well known for their selectivity, sensitivity,
response time, local observation (this is possible via fluorescence imaging). Moreover, the
remote sensing is also possible.
These facts together, establish the great importance given by the scientists all over the world, 
to develop selective cation sensors, more specifically, based on PET mechanism.
S.l.3,3 Cation sensors; Targeting main group Elements
Na (I)
Most of the animal cells preserve large differential in their intracellular and extracellular 
concentration of the Na (I) ions. Therefore knowledge of concentration of the Na (I) ions is 
necessary to understand the physiological processes at the cellular level. Consequently, 
anthracene and naphthalene based PET sensors (1-3) have been developed by Gunnlaugsson 
et a l2\  Geu et al.28 and Huarui He et al.29 to detect mainly Na (I) ions (See Fig 5).
Geu et al also examined the degree of variation of PET quenching the fluorescence upon 
complexation with Li (I), Na (I), K (I) and Rb (I).
1 2  3
Figure 5:- Depicting ‘ Off-On-type' PET sensors developed by Gunnlaugsson et aL and He et al, comprising 
crown ether 1 and aza-crown ether 3 as receptor moieties. PET sensor designed by Geu et al based on
azacoranand system 2.
Kfll
The determination of extracellular concentrations of K (I) ions is also necessary to monitor 
biological processes, similar to Na (I) ions. Therefore Huari He et al.29 developed another 
highly selective PET sensor 4, targeted for K (I) ions. 4-aminonaphthalimide acted as the 
fluorophore, while the diaza-18-crown-6 acted the role of an ionophore (see Fig-6). When the
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K (I) selectively binds the aza crown ether, it prevented PET from the anisidine donor,
resulting in emission enhancement. Kaur et al.30 also prepared naphthalene based, tripodal
multifunctional probe 5. The results of their investigation suggested that Na (I) initially binds
with tripod before K (I) is permitted to do so. The sensing was attributed to AND type
molecular gates. Also it was noted that through excited state intermolecular proton transfer
(ESIPT) there is keto and enol forms of 3 forms which facilitates the ratiometric fluorescence
determination of Mg (II).
oN-
Polymer
4 5
Figure 6:- Depicting the PET sensor for K (I) by Huari et aL (Left) and Tripodal multifunctional probe 
designed by Kaur et a l for Na (I), K (I) and Mg (II) based on PET (Right)
Li (I)
Detection of Li (I) in the biological samples is of great interest, in terms of treatment for 
manic depressive psychosis and other related illnesses. Presently this is being carried out with 
Li (I) selective electrodes. Owning to its small size and high charge density, selective 
determination of Li (I) in the presence of Na (I) has become a challenging task. 
Gunnlaugsson et a l31 have developed another PET sensor 6, selective to Li (I) ions. Here the 
naphthalene group acts as a fluorophore while the amine crown ether accepts the metal ion 
and serves as a receptor. This was found to be an ‘ Off-On-type ’ PET sensor as upon the 
addition of Li (I) in acetonitrile to 6, resulted in emission enhancement. Further, there were no 
significant changes in emission upon addition of group I and II cations. This indicates the 
PET sensor is selective to Li (I). The selectivity was attributed to size discrimination by the 
crown ether.
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6
Figure 10:- An Off-On-type PET sensor for Li (I), developed by Gunnalaugson et aL
5.1.3.4 Targeting Alkaline Earth metal ions as analytes
Ca (II)
The measurement of concentration of cytosolic free Ca (II) is an inevitable requirement to 
evaluate the role of calcium as an intracellular messenger. This is important to compare the 
stimuli and responses which are varying continuously. Currently, the concentration of calcium 
ions is monitored via an indicator. This is known as “ Quin 2’, however this is suffering from 
severe limitations in terms of too short, excitation wavelength (339 nm). This causes auto 
fluorescence in the cells, thus resulting in biological side effects. Further it penetrates poorly 
into microscope-optics, resulting in inefficiency.
In 1990 A. P. de Silva and Nimal33 designed a PET sensor for submicromolar Ca(II). In 
their model they used bis(2-ammophenoxy)ethane-N,N,N,N’-tetraacetic acid(BAPTA) as the 
receptor and anthracene was incorporated as the fluorophore to yield 7 (see Fig-13).
7 8 
Figure 13:- The PET sensors 8 -QCal (Left) and 9 - QCa2 (Right) designed and developed to detect
micromolar calcium
The development of sensors for calcium ion, however, seems to be still in its infancy.
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5.1.3.5 Targeting Transition Metal ions 
Zn (II)
To understand the importance of Zn (II) recognition, we shall have an idea on its significance 
exhibited in many cellular roles. This is released from nerve terminals through excitatory 
signals and then binds to N-methyl-D-aspartate receptor (NMDA). Further Zn (II) is co-stored 
with insulin in secretory vesicles of pancreatic cells. Zn (II) is an essential constituent of 
many protein scaffolds (eg:- Carbonic anhydrase and Zinc finger proteins). Zn (II) suppresses 
apoptosis.
Its role has been recognized in DNA and RNA synthesis. Although many significant cellular 
roles have come to light, Zn (II) regulation within the cells still needs to be understood, when 
compared to aforementioned alkali and alkaline earth metals. As such several chemical tools 
were developed to detect magnetically as well as spectroscopically silent, Zn (II) ions. One 
such tool is the fluorescent sensors based on PET.
The fluorophores were selected from a wide range of organic molecules, such as amino 
fluorescein, 1,8 naphthalimide, anthracene, pyrene and quinoline to name a few. Amino 
fluorescein based Zn (II) sensors (10-11) were developed by Hirano et al. , Burdette et 
al35,36 and Nolan et al.31 (see Fig 14-15). Hirano has reported that carboxylic acid group was 
the main cause for selectivity. It is because the ionic radius of Cd (II) is larger than that of Zn 
(II), hence carboxylate coordinates instead of nitrogen adjacent to the benzene ring. They 
have tested and proved that this hypothesis was correct indeed. Burdette et a?5*36, on the other 
hand, initially integrated aniline nitrogen in between the receptor and fluorophore to enhance 
the quantum yield of the fluorescence. Later on, they synthesized a bi-substituted ligand on a 
fluorescein platform (12-13). Fluorescent enhancement is observed corresponding to the 
binding of Zn (II), which inhibits the PET quenching pathway (from benzilic amines to 
fluorescein).
The sensor design for Zn (II), often lies in overcoming the challenge to retain the delicate 
balance between the pH and the binding affinity of Zn (II). The design was further improved
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by Nolan, who incorporated a mono substituted fluorescein platform for their sensor.
Fabbrizzi and co-workers have appended anthracene to dioxocyclam to produce ‘Off-On-type’
PET sensors (14-17). The design was based on the special affinity exhibited by transition
metal ions towards amines and amide groups (see Fig-15).
■ O
' a
12
Figure 14:- The amino fluorescein derivatized PET sensor developed by Hirano et a l The PET sensor with
Aniline spacer from the Zn-Pyridine family for Zn (II)
HN
r  o\  NH H N ------
14-17
Figure 15:- The PET sensors developed by Fabbrizzi et a l for Zn (II) and Cd (II)
Apart from amino fluorescein and anthracene, naphthalene based PET sensors were also
developed for Zn (II). Moro et al.38, Tamanini et al.39, Wang et al.40 and Salman et al.41 used
naphthalimide as fluorophores, while Kubo et al.42 utilised naphthyl pendants
(see Figure 16-18). The di(2-picolylamine), cyclic crown ether and bis imidazole were
employed as receptors respectively. Moro incorporated naphthalimide to di(2-picolylamine)
and produced a ‘Off- On-type’ PET sensor 18 to evaluate ATP levels. When the receptor
binds with the Zn (II), a modest enhancement in the emission intensity was observed. This
was attributed to two factors competing with each other. Firstly, binding of Zn (II) by the
DPA inhibits PET between DPA and naphthalimide. This has resulted in emission
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enhancement. On the other hand, there is a de-excitation channel caused by the interaction
between NH group and that of Zn (II), which moderates the emission. When the Zinc
complex is brought into contact with ATP, however, it has decreased this interaction, which
in turn results in considerable emission enhancement.
The first cyclam based PET sensor 19 for Zn (II) ions were developed by Tamanini et al,39 
The selectivity of the sensor in the presence Cd (II) was also established. Kubo and co­
workers developed both ‘Off-Orf and 4On-Off systems (20-24). The emission enhancement 
observed upon cation binding with the crown ether was attributed to the inhibition of PET 
occurring from nitrogen atoms of the receptor to the fluorophore.
18
Figure 16:- The PET sensor developed by Moro et al. for detecting ATP levels
k A  r" l /
19
Figure 17:-The first Cyclam derivatized PET sensor developed by Emiliano et al selective
to Zn (II
I
X.
t
w °
iJ5
20-24
Figure 18: -The PET sensor developed by Kubo et .al, which could detect Zn (II) and SCN'
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Wang et a/.40 selected N,N-bis(2-pyridylmethyl)ethylenediamine as the receptor segment for
their PET sensor 25 (see Fig 19) Their selection was based on two advantages. Firstly, the
receptor has a great deal of affinity for Zn (II) and secondly it was based on its high potential
for cell permeance. A benzene ring was used as a spacer, based on ‘’virtually” decoupled
fluorophore-receptor strategy.
The PET process is attributed to the aniline nitrogen, where the lone pair of electrons was 
transferred to fluorophore. Upon metal binding, however, this lone pair was utilised in 
forming a coordinate bond. This has lead to emission enhancement. In 2006, Salman et al. 
have reported a PET sensor 26 that is selective to Zn (II), in that bisimidazole acted the role as 
a receptor unit (see Fig-19). The complexing moiety, however, was electronically decoupled 
from its fluorophore, namely the naphthaleneimide moiety. Upon binding of Zn (II) to the 
bisimidazole moiety, the emission enhancement was observed. This could be attributed to 
prevention of the PET process that take place from the lone pair nitrogen atoms of the 
imidazole to the fluorophore, as the lone pair is now involved in forming the coordinate bond.
25 26
Figure 19:-The PET sensor developed by Wang et aL based on virtually decoupled strategy (Left), 
and PET sensor designed by Salman et aL (Right)
The 2,2’-bipyridine ligand is a widely studied bidentate ligand in coordination chemistry. It 
has, however, hardly been used for the synthesis of a sensor. Fages et al.43 noted this and have 
synthesized a pyrene labelled bipyridine ligand 27 (see Fig-20). This comprises the pyrene as 
the fluorophore while the bipy acted as the ion-receptor. Contrary to the usual enhancement 
of fluorescence upon binding to Zn (II), a dramatic fluorescence quenching was observed. 
This infers, that there is significant PET taking place between the excited pyrene nucleus and 
the Zn bound receptor moiety. The complexation of the hard Lewis acid Zn (II) has increased 
the reduction potential of the bipy fragments. Hence, the bpy acts as an acceptor of electrons,
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whereas the excited pyrene is the donor. This makes this sensor belong to the category of
4On-OJf-type’ PET sensor.
27
Figure 20:-The PET sensor based on bi pyridine ligand acting as fluorescence quencher upon
binding with Zn (II)
Very recently, Xue et al.44 have developed an interesting sensor 28 (see Fig-21) which could 
detect both Cd (II) through PET and Zn (II) through ICT. Since the Cd (II) and Zn (II) belong 
to the same group (with a d 10 configuration), the biggest challenge in developing Cd(II) 
sensors lies in overcoming the interference (in terms of giving similar spectral changes) by 
Zn(II), when coordinated in fluorescent sensors. As expected, the operation of PET 
mechanism between the receptor moiety (amine N atom of DPA) and the fluorophore 
(quinoline) is severely inhibited upon metal binding. This has resulted in very high 
fluorescence enhancement (40 fold). A negligible emission shift was also observed. On the 
other hand ICT mechanism provided a red shift coupled with negligible emission 
enhancement. This has resulted in very distinct colour changes; to an extent it was visible to 
the 'naked eye’.
28
Figure 21:- A dual modality sensor acts on PET as well as through ICT
Cd (II)
As a d10 second row transition metal element, cadmium also has attracted the attention of PET 
sensor designers. This is mainly because of the health risk and environmental risk induced by 
the excessive usage of Cd (II) (in batteries, fertilisers etc.). Cadmium is found to be the cause
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of profound biological effects (renal dysfunction, reduced lung capacity, while the tendency
for accumulation in kidneys, thyroids, and spleen results in adverse physiological
conditions).45 It was found recently that demineralisation of bones is caused by Cd (II)
activating the osteoclast bone cells.46 Gunnlaugsson et al.45 have reported two sensors 29-30.
The sensor contains anthracene as the fluorophore and the simple iminodiacetate group as the
receptor moiety (see Fig-22). The reason for their selection is two-fold. Firstly, anthracene is
well known for its photophysical properties and secondly the aniline based receptor would
undergo protonation, only in very high acidic conditions. Furthermore, they have used two
receptor units in the single system. This has facilitated the effective PET rate quenching from
the receptor to fluorophore, resulting in luminescent switching.
29-30
Figure 22:-The PET sensor based upon iminodiacetate on athracene platform
Hg (II)
Heavy metal contamination and its toxicological effects have been widely studied. Hg (II) is 
used largely in the industrial processes, which eventually causes harm and health risks. 
Similar to Cd (II), Hg (II) adverse impacts had lead to several neurological diseases (methyl 
mercury is a potent neurotoxin.47). Therefore the considerable interest shown in developing 
sensors for Hg (II) is no surprise.
Boron dipyrromethene (BODIPY) and antharacene have been widely employed as 
fluorophores. Very recently Lu et al coupled two aniline units to BODIPY to produce a water 
soluble PET sensor 31 (see Fig-23). The sensor displayed high fluorescence emission 
enhancement upon binding with Hg (II). This was attributed to the inhibition of PET, upon
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metal binding. Further, they have tried the metal binding with Zn (II) and Cd (II), where no
significant change was observed. The emission enhancement is expected due to inhibition of
reductive PET occurring from the receptor to the fluorophore. Since, oxidative PET from the
fluorophore to the receptor (which quenches the fluorescence) also occurs simultaneously, the
enhancement is not significant. In contrast, Wang et al.4* have appended anthracene to cholic
acid moiety to produce a sensor 32 (see Fig-23) for methyl mercury (I). In the unbound state,
PET occurred from preorganized dithiocarbamate pending groups (which are part of the
cholic acid moiety) to the fluorophore. This was retarded by the binding of Hg (II) with
dithiocarbamate upon metal binding. This has lead to fluorescence enhancement. Therefore
contribute to ‘ Off-On-type' PET sensor for Hg (II). Selectivity of the sensor was also studied
in detail.
31 32
Figure 23:-THE PET sensor developed for Hg (II) based on BODIPY cholic acid derivatized PET sensor,
capable of detecting Hg (II) and MeHg (II).
There were two—in—one PET sensors also have been developed. For instance, Sung et a l49
have designed and developed a sensor 33 to detect Fe (III) and Hg (II). In this system, it 
comprises anthracene as fluorophore and the amide/p-amino alcohol-a tridentate ionophore as 
the receptor moiety (see Fig-24).
electron
transfer.
Light
33
Figure 24:-The PET sensor prepared by Sung et aL based on Tridentate ionophore
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Ag(I)
Their presence in various commercial sectors and their presence in augmented industrial 
sludge, environmental contamination and similar reasons have raised awareness in detecting 
Ag (I) in the respective fields. Not much interest, however, has been shown by the PET sensor 
designers in the recent past. Wang et a l50 have decided to address this niche area of research. 
They have developed a coumarin based PET sensor 34 (see Fig-25). Upon binding with 
Ag (I), PET was retarded thus resulted in fluorescence enhancement.
34
Figure 25:- The preparative pathway for CS1 -  PET sensor for Ag (I)
5. h  3, 5.1  Ratiometric Sensors fo r  A g (I)
The distinct advantage of the ratiometric measurement is its ability to minimise or nullified 
the possible variability due to differences in the instrumental efficiency and composition of 
the sensor. Yang et al.51 have reported a ratiometric fluorescent sensor for Ag (I) with high 
selectivity and sensitivity. The selection of pyrene is justified by its extreme sensitivity to the 
polarity of local environment. The binding of Ag (I), with pyrene-tethered receptor resulted in 
self assembled complex. This has lead to dramatic increase in the fluorescence intensities of 
the excimer and a simultaneous, dramatic reduction of the monomer’s fluorescence intensity.
Cu (II)
Copper takes part in many fundamental biological processes in all currently known life forms.
On the other hand fluctuations in its role in homeostasis will lead to neurodegenerative 
diseases. Thus it is an inevitable requirement to have fluorescent sensors which could detect 
copper at the molecular level at sub-cellular resolution. Contrary to Zn (II) ions, the available 
literature on Cu (II) sensing is sparse. The challenge, however, lies, in increasing the 
emission enhancement, as usually upon metal binding emission enhancement is negligible due
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to its intrinsic quenching behaviour, anthracenes, naphthalimides are some of the fluorophores
employed in producing both ‘Off-On’ and ‘On-Off type sensors. Guangjie He et al,55
employed coumarin and appended to dibenzyl hydrozone 36, while, Kamila et a l52
incorporated naphthalene into P-aminobisphosphonate 37 and developed PET sensors
(see Fig 26-27). Guangjie He attributed the emission enhancement upon binding of Cu (II) to
the inhibition of PET occurring between lone pair of N atoms and the fluorophore. This was
made possible by carefully tuning the redox potential of the fluorophore. Further, the
selectivity of the sensor with a range of transition elements (Mn (II), Cr (III), Co (II), Ni (II),
Cd (II), Hg (II), Pb (II) and Ag (I)) also was established. The ‘ On-Off-type' sensor developed
by Kamila and co-workers exhibited a clear fluorescence quenching.
0 = P  OH
36 37
Figure 29:-The PET sensors for Cu (II) developed by He et a l. and Kamila et at. based on dibenzyl 
hydrazone (Left) and p-amino bisphosphonate acting as receptor moieties respectively.
5.1.3.6 Targeting Lanthanide Ions
Ce (III) & Y (III)
Sensors were developed using fluorophores such as anthracene and quinine. In 2002, 
Ghosh et al.53 appended anthracene to thiophene derivatized TREN in a tripodal frame work 
to develop a PET sensor 38. This is believed to be the first PET sensor for Ce (III). 
Fluorescence quenching in the unbound state was attributed to PET, from lone pair of strong 
tertiary amines and also from the weak sulphur donors of thiophene moiety towards the 
fluorophore.
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Okamoto et.al54 devised a relatively more complex PET sensor 39, in that quinone was
tethered to a Zn-Porphyrin derivative (ZnP). A dramatic emission enhancement was observed
upon metal binding (strong coordination of Y (III) with a quinone receptor moiety), due to the
inhibition of PET from ZnP to the quinone based receptor.
38 39
Figure 31:-The PET sensor based on Tripodal frame work as thiophene moiety
A review of the literature revealed, that this particular area of research is achieving new 
heights every now and then with growing interest in PET sensors from the bio-chemical 
research community. As one of the pioneers of PET sensor development, de Silva uses words 
to describe the importance and significance of this research segment. A.P. De Silva is the one 
who perfected PET with his famous fluorophore-spacer-receptor model, which was initially 
proposed by Weller et al.19 In de Silva’s words;
“Hardly a week goes by without a PET Sensor being introduced”
Therefore interested readers are referred to these publications published elsewhere 55-57
5.2 Results and Discussion
5.2.1 Importance of Fluorimetric Evaluation
The development of chemo sensors for a specific target, especially in aqueous systems will be 
confronted with two major difficulties. Firstly, the development of a suitable binding site58 for 
the target molecule and secondly manipulating the receptor with a signal read-out device. Of 
these two difficulties, development of a precise binding motif towards the target molecule is 
of paramount importance. In order to realise this objective, the selection of a suitable
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chromophore and the evaluation of its capability to act as luminescent sensor is a must
(as there are instances, where the chromophore was inefficient upon binding with the ligand).
However, although some of the synthetic steps required for a designed ligand may be long
and low yielding, the synthesis of even relatively low quantities (few milligrams) of a
fluorescent chemo sensor may be good enough for thousands of analyses.
It can be seen from the previous chapters that the ligands for these potential sensors, 
however, were prepared in good yield. The next objective will be to measure the efficacy of 
these ligands in terms of changes in luminescence upon binding with the desired analytes 
(in this case, cations, such as Cu (II), Zn (II), Mn (II), etc).
As such, the newly synthesized multidentate ligands were dissolved in appropriate 
solvents and the changes in luminescence were observed upon the addition of a large excess 
of the metal perchlorates (Zn(ClC>4)2, Cu(C1 0 4 )2, Mn(ClC>4)2, Gd(C1 0 4 )3  and Ca(C1 0 4 )2). 
The spectroscopic behaviour of EDTA bisamides of N-(2-Aminoethyl)-l,8-naphthalimide 
(L1) and 2-amino anthraquinone (L5) (see Fig-1), in the presence of the transition metal ions 
(Zn (II), Cu (II) and Mn (II)) in solution was studied. DTPA analogues (see Fig- 2-3) in their 
protected, deprotected and complexed forms (with lanthanides Gd (III), Eu (III), and Yb (III)) 
were studied in detail. DTPA based bisamide of N-(2-Aminoethyl)-l,8-naphthalimide (L14) 
(see Fig-4), in the presence of transition (Zn (II), Cu (II), Mn (II), lanthanide (Gd (III)) and 
alkaline earth (Ca (II)) metal ions were assessed. Water insoluble ligands (L1, L5 and L14) 
were dissolved in dimethylformamide and dimethyl sulphoxide and L10 and L12 were 
dissolved in dichloromethane. Water-soluble ligands (L11, L13 and L15) and complexes of 
DTPA analogues were dissolved in distilled water.
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5
Figure 1:- EDTA bisamides of N-(2-AminoethyI)-l, 8-naphthalimide (L1), 2-Aminoanthraquinone (L5)
L11
10. ii .Figure 2:- Depicting the Protected (L ) Deprotected (L ) forms of symmetric naphtha
derivative
o
.OH
HO'
.OH
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O
12 13
12 13Figure 3:- Depicting the Protected (L ) Deprotected (L ) forms of Asymmetric naphtha
derivative
Figure 4:- DTPA bisamides of N-(2-Aminoethyl)-l, 8- naphthalimide (L14) 
and 4-Aminomethyl pyridine (L 15)
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5.2.L1 Spectrofluorimetric Evaluation of the EDTA Bisamides
Evaluation o f  EDTA bisamide o f  N -(2-A m inoethyl)-l, 8-naphthalim ide (L1)  and 2-Amino Anthraquinone (L5)  
Spectrofluorimetric measurements allow us to evaluate the impact caused on the emission
properties of the ligands due to coordination of the transition metal cations. Excitation of the
ligand at 370 nm resulted in an emission maximum at 450 nm. It could be seen from the
emission spectra of L1 (see Fig-5), that while addition of a large excess of Zn (II) to the ligand
solution causes emission enhancement (by a factor of 2.0), addition of Cu (II) in large excess,
causes quenching of fluorescence (by a factor of 1.5), on the respective ligand. It could also
be observed, that addition of Mn (II) hardly causes any change (by a factor 1.0) on the
emission properties of L 1. Similar observations were noted for L5, though emission
enhancement (by a factor of 1.0) by the addition of Zn (II) was not so significant (see Fig-6).
To explain these observations, a number of factors that modulate the photophysical 
properties of a fluorophore come to mind. Electron and energy transfer processes, changes of 
electronic density and the destabilisation of a non-emissive n-7i* excited state need 
consideration. Among these factors photo induced electron transfer mechanism could be 
considered as the major influencing factor. Further, this argument is supported by the fact that 
the greatest effect on the emission enhancement was caused by Zn (II). Zn (II), having a d 10 
electronic configuration, does not usually contribute to EET mechanisms for the deactivation 
of the excited state.60 Further it could be reasonably suggested, the considerable fluorescence 
enhancement is due to the inhibition of PET process, which becomes thermodynamically less 
favourable upon coordination with a metal ion.61
In L5, however, the lone pairs of tertiary nitrogens, carboxylate oxygens and amide 
oxygens do not quench the luminescence very much. This results in a moderate emission 
enhancement upon binding of Zn (II).
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Intensity m odulation by P E T
On the other hand, quenching of fluorescence by Cu (II) could be reasonably explained by the 
PET mechanism. A possible explanation is that Cu (II) induced PET occurs from fluorophores 
in L1 and L5 (naphthalimide moiety and anthraquinone moiety respectively) to their 
respective receptor moieties. While L1 and L5 act as L On-off-type ’ sensor for Cu (II), 
L1 could also act as an ‘ Off-On-type ’ PET sensor with regard to Zn (II). The insignificant 
fluorescence intensity modulation exhibited by Mn (II) in L1 also could be reasonably 
accounted for by the oxidative PET occurring from the fluorophore to the receptor moiety 
upon metal binding.
Stokes sh ift
The Stokes shift (v a -v f )  is an important characteristic of fluorescent compounds. The Stokes 
shift is a parameter which indicates the difference in the properties and structure of the 
fluorophores between the ground (So) and first singlet excited state (Si). It is calculated by the 
following equation.
( v a - v f )  = ( 1 / ^ - a -  1A .f)x  1 0 7 c m ' 1
The values of Stokes shift are in the range from 4038- 4804 cm'1 for L5. On the other 
hand, values of Stokes shift are in the range from 6140- 6594 cm'1 for L1. The relatively large 
Stokes shift displayed by L 1 indicates a high potential for bio-imaging. Once again the 
aforementioned values are in good agreement with an analogous compound reported by 
Chovelon et al.62
When the UV-Vis spectrum was recorded for L1 a broad absorption was observed 
between 250 and 400 nm. Within the spectrum an internal charge transfer (ICT) state arises
from the 71-71* electron transfer occurring with Aa maximum at 345 nm. The observation is in
62good agreement with those values reported in the literature.
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The molar extinction coefficient 6 at the absorption maxima is 21,197 M_1cm 1 for L1.
The observed value is in close agreement with the expected value, as it is two-fold larger than 
those of analogous monomeric N-methyl-1,8-naphthalimide.15a
3
-2-
®Ocoo</)
o3
 Ligand
 Cu
 Mn
 Znu.
H-0
V)
c1 
c
360 420 480 540 600
Wave length (nm)
Figure 5:- Em ission spectra of EDTA bisam ide of N-(2-Aminoethyl)-1, 8-naphthalimide (L1)
(Excitation at 370nm)
Potential Multimodal Imaging Agents
3
3
Oc0)o</>£o
3
ll
 Ligand
 Cu
 Mn
 Zn
o
c
I
360 420 480 540 600
Wave length (nm)
F ig u re  6:- E m ission  sp ectra  o f EDTA b isam ide o f 2-Am inoanthraquinone (L5)
(Excitation at 345nm)
5.2.1.2 Spectrofluorometric Evaluation o f DTPA Analogues
Fluorescence on binding with Lanthanides
Unfortunately, the background fluorescence of biological samples, can at times, limit the use 
of luminescent probes in imaging. The usage of luminescent complexes based on lanthanides, 
brings elegant solution to this problem. This is possible due to the long lived luminescence of 
the lanthanide complexes in comparison to relatively negligible life time of the background 
emission, from the biological samples.
However, in the following experiments we have not concerned ourselves with the 
lanthanide phosphorescence spectrum. Instead, we are interested by changes in the 
fluorescence spectrum on lanthanide binding.
The emission profiles of protected symmetric ligand L10 and deprotected symmetric 
ligand exhibited makerd difference. Furthermore, the relative emission intensities of the free 
ligand L11 exhibited marked difference, when compared to Ln -Gd, Ln-Eu, Ln-Yb and 
observed in the following order: L11 < L11-Yb3+ < L11-Eu3+< L11- Gd3+. This indicates the
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successful formation of the respective complexes (see Fig 7-13). A similar behaviour was
observed in the case of L 13 and its gadolinium complex (L13-Gd), once again, indicating the
complex formation.
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Figure 7:- Lum inescence spectra of Symmetric Ligand-Protected (L10) 
(Excitation at 336 nm and Emission at 383 nm)
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Figure 8:- Lum inescence Spectra of Gd complex of Symmetric Ligand (Gd-L11) 
(Excitation at 345 nm and Emission at 390 nm)
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F ig u re  9:- Lum inescence spectra of Eu com plex of Symmetric Ligand (Eu-L11) 
(E x c ita tio n  a t  345 nm  a n d  E m ission  a t  393 nm )
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F ig u re  10:- Lum inescence spectra of Yb complex of Symmetric Ligand (Yb-L11) 
(E x c ita tio n  a t  345 nm  a n d  E m ission a t  396 nm )
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F ig u re  11:- Em ission Spectra of Asymmetric Ligand-Protected (L ) 
(E x c ita tio n  a t  335  nm  a n d  E m ission  a t  383 nm)
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F ig u re  12:- Emission Spectra of Asymmetric Ligand-Deprotected (L13) 
(E x c ita tio n  a t  346 nm  an d  E m ission  a t  396 nm )
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F ig u re  13:- Lum inescence Spectra of Gd com plex of Asymmetric Ligand (Gd-L13)
(Excitation at 345 nm and Emission at 396 nm)
5.2.1.3 Spectrofluorometric Evaluation o f DTPA based bisamides
Evaluation o f  DTPA bisamide o f  N-(2-Aminoethyl)-l, 8-naphthalimide
Luminescence spectra obtained upon addition of large excess of Gd (III), Zn (II), Cu (II), Mn 
(II) and Ca (II), to a solution of DTPA bisamide of N-(2-Aminoethyl)-l,8-naphthalimide (L14) 
(see Fig-4) is depicted in Fig-14. The most striking feature of the spectra is the complete 
quenching of fluorescence upon coordination with Cu (II) ions. The phenomena could be 
explained by considering the redox potential of the fluorophore and the Cu (II) ions. 
This could serve to describe the influence of PET mechanism on the aforementioned 
observation.
Cu (II) is a redox active species with an unfilled d orbital and can quench fluorescence 
through electron or energy transfer mechanisms. The phenomenal observation of complete 
quenching, however, requires an aid of another mechanism to explain the observation. 
Further, for the PET mechanism to be activated it requires, the oxidation potential of the 
fluorophore should be higher than that of the receptor.
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The complete quenching was observed upon addition of Cu (II), when exited at 314 nm.
Furthermore, luminescence could be observed upon addition of Cu (II), provided L14 is
excited at 353 nm (see Fig-15). A similar, complete quenching behaviour of the Cu (II) was
observed in a two-component system, where the fluorescence fragment, anthracene was
appended to a dioxotetraamine ligand.66 In both these examples the luminescent sensor to act
as ‘Off-On-type’ PET sensor.
The luminescence spectra of L14 have another striking feature, namely the emission 
enhancement caused by the coordination with Mn (II) and the moderate emission exhibited by 
Zn (II). This is an unusual situation. A complete quenching of fluorescence by Cu (II) is a 
rare observation, but not a unique observation. The moderate emission enhancement upon 
addition of Zn (II) is also not an unusual observation. What is, however, really unusual is the 
strong emission enhancement caused by Mn (II) when Zn (II) does not.
The observation is very difficult to explain in terms of the known theories. A possible 
explanation, however, may be given in terms of conformational changes of the chromophore 
with respect to the metal centre or indeed the other chromophore on binding to the Mn (II) 
centre; hence due to the different confirmations, quenching may be more prominent in the 
Zn (II) complex than in the Mn (II) complex.
It could be seen from the above arguments that a plausible explanation for unusual 
observation is not forthcoming, given that we have limited knowledge of the coordination 
modes of L14 and the relative positioning of the chromophore.
Another notable feature of the spectra is the variation of the emission intensity of the 
secondary peak. Unlike the spectra of L1, L14 clearly depicts a shoulder like peak (i.e 
secondary peak) at 455 nm, apart from the primary peak which appears at 392 nm. Moreover, 
the ratio of emission intensity (/392 nJhss nm) was observed descending in the following order, 
upon addition of various metal ions: Mn (II) > Ca (II) > Gd (II) > Zn (II) 
(1.55>1.16>1.35>1.31). Furthermore, the secondary peak which appears around 455 nm
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could be attributed to an excimeric species. The observation is in good agreement with the
previous findings, reported by Barros et al.]5h for 1,8-alkyldinaphthalimides, in that the
excimer emission was observed at 470 nm.
A comparision with emission spectra of L1 and L14
While the emission spectra of L 1 exhibited intense structureless band with the vibronically 
structured features, L 14 exhibited a broad band characteristic with the fine structure. 
Furthermore it has been reported that EDTA derivative of a pyrene, give rise to a static 
excimer. In contrast, emission spectra of the DTPA analogue of pyrene indicated the presence 
of dynamic excimer. Therefore, it is most likely to have a similar situation with L1 and L14. 
In order to arrive at an unambiguous solution, density functional theory may be utilised.
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Figure 14:- L um inescence spectra of DTPA bisam ide of N-(2-Aminoethyl)-1, 8-naphthalimide (L  ) 
(In the p resen ce o f various metal ions, Excitation at 314 nm)
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F igu re  15:- Lum inescence spectra of DTPA bisamide of N-(2-Aminoethyl)-1, 8-naphthalimide (L14)
(in the presence of e x c e ss  Cu (II))
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F igu re  16:- Lum inescence spectra of DTPA bisamide of N-(2-Aminoethyl)-1, 8-Naphthalimide (L14)
(in the presence of e x cess  Ca (II))
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Figure 17:- L um inescence  sp e c tra  of DTPA b isam ide  of N-(2-Aminoethyl)-1, 8-naphthalim ide ( L 14)
(in th e  p re se n c e  of e x c e ss  Gd (III))
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Figure 18:- L u m in escen ce  sp e c tra  of DTPA b isam ide of N-(2-Aminoethyl)-1, 8-naphthalim ide ( L 14)
(in th e  p re sen ce  of ex c e ss  Mn (II))
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Figure 19:- Lum inescence spectra of DTPA bisamide of N-(2-Aminoethyl)-1, 8-naphthalimide (L 14)
(in the presence of e x c e ss  Zn (II))
Evaluation o f DTPA bisamide o f  4-Aminomethyl pyridine
The luminescence spectra of L 15 depicted in Fig-20. L15 was excited at different wavelengths 
and the variation in the emission wavelengths observed. There are two observations, which 
are worthy to mention. Firstly, the position of the primary peak (Xem - 386 nm) does not vary, 
irrespective of the two excitation wavelengths, 314 nm and 328 nm. A distinct red shift, 
however, could be observed when excited at 370 nm. As this peak appears at 446 nm, most 
likely, it could be attributed to an excimeric species.68 It is because, L15 contains two identical 
fluorophores whose mutual distance can be altered upon metal binding 
(especially with a flexible interlink and the related confirmational changes).
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Figure 20:- L um inescence spectra of DTPA bisamide of 4-Amino methyl pyridine (L15)
5.3 Experimental Section
The photophysical data for luminescence were obtained on a JobinYvon-Horiba Fluorolog 
spectrometer fitted with a JYTBX picosecond photo detection module. Water-soluble EDTA 
bisamides were dissolved in water. Water insoluble bisamides and complexes were dissolved 
in chloroform and DMSO as required. Although all of the new ligands and complexes 
prepared were air stable both in the solid state and solution, some of the ligands and 
complexes were found to be mildly hygroscopic, when left in the open atmosphere for 
prolong periods of time.
5.4 Conclusion
As the project seeks to develop Multimodal Imaging Agents, bearing good relaxivities and 
optical properties, it’s crucial to evaluate the optical properties. With this objective in mind, 
luminescence measurements were carried out with series of ligands (L1, L5, L10- L13, and L14- 
L15). A comparison of luminescence spectra of DTPA analogues of Symmetric naphtha 
derivative (L10- L11) indicated the success of complexation with Gd (III) and/or Eu (III).
Luminescent measurements of EDTA bisamides (L1) yielded good results; two fold 
enhancement of emission upon binding with Zn (II) is commendable, positioning them as
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potential Zn (II) sensors. On the other hand, complete quenching of fluorescence observed
with DTPA bisamide of N,N-(2-Aminoethyl)-l,8-naphthalimide (L15) upon binding with
Cu (II) is highly commendable. This also justifies the capability of the ligand to act as a PET
sensor for Cu (II). The potential for L14 to act as a PET sensor for Mn (II) was established.
The intramolecular excimer formation is clearly displayed by L14 and L15. Moreover, L14
makes it possible to detect Mn (II) cation ratiometrically, besides simple PET signalling,
thereby eliminating most or all of the possible variability due to differences in instrumental
efficiency and content of effective dye. Further work could be concentrated on the pH
dependence of these ligands particularly L1, L5 and L 14.
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